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ABSTRACT 
GEORGE DANIEL GRASS. The role of CD147 in Breast Cancer Progression 
(Under the direction of BRYAN P. TOOLE) 
In the U.S., approximately 40,000 women will die from breast cancer this year, 
while an additional 230,500 women will be newly diagnosed with invasive breast disease. 
Despite tremendous advancement leading to earlier detection and novel therapeutic 
approaches, recurrent metastatic breast cancer remains a major cause of mortality. 
Invasive breast cancer cells employ specialized actin-rich protrusions called invadopodia, 
which are enriched in proteases, to degrade the extracellular matrix and these structures 
correlate with metastasis in vivo. The multifunctional immunoglobulin superfamily 
protein emmprin (CD 147) is highly enriched'on tht! surface of malignant breast cancer 
cells and is associated with matrix metalloproteinase (MMP) induction and invasion. In 
this dissertation we found that CD147 regulates the activity of invadopodia in non-
1 
transformed breast epithelial cells and invasive breast cancer cells by regulating the 
expression and localization of membrane type-l MMP (MTI-MMP). Furthermore, we 
discovered that up-regulation of CD 147 regulates invasiveness by facilitating the 
assembly of multi-protein signaling complexes containing CD 147, CD44 and EGFR. 
Assembly of these complexes leads to the activation of EGFR-Ras-MEK-ERK signaling 
cascades. We further found that Ras regulates CD 147 expression and may participate in 
a complex feedback loop involving hyaluronan-CD44 interactions and ERK signaling. 
Lastly, we observed that sub-populations of cells with differential CD147 surface 
expression correlate with distinct functional phenotypes. Our work has begun to unravel 
xii 
the complexity of CD 147 function in breast cancer invasion and provides strong evidence 
that CD 147 should be a therapeutic target in future studies. 
xiii 
Chapter 1: An Overview of CD147 Biology 
Introduction 
CD147 is a type I integral membrane protein belonging to the Ig superfamily that 
is variably glycosylated and expressed across several tissue types. The expression of 
CD 147 is elevated on the surfaces of various cancer types, whereas the expression in 
most normal tissues is at much lower levels. CD147 was originally identified as a tumor-
associated protein that stimulates matrix metalloproteinase (MMP) production in 
'", :'. r 
fibroblasts, but over the years it has become cle.9-r1}hat CD147 is a molecule with 
pleiotropic biology. In addition to MMP induction, the role of CD 147 in cancer 
progression has been associated with multi -therapy resistance, angiogenesis, migration, 
invasion and chaperoning of metabolic transporters to the c~ll surface. 
\ 
CD147 Nomenclature and Gene and Protein Structure 
Nomenclature 
CD147 was identified and characterized independently under numerous names in 
various species and tissues using different experimental protocols: RET-PE2 (Finnemann 
et a!., 1997), CE9 (Nehme et aI., 1993) and OX-47 (Fossum et aI., 1991) in rats, gp42 
(Altruda et aI., 1989) and basigin (Miyauchi et aI., 1990) in mice, HT7 (Seulberger et aI., 
1990), neurothelin (Schlosshauer et a!., 1995), and 5All (Fadool and Linser, 1993) in 
1 
chickens, the human leukocyte-activation associated antigen M6 (Kasinrerk et ai., 1992), 
the blood group Oka antigen (Spring et ai., 1997), the hepatoma-associated antigen 
HAb18G (Jiang et aI., 2001) and matrix-metalloproteinase (MMP)-inducing factor, 
emmprin (Biswas et ai., 1995) in humans. CD147 was first functionally characterized by 
Biswas and colleagues (Biswas, 1984; Ellis et ai., 1989) using a co-culture system with 
lung carcinoma cells and fibroblasts, in which they identified a Tumor cell-derived 
Collagenase-Stimulatory Factor (TCSF) that was present on the cell surface and in 
conditioned media. In later years, in addition to collagenase (matrix metalloproteinase-1; 
MMP-1), TCSF was found to stimulate increases in both message and protein levels of 
MMP-2 and MMP-3 and was renamed to Extracellular Matrix Metalloilloteinase Inducer 
(emmprin) (Biswas et ai., 1995; Kataoka et aI., t993) .. It is now clear that all of the above 
~- '. 
"J;i ,~l--
designated proteins are in fact the same and are now commonly termed CD147 
(Kanekura et aI., 1991; Kasinrerk et aI., 1992; Yan et ai., 2005). 
Gene Structure 
\ 
The gene locus for CD147 is located at chromosome 19p13.3 in human (Kaname 
et ai., 1993) and was originally thought to contain eight exons spanning over 10.8 
kilobases (Guo et al., 1998), but new evidence suggests that the CD147 gene contains 10 
exons that span 15,000 nucleotides (Belton et ai., 2008; Liao et ai., 2011). Interestingly, 
the CD147 gene displays many unique features including: a multi-exon 3' -untranslated 
region (3' -UTR), immunoglobulin (Ig)-like domains encoded by paired exons, and a 
junctional exon of the second Ig-like domain encoding the transmembrane domain and 
part of the cytoplasmic domain (Guo et ai., 1998). The CD147 gene is flanked on the 5' 
end with a CpG island (CGI)-rich sequence in the promoter region, which was previously 
2 
described to lack CAAT or TAT A boxes, but subsequent evidence suggests this promoter 
region may contain a TATA box (Liang et aI., 2002). The mouse CD147 gene is located 
on chromosome 10 and is smaller in size compared to the human gene due to shorter 
intronic sequences interspersed between size-conserved exonic sequences (Cheng et aI., 
1994; Guo et aI., 1998; Miyauchi et aI., 1995). 
Message and Protein Organization 
Based on data in the Entrez Gene database, the CD 147 gene is encoded into 4 
variant transcripts, designated as CD 147 -1,2,3 and 4 (Figure 1-1). Recent findings have 
demonstrated that alternative splice variants of CD147 are formed: a tissue specific 
variant resulting in three Ig-like domains (CD147-1) was identified in the retina (Hanna 
,. ,-J
't 
f." / ~ 
., . .,., i tI flr ' 
et aI., 2003; Ochrietor et aI., 2003) as well as tw%ther variants lacking the N-terminal 
Ig-like domain (CD147-3 and CD147-4) (Belton et aI., 2008; Liao et aI., 2011). 
However, CD147-2 is the most abundant, widely distributed and best characterized , 
isoform and will be designated as CD147 hereafter. Sequence analysis of CD147 by 
\ 
several groups revealed that it is a single-chain type I transmembrane molecule and 
member of the Ig superfamily (IgSF). The mRNA transcript for CD147 encodes a 269 
amino acid protein that is composed of a 21 amino acid signal sequence, a 186 residue-
long extracellular portion consisting of two Ig -like domains at the N -terminus, a 21 
amino acid transmembrane domain, and a 41 residue cytoplasmic domain at the C-
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Figure 1-1. CD147 isoforms. CD147 alternative splice variant protein structures. 
CD 147 -2 is the most abundant and best characterized isoform and will be designated 
as CD 147 hereafter. 
Due to the presence of certain sequence motifs, CD 147 has been described to 
have homology to both the major histocompatibility complex class II (MHC II) beta-
chains and Ig variable domain (V); this has led ,sam~' investigators to propose that CD147 
'; ";;-Il ' 
may be an evolutionary intermediate between a primordial Ig form and MHC II-beta 
chain-like and V domain-containing molecules (Altruda et ai., 1989; Fossum et ai., 1991; 
Kanekura et ai., 1991; Miyauchi et aI., 1990; Miyauchi et at, 1991). In line with this, 
high resolution crystallography has revealed that CD147 contains aN-terminal IgC2 
\ 
domain and a membrane proximal IgI domain that are organized in a unique manner, thus 
distinguishing CD147 from other IgSF proteins (Yu et aI., 2008). The protein sequence 
shows varying conservation across several species, especially in the extracellular 
domains, but the linker sequence between the Ig-like domains, the cysteine residues, 
asparagine glycosylation sites, transmembrane domain, and cytoplasmic domain 
demonstrate strong homology (Fossum et aI., 1991; Miyauchi et ai., 1995; Schuster et ai., 
1996; Seulberger et ai., 1990; Yu et ai., 2008). Interestingly, the highly conserved 
regions of CD147 contain unique structural characteristics. The flexible 5-residue linker 
4 
domain has been shown to provide CD147 a great deal of domain mobility, possibly 
allowing the first IgC2 domain to alter its orientation to interact with ligands or adjacent 
binding partners (Yu et aI., 2008). The transmembrane domain contains a uniquely-
embedded charged glutamic acid residue in the hydrophobic-rich sequence as well as a 
leucine zipper motif (Yan et aI., 2005). Proteins with these characteristics have been 
shown to oligomerize into multi-protein complexes and are often involved in cell 
signaling events: this is especially recognized in immune cell receptor complexes 
(Humphrey et aI., 2005). Support for this homo- or hetero- oligomerization is found in a 
study identifying that polyleucine rich transmembrane domains with an embedded 
glutamate residue confer strong interactions between a-helices, possibly via hydrogen 
bonding (Zhou et aI., 2001). ... .-', 
The predicted molecular weight from the sequence of CD147 is 27-29 kDa, yet 
many investigators discovered that CD147 migrates on sodium dodecyl-sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) between 31-65 kDa. Originally, 
discovered as a protein that carries a developmentally-regulated\carbohydrate moiety, in 
conjunction with three conserved N-glycosylation sites, CD147 is classified as a 
glycoprotein. Studies with glycosylation inhibitors and specific lectins revealed that 
approximately 50% of the mass of CD147 is due to carbohydrate side groups bearing 
~1,6-branched, polylactosamine-type sugars, fucosylations, Lewisx glycan epitopes, and 
sialylations (Kamada et aI., 1987; Riethdorf et aI., 2006; Tang et aI., 2004a; Yang et aI., 
2011). CD147 glycoforms were previously characterized as low-glycosylated (LG) and 
high-glycosylated (RG) forms, representing -32 kDa and -45-65 kDa, respectively (Tang 
et ai., 2004a). The LG-CD147 was found to contain a high-mannose carbohydrate, 
5 
whereas the HG-CD147 was enriched for branched polylactosamine chains. It is clear 
that CD147 is heterogeneously glycosylated across many tissue and cell types (Nakai et 
aI., 2006) and even shows variations in glycosylation in cell lines derived from the same 
tissue of origin (Riethdorf et aI., 2006). Currently, it is unclear whether different CD147 
glycoforms have different biological functions. 
Very little data exists on how CD147 glycosylation status is regulated. Currently 
the only published mechanistic data describes a role for caveolin-1 in regulating CD147 
glycosylation. It was recognized that CD147 associates with caveolin-1 mostly on the 
cell surface via its membrane proximal IgI domain and that this association attenuates 
CD 147 self-aggregation (Tang and Hemler, 2004). Further evaluation of this interaction, 
revealed that LG-CD147 preferentially associat~~;With caveolin-1 and that the caveolin-
1-CD147 interaction inhibited CD 147-induced MMP induction (Tang et aI., 2004a). The 
authors of these studies proposed that caveolin-l associates with CD 147 during its transit 
through the golgi and two divergent pathways regulate CD1147 glycosylation status: 1) 
CD 147 associates with caveolin-1 and is escorted to the cell surface forming caveolin-l-
CD147 complexes possibly in membrane compartments adjacent to lipid rafts; 2) N-
acetylglucosaminyltransferase V initiates the addition of ~ 1 ,6-branched polylactosamine-
type sugars on CD147, forming HG-CD147, which does not bind caveolin-1 and is 
thought to be the major active form of CD147 in relation to MMP induction. However, 
other studies have found that up-regUlation of caveolin-1 increases MMP synthesis (Jia et 
aI., 2006). Further clarification of this mechanism is needed as these authors previously 
published apparently contradictory data suggesting that HG-CD147 associated with 
caveolin-1and that the majority of the identified CD147-caveolin-1 complex was isolated 
6 
after cell surface biotinylation (Tang and Hemler, 2004). However, there may be a small 
sub-population of caveolin-l in the golgi that regulates CD 147 glycosylation distinct 
from caveolin-l pools present on the cell surface. Alternatively, a less clarified 
mechanism has also suggested that hypoxia increases the HG-CDI47 glycoform, which is 
independent of an increase in transcription (Floch et aI., 2011). 
Regulation of CD147 Expression 
Transcriptional Regulation 
As mentioned previously, prior characterization of the promoter region ofCD147, 
t. ,J, 
consisting of 950 base pairs (bp) upstream oftQe-~nscription start site, revealed that it is 
enriched in a CGI and contained consensus binding sites for the transcription factor (TF) 
specificity protein 1 (Spl) and activator protein 2 (AP-2) (Guo et aI., 1998). Subsequent 
promoter analysis demonstrated that a fragment 471 bp upstream of the previously 
identified coding region was necessary to mediate CD147 trans<!ription: deletion analysis 
of this fragment revealed that a 30 bp element from -142 to -112 bp, containing 
overlapping binding sites for Sp 1, AP-l, early growth response protein 2 (EGR2), and 
transcription factor II (TFII), was sufficient to initiate CD 147 transcription. Of these 
potential regulatory TFs, only Spl demonstrated binding to the 30 bp region and 
cooperated with Sp3 to augment CD147 transcription. Interestingly, this study also 
identified a negative regulatory element in the 5' -flanking segment consisting of the -
1413 to -1024 bp region, though this regulatory region needs further evaluation (Liang et 
ai.,2002). Further studies, demonstrated that a 66 bp region (-108 to -42) containing the 
7 
third Sp 1 binding site, was the minimal essential element needed to regulate constitutive 
CD147 expression (Kong et aI., 2011b). Though Spl appears to be the main 
transcriptional regulator of CD147, other studies also support a role for EGR2 (Dai et aI., 
2012). In addition to this first recognized promoter, a new study found that an alternative 
promoter located in the -656 to -473 bp region upstream of exon 1 regulated CD 147 -3/4 
expression, which was distinct from the promoter regulating CDI47-1/2 (Liao et aI., 
2011). 
Due to the fact that Sp 1 binds to CpG motifs present in CGIs, which can be 
epigenetically modified by methylation, Sp I-mediated transcriptional initiation can be 
regulated by altered binding affinity to methylated CpG motifs present in promoters 
t· :"J 
(Deaton and Bird, 2011). In support of this, t~/C,/)I47 promoter was found to be 
hypomethylated in cancer tissue compared to normal tissue, resulting in increased Sp 1 
binding and subsequently increased CDI47 expression (Kong et aI., 2011a). This 
evidence clearly supports the idea that CDI47 expression iJ regulated via Spi-mediated 
events. Although previous studies demonstrated that Sp 1 is a ubiquitous TF that is a 
constitutive activator of housekeeping genes, accumulating evidence now suggests it is 
also involved in the regulation of inducible genes (Wierstra, 2008). 
In addition to SpI, CD147 has been shown to be regulated by Snail-l (Snail) 
(Kuphal et aI., 2005) and Snail-2 (Slug) (Wu et aI., 2011a), TFs that orchestrate the 
epithelial-mesenchymal transition (EMT). The latter study by Wu et. al determined that 
Slug, but not Snail, binds to an E-box 2 domain located in a 306 bp region of the CD 147 
promoter (-644 to -338), which results in CDI47 transcription. Interestingly, 
transforming growth factor-beta (TGF-~)-induced CDI47 expression was attenuated by 
8 
knockdown of other EMT-related TFs, such as ZEB-l and ZEB-2; this down-regulation 
of CD147 may be due to upstream regulation of factors that directly bind to the CD147 
promoter rather than direct promoter activation. A possible association between the E-
twenty six (ETS) TF family member PEA3 and CD147 may exist, but this study only 
demonstrated a co-staining pattern in tumor tissues (Davidson et ai., 2003b). Treatment 
of ovarian cancer cells with signal transducers and activators of transcription 3 (ST AT3) 
decoy oligodeoxynucleotides resulted in decreased CD147 expression, suggesting that 
STAT3 may have a role in regulating CD147 transcription (Zhang et aI., 2010). In 
addition, a transcriptionally active fragment of Sterol-Carrier Protein 2 (SCP-2), which 
regulates cycling of endogenous cholesterol between membrane compartments, thus 
altering cholesterol metabolism, was found to incr~'ase CD 147 transcription (Ko and 
1-- I, 
,- "' '0,,1 '1',' ; /r 
Puglielli,2007). This study identified a high affinity binding site in the -245 to -95 bp 
region and a low affinity binding site between the -392 to -242 bp region in the CD147 
promoter. A recent study employing a 1 kb fragment upstr~am of the mouse CD147 
coding sequence found an E2F binding site that mediated nitric oxide (NO)-induced 
\ 
repression of CD 147 in cardiomyocytes, which was dependent on a cyclic guanosine 
monophosphate (cGMP)-dependent protein kinase G (PKG) pathway (Tarin et aI., 2011). 
Thus, it is clear that many transcriptional regulators influence CD 147 expression in 
various cellular contexts. 
Control of CD147 expression by cis-regulatory elements and sequence 
variations/polymorphisms has also been described. Recently, the seed regions of let-7, a 
tumor-suppressive non-protein coding microRNA (miRNA) family, was shown to have 
complementary sequence to the 3' -UTR of CD 147, with let -7b being the most 
9 
complementary (Fu et aI., 2011a; Fu et aI., 2011b). In addition, miRNA-492 was found 
to interact with the CD 147 3' -UTR; interestingly, the efficiency to suppress CD147 
expression was dependent on a single nucleotide polymorphism (SNP) located at the 4th 
nucleotide complementary to the miRNA-492 seed region (Wu et aI., 2011 b). It is 
thought that --2-6 contiguous base pairs in the seed region of miRN As are needed for 
effective miRNA-mRNA duplex formation and target suppression (Brodersen and 
Voinnet, 2009), hence the SNP in the miRNA-492 binding site may alter affinity to the 
CD 147 3' -UTR resulting in differential suppression of CD 147. Other SNPs located in 
the membrane-proximal IgI domain and 3'-UTR have been shown to alter CD147 
expression in the equine genus (Koho et aI., 2012), though the relevance in humans is 
currently unknown. .,. ;'J 
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Regulators o(CD147 Upstream of Transcription Factors 
Many studies have identified factors upstream of the CD 147 transcription 
1 
initiators and repressors mentioned above. Some of the earliest studies identified an 
\ 
increase in CD147 expression after activation of lymphocytes with granulocyte 
macrophage colony-stimulating factor (GM-CSF), concanavalin-A or 
phytohemagglutinin (Kasinrerk et aI., 1992; Paterson et aI., 1987). Additionally, 
endothelial cells that invaded co-cultured brain tissue demonstrated increased CD 147 
expression (Risau et aI., 1986). These earlier studies set the premise that CD147 may be 
an inducible molecule in both physiological and pathological contexts. 
Over the years many soluble factors such as growth factors, cytokines and 
hormones have been shown to regulate CD147 expression (see Table 1-1). In breast 
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cancer cells, epidermal growth factor (EGF) and amphiregulin induced the expression of 
CD147 via a EGF receptor (EGFR) kinase activation pathway (Menashi et aI., 2003; Xu 
et aI., 2011). In addition, TGF~ induced CD147 expression via a phosphatidylinositol-3-
kinase (PI3K) -Akt pathway in hepatocytes (Wu et aI., 20lla). 
Since CD147 most likely has a role in inflammation, ischemic injury, 
atherosclerosis, rheumatoid arthritis and tissue repair (Gabison et aI., 2009; Yan et aI., 
2005), it is no surprise that it is regulated by inflammatory mediators. A coculture model 
between macrophages and breast or ovarian cancer cells demonstrated that cancer-
associated CD147 is induced via a tumor necrosis factor alpha (TNFu)-c-Jun-N-terminal 
kinase 2 (JNKII)-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KP) 
pathway (Hagemann et aI., 2005). CD147 is;reglijftted by hydrogen peroxide (Siwik et 
aI., 2008) and the cytokine interleukin-18 (IL-18) in both cardiomyocytes (Reddy et aI., 
2010) and smooth muscle cells (Venkatesan et aI., 2009). Preliminary evidence suggests 
that IL-l may also regulate CD 147 expression in corneal fi~roblasts, though in other cell 
types this does not seem to be the case (Braundmeier et aI., 2006; Gabison et aI., 2009). 
Another cytokine that regulates CD147 expression is receptor activator of NF-K~ ligand 
(RANKL), an osteoclastogenic mediator involved in bone remodeling in physiologic and 
pathologic states (Rucci et aI., 2010; Si et aI., 2003). Furthermore, in support of CD147 
involvement in inflammation, treatment of cells with C-reactive protein (CRP) induced 
CD147 transcription (Abe et aI., 2006) and iron deficiency upregulated CD147 via a p38-
NFK~ related pathway (Fan et aI., 20llb). NO treatment negatively regulated CD147 
expression in cardiomyocytes, but had no regulatory role in macrophages, indicating cell-
type specific regulation (Tarin et aI., 2011). A recent finding also suggested a role for 
11 
prostaglandin E2 in regulating CD147 expression and this may involve an interaction 
with the non-tyrosine kinase c-Src (Lee et aI., 2011). 
Regulation of CD147 by sex hormones has been suggested by studies involving 
analysis of the menstrual cycle, pregnancy, and peri-implantation events. These studies 
found that CD147 expression was induced by both estrogen and progesterone, with the 
latter possibly regulating post-transcriptional glycosylations of the core protein 
(Braundmeier et aI., 2006; Noguchi et aI., 2003; Xiao et aI., 2002). Analysis of estrogen 
receptor (ER)-a or -~ null mice demonstrated that CD 147 is regulated by ERa in select 
tissues, whereas in others it is independent of estrogen signaling. Furthermore, the 
regulation of CD 147 expression seemed to be at the translational level rather than 
... ', 
transcriptional (Chen et aI., 2010). Other horm9~-that have been shown to regulate 
CD147 expression include the peptides Thyroid-stimulating hormone (TSH) (Fanelli et 
aI., 2003; Nehme et aI., 1995) and Angiotensin II (Pons et aI., 2011; Yang et aI., 2010a). 
Also, somatostatin was shown to increase CD 147 cell surfate levels in intestinal 
epithelial cells (Saksena et aI., 2009). Interestingly, these hormones signal through G 
protein-coupled receptors (GPCRs), suggesting CD 147 can be modulated via this 
pathway_ 
Other pathways that have been shown to regulate CD147 expression include: the 
Protein Kinase C delta (PKC8)-ERK pathway in activated macrophages (Wang et aI., 
2011 b) and ~6 integrin-Fyn kinase signaling in oral squamous cell carcinoma (Ramos 
and Dang, 2011). Elevated expression of the scaffold protein receptor for activated 
protein kinase C 1 (RACK 1) was shown to increase CD 147 expression in breast cancer 
(Cao et aI., 2010). Also, Notch1 signaling has been shown to regulate CD147 expression 
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in breast cancer, though the exact mechanism of regulation is currently unknown (Wang 
et aI., 2011a). An additional mechanism regulating CD147 expression is a positive 
feedback mechanism. This was demonstrated by treating fibroblasts with a recombinant 
soluble form of the extracellular domain of CD 147 (rbCD 147), which in turn, increased 
CD147 transcription (Tang et aI., 2004b). 
Interestingly, CD147 also appears to be regulated by several molecules involved 
in cell metabolism. As mentioned above, CD147 is regulated by a transcriptionally-
active fragment of SCP-2, a protein involved in cholesterol metabolism (Ko and Puglielli, 
2007) as well as TSH, a hormone that regulates global metabolism (Fanelli et aI., 2003; 
Nehme et aI., 1995). In this latter case, TSH induced CD147 expression in thyroid cells 
t· ,", 
via a cyclic adenosine monophosphate (cAMP}~~~}tited pathway, but interestingly this 
regulation was at the post-transcriptional level. Also, peroxisome proliferator-activated 
receptor alpha and gamma (PPARa/y) TFs have been shown to regulate CD147 
expression, with the latter suppressing CD147 translation irl activated macrophages (Ge 
et aI., 2007; Konig et aI., 2010). In relation to this aforementioned regulatory network, 
up-regulation of PPARy-coactivator 1 alpha (PGC-1a) resulted in elevated CD147 
expression in skeletal muscle cells (Benton et aI., 2008). Additionally, the adipocytokine, 
nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme involved in generating 
nicotinamide adenine dinucleotide (NAD), has been shown to increase CD147 expression 
via an ERK-p38-NF-K~ pathway (Fan et aI., 2011a). In a recent study, it was 
demonstrated that elevated glucose concentration induces CD 147 transcription (Bao et 
aI.,2010). This compilation of data strongly suggests that CD147 may be a protein 
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related to the cellular response of metabolic stress or aids in the general metabolism of 
the cell. 
In addition to being regulated by soluble factors that activate various signaling 
pathways, CD147 expression and cellular localization is determined by protein binding 
partners. One of the most studied and best characterized binding partners of CDl47 are 
the family of MonoCarboxylate Transporters (MCTs). MCTs are proton-coupled 
transporters that mediate transit of L-Iactate, pyruvate, and ketone bodies across the 
plasma membrane (Halestrap, 201Ia). Earlier studies indicated that CDl47 is tightly 
associated with MCT1 and MCT4 via a transmembrane/cytoplasmic domain interaction 
(Kirk et aI., 2000), which was later determined to be mediated mainly by hydrophobic 
" :', 
interactions in the c-terminal aspect of the tran8;Ul~fobrane domain rather than ionic 
interactions with the glutamate residue (Finch et aI., 2009; Wilson et aI., 2009). This was 
later followed up with a fluorescence resonance energy transfer (FRET) study 
demonstrating that CD147 and MCTs interact and form a hJterotetramer complex 
consisting of two central oligomerized CD147 molecules associated with peripherally 
localized MCTs (Wilson et aI., 2002). 
As it is clear that CD147 and the MCT isoforms 1,3, and 4 associate (Halestrap, 
201Ia), other studies evaluated whether either interacting member regulated expression 
or localization of the other. Knockdown of MCT I expression resulted in an alteration of 
the CDl47 glycoforms expressed, with a proclivity to accumulate the high-mannose form 
of CD147 relative to the highly-complex branched glycoform (Deora et aI., 2005); 
interestingly no changes in mRNA were found with MCTI knockdown, indicating 
regulation at the post -transcriptional level. In addition to regulation of CD 147 protein, 
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specific membrane localization to the basolateral (BL) membrane was determined by 
dominant BL signals in MCT3 and MCT4, whereas CD147 contains a dominant BL 
signal at leucine 252 (Deora et a!., 2004) that directs MCTllocalization. MCT3 
knockout mice supported this conclusion as well, as they demonstrated reduced CD 147 
trafficking to the basolateral membrane (Daniele et aI., 2008). A similar study found that 
depletion of MCT4 in metastatic breast cancer cells resulted in an enrichment of the high 
mannose glycoform of CD147, which did not traffic to the cell surface and remained 
confined to the endoplasmic reticulum; this study also found that there was no difference 
in mRNA levels of CD147 (Gallagher et a!., 2007). Also, knockdown of CD147 resulted 
in decreased MCT4 protein, but not message, and caused an enrichment of MCT4 in 
endolysosomes, possibly leading to increased MCT4 degradation. Other studies also 
"~~I ~i/~ 
found that a dual knockdown ofMCTI and MCT4 resulted in decreased CD147 
expression and surface localization (Floch et aI., 2011). 
Additional studies have suggested that CD147 exprJssion is necessary for MCT 
membrane localization and this seems to be independent of the G;harged glutamate residue 
imbedded in the CDI47 transmembrane domain (Deora et aI., 2005; Kirk et aI., 2000; 
Manoharan et a!., 2006). This is further supported by studies demonstrating that CD147-
null mice were found to have decreased surface expression of MCT 1/3/4, even when 
MCT transcription was still present (Philp et aI., 2003). A recent study demonstrated that 
the affinity of interaction between CD 147 and MCT 1 is moderate ( --1 ~M), 
approximately the same as for an antibody-antigen complex (Howard et aI., 2010). This 
compilation of data strongly suggests that CD147 and MCTs regulate each other post-
transcriptionally and act as co-chaperones. 
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Another protein class that regulates CD 147 cell surface expression is the 
cyclosporine A-sensitive (CspA) cyclophilin protein family. Cyclophilins contain 
peptidyl-prolyl cis-trans isomerase (PPlase) activity, are known to regulate protein 
trafficking, and act as intercellular mediators in inflammatory events (Yurchenko et aI., 
2010). Earlier studies found that CD147 cell surface expression was decreased by 
treatment with the immunosuppressive drug CspA (Yurchenko et aI., 2005) and that the 
proline 211 residue located near the CD147 transmembrane domain facilitates interaction 
with Cyclophilin 60 (Pushkarsky et aI., 2005), which may be involved in escorting 
CD147 to the cell surface. 
Membrane-type 1 MMP (MT1-MMP; MMP-14) has been shown to associate with 
CD 147 at the cell surface and decreases cell sur:£a~>CD 147 by cleaving it in the linker 
'j 
region between the Ig-like domains (Egawa et aI., 2006). Further analysis demonstrated 
that CD147 associated with both the pro and active forms ofMT1-MMP (Niiya et aI., 
2009). Surface expression ofMTI-MMP is tightly regulatetl by protease-mediate 
cleavage of the propeptide during transport from the golgi to the. plasma membrane 
(Zucker et aI., 2002). Thus, association ofCD147 with the pro and active form ofMTl-
MMP may indicate a role in regulating cell surface expression of one another. 
Studies evaluating the turnover of CD147 are scant. One study suggests that 
CD147 is ubiquitinated and degraded in the proteasome. They further suggested that this 
is regulated by the enzyme ubiquitin carboxyl-terminal esterase L1 (UCH-L1) and N-
glycosylation (Wang et aI., 2008), where decreased glycosylation increases CD147 
ubiquitination and subsequent degradation. Furthermore, another study suggested that 
CD147 does not appreciably localize in lysosomal compartments following 
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internalization (Eyster et aI., 2011). An opposing study suggests that CD147 is 
downregulated via a p53-mediated lysosomal pathway instead of a proteasomal 
degradation mechanism (Zhu et aI., 2009). Thus, it remains unclear as to which pathway 
CD147 is primarily degraded. 
It is apparent that CD 147 is regulated by complex signaling networks in different 
physiological, pathological and tissue-specific contexts. The regulation of CD147 
expression by various transcription factors, soluble mediators and binding partners 
underscores the complexity of CD 147 function. 
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Table 1-1. Regulators of CD147 Expression and Localization. 
Regulator Pathway Message/Protein/Both Surface/Soluble Cell Type 
GM-CSF - - l' Surface levels lymphocyte 
EGF/Amphiregulin EGFR l'Both - Breast cancer 
TGF~ PI3K/Akt l'Both - Hepatocyte 
VEGF-O - - l' Surface levels Endothelial 




Il-18 PI3K/ Akt-ERK; l'Both Smooth muscle; 
JNK/Sp1 - cardiac muscle 
RANKl - l'Both - Breast Cancer 
C-reactive protein l'Message - Macrophage 
Iron deficiency p38- NF-K~ l' Both - Macrophages 
Nitric oxide cGMP -J., Message - Cardiac muscle 
PGE2 (decreased) c-Src -J., Protei n - Endometrial and 
Stromal 
Estrogen - l'Message Reproductive 
ERa - l'Message Reproductive 
(tissue specific) 
Progesterone - Post-transcription ..... - Reproductive 
TSH cAMP Post -transcr+ption;.fi~: 0 - Thyroid cells 
Angiotensin II COX-2-PGE2; l' Both; message - Macrophages; 
p38-ERK RPE 
Somatostatin - - l' Su rface levels Intestinal 
SCP-2 - l'Message - -
PPARy NF-K~ -J., Protein - Macrophage 
PPARa l'Message l - Hepatocytes 
PGC-1a - l' Protein - Skeletal muscle 
RACK1 - l' Protein - Breast cancer 
STAT3 (decreased) - -J., Protein - \ Ovarian cancer 
NOTCH - -J., Protein - Breast cancer 
(decreased) 
Glucose (high) - l' Both - Monocytes 
C0147 - l' Both l'Soluble Co-culture breast 
C0147 cancer w/ 
fibroblast 
NAMPT p38- NF-K~ l' Both - Macrophages 
MCT1 (decreased) - Post-transcription -J., Surface levels Various cells 
Cyclophilin 60 - - l' Surface levels Various cells 
MT1-MMP - - l'Soluble Various cancers 
C0147 
See text for references. 
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CD147 Expression Patterns and Subcellular Localization 
Expression in Normal and Cancer Tissue 
Numerous investigators have indicated that CD 147 is expressed in various tissues. 
Earlier studies identified that CD 147 was expressed in many epithelia, neuronal, 
lymphoid and myeloid cell types (Arjonen et aI., 2011; Fossum et aI., 1991; Kanekura et 
aI., 1991; Kasinrerk et aI., 1992; Nakai et aI., 2006), though with various glycoforms. A 
tissue array analysis of CD147 expression in various normal and cancer tissues 
demonstrated that a limited number of normal cells express CD 147, whereas elevated 
expression of CD 147 was recognized in the majority of malignant cancers compared to 
their benign counterparts (Riethdorf et aI., 2006); squamous cell carcinoma (SCC), 
,. . ," ~', . 
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pancreatic, chromophobic kidney, hepatocellular ,Ifnedullary breast adenocarcinoma and 
glioblastoma multiforme demonstrated the highest incidence of expression. 
Expression of CD147 was found to have negative prpgnostic value for patients 
with serous ovarian carcinoma (Davidson et aI., 2003a), breast cancer (Liu et aI., 2010; 
\ 
Reimers et aI., 2004), acute lymphoblastic leukemia (Beesley et aI., 2005), clear cell renal 
cell carcinoma (Jin et aI., 2006), hepatocellular carcinoma (Zhang et aI., 2006), gastric 
carcinoma (Zheng et aI., 2006), endometrial carcinoma (Ueda et aI., 2007) lung 
adenocarcinoma (Sienel et aI., 2008), differentiated thyroid carcinoma (Tan et aI., 2008), 
colorectal cancer (Buergy et aI., 2009), prostate cancer (Han et aI., 2009), adenoid cystic 
carcinoma of salivary glands (Yang et aI., 2010b) and pediatric medulloblastoma (Chu et 
aI., 2011). In addition to relative expression levels in tumor tissue samples, specific 
localization of CD147 to plasma membrane was a strong prognosticator for survival in 
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lung adenocarcinoma in the absence of increased CD147 expression (Sienel et aI., 2008). 
Similarly, a borderline relationship between overall survival and surface CD147 staining 
was identified in laryngeal SCC (Rosenthal et aI., 2003). 
Characterization of Cytoplasmic CD147 
In support of the histological studies above, CD 147 localization was originally 
identified on the cell surface with a proclivity to localize at cell-cell interfaces (Ellis et 
aI., 1989; Hubbard et aI., 1985; Schlosshauer et aI., 1995). As imaging techniques have 
improved, it is becoming clearer that CD 147 is also localized in the cytoplasm of various 
cells. The characterization of these cytoplasmic CD147-positive signals is just 
beginning. A novel study by Eyster et al. found that an Arf6-GTPase mutant expressed 
t. of,' • 
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in HeLa cells led to enlarged vacuolar-type stru;ctJres enriched with clathrin-independent 
endocytic (CIE) cargo; in this study, they found that CD147, CD44, CD98 and GLUT 1 
were novel cargo internalized via CIE (Eyster et aI., 2009). Interestingly, they found that 
l 
CD147, CD44 and CD98 rapidly joined the recycling tubular endosomes via the 
\ 
juxtanuclear endocytic recycling compartment; this rapid transit, in contrast to other CIE 
cargo, may be due to the dynamic processes each of these proteins take part in, such as 
nutrient uptake and ECM remodeling. Additional studies found that CD 147 did not sort 
to late endosomes and therefore did not appear to be degraded by I ysosomes; cell surface 
expression of CD 147 was minimally affected by up-regulation of membrane-associated 
RING-CH E3 ubiquitin ligases, which reduced surface expression of other CIE cargo 
members (Eyster et ai., 2011). Other studies have recognized that CD147 requires 
clathrin-dependent sorting to localize to the basolateral membrane, but is independent of 
the adaptor protein AP1B (Castorino et aI., 2011; Deborde et aI., 2008). Thus, it appears 
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that CD 147 may recycle from the cell surface rapidly and in some cells this mayor may 
not rely on clathrin. 
Characterization of Extracellular Vesicle-associated CD147 
In addition to cytoplasmic vesicular localization, CD 147 has also been identified 
in extracellular vesicles. In the initial characterization of CD147 in cancer, it was 
recognized that it was also present in tumor-conditioned media (Ellis et aI., 1989). 
Subsequent studies suggested that CD147 was released from the cell surface in a full 
length soluble form (Taylor et aI., 2002) or a 22-kDa proteolytic cleavage product 
(Egawa et aI., 2006) not associated with vesicles; whereas another study demonstrated 
that CD 147 was associated with an ERK -dependent ~eleased microvesicle, but the vesicle 
,.. :", 
degraded releasing CD147 into the media (sidh~~al., 2004). Microvesicle-associated 
CD147 was shown to be released from ovarian cancer cells and this elicited an 
angiogenic phenotype in endothelial cells (Millimaggi et aI., 2007). Since lipid rafts may 
1 
be a point of origin for microvesicles (Muralidharan-Chari et aI., 2010), preceding 
\ 
CD 147 accumulation in lipid rafts may lead to enrichment of CD 147 in microvesicles. 
Other studies have found that CD 147 localizes in exosomes, which arise from 
inward budding of endosomal membranes forming a late-endosome-associated 
multivesicular body (MVB). Those MVBs that do not fuse with lysosomes, may act as a 
temporary storage compartment that can later fuse with the plasma membrane releasing 
exosomes (Stoorvogel et aI., 2002). CD147 has been found in exosomes derived from 
the malignant ascites of ovarian cancer patients (Keller et aI., 2009) and in bladder cancer 
(Welton et aI., 2010). In addition, CD147 is enriched in exosomes released by 
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cardiomyocyte progenitor cells, which stimulated endothelial cell migration (Vrijsen et 
aI.,2010). Currently, the exact mechanism regulating the release of CD147 from the cell 
surface or how vesicle-associated CD 147 functions in various aspects of cell biology is 
unknown. 
The Multi-functional Nature of CD147 Biology 
CD147 Function Identified in Knockout Models 
It is clear that CD147 is a ubiquitously expressed molecule attributed with many 
biological functions in physiologic and pathologic contexts. Two of the earliest credited 
, . .. ~', 
functions of CD147 include a MMP-inducer ori~t~or cells (Ellis et aI., 1989) and a cell 
recognition molecule involved in neuronal-glial patterning and aggregation (Fadool and 
Linser, 1993). Subsequently, more understanding of the role of CD147 in cell biology 
came from knock-out mice and mutant Drosophila strains. 1 
Mice lacking the CD147 gene display a variety of adverse phenotypes. 
Experiments revealed that the majority of CD 147 -null embryos died around the time of 
initial blastocyst implantation, though different unknown modifier regions surrounding 
the CD147 gene may attenuate this death rate (Chen et aI., 2004), and the few that 
implanted subsequently died at post-implantation (Igakura et aI., 1998). In the rare event 
that an embryo successfully implanted, the offspring were small in size and usually died 
before one month due to difficulty of breathing attributed to interstitial pneumonia. It 
was also noted that the surviving male CD 147-null mice were sterile due to 
spermatogenesis arresting in meiosis I and female null mice have problems with 
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fertilization (Igakura et aI., 1998; Kuno et aI., 1998). Further studies revealed that 
CDl47-null mice have abnormalities in spatial learning, memory, and sensory perception 
to painful stimuli and noxious odors (Igakura et aI., 1996; Naruhashi et aI., 1997). 
Additionally, CDl47-null animals displayed an exacerbated mixed lymphocyte reaction, 
an assay that measures susceptibility to graft rejection via incompatibilities in major 
histocompatibility complex antigens (Igakura et aI., 1996) and when challenged with 
ligation of the ureter they demonstrated less fibrosis, matrix remodeling, and infiltration 
of macrophages (Kato et aI., 2011). 
Other studies with CD 147 -null mice found delayed entrance into dark 
compartments, which led to subsequent studies describing retinal dysfunction as early as 
.' :If 
five weeks leading to blindness (Hori et aI., ~~Ochrietor et aI., 2001; Ochrietor et aI., 
2002). In light of this identified vision impairment, earlier studies demonstrating 
neurological deficits may be due to preceding vision abnormalities, since the mice used in 
the behavioral studies were 3-5 months old (Naruhashi et ai., 1997), whereas functional 
retinal abnormalities were identified as early as eye opening (Ochrietor et aI., 2002). One 
of the main mechanisms suggested to contribute to retinal pathology in CD 147 -null mice 
is a disturbed metabolic interface between cellular constituents regulating retinal 
physiology; this is attributed to reduced MCT surface expression (Ochrietor and Linser, 
2004; Philp et aI., 2003). As mentioned previously, CD147 participates in a co-
chaperone relationship with MCT1, MCT3, and MCT4 and this was further confirmed in 
vivo with a studying identifying a similar relationship across a diverse set of specific 
tissue and cell types (Nakai et aI., 2006). These results in conjunction with the various in 
vitro studies strongly support a role of CD147 in regulating MCT surface expression. 
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Evaluation of CD147 function in other model systems revealed additional 
biological roles. Up-regulation of CD147 in High five insect cells causes a drastic 
change in cytoskeletal organization characterized by an induced elaborate microfilament 
and microtubule network, which seemed to be independent of cell contact or conditioned 
media from CD 147-upregulated cells (Curtin et aI., 2005). Depletion of CD147 in 
Drosophila has also revealed several other interesting phenotypes. For instance, CD147-
null fruit flies are embryonic lethal and flies manipulated to lack CD147 only in the eye 
demonstrate that CD 147 regulates cell architecture. These studies found that the absence 
of CD 147 in photoreceptors leads to misplacement of nuclei, rough endoplasmic 
reticulum and mitochondria, possibly due to perturbed interactions with integrins; 
interestingly these phenotypes could be rescued-with the mouse CD147 gene. Additional 
,. .. l • 
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phenotypes identified in CD 147 -depleted flies include misplaced epithelial glia cells 
surrounding photoreceptors, altered synaptic vesicle release, and a greatly reduced 
presence of glial capitate projections induced by CDI47-as~ociated photoreceptors 
(Curtin et aI., 2007). Other studies further identified that CD147 may act in a cell-cell 
interaction module in the neuromuscular junction by regulating synaptic cytoskeletal 
architecture and vesicle dynamics (Besse et aI., 2007). A study screening mutations in 
CD 147 identified that specific residues in the extracellular domains and transmembrane 
domain are vital for proper function (Munro et aI., 2010), yet other studies also suggest a 
prominent role for the conserved YEKRRK sequence in the cytoplasmic tail of CD 147 
for function (Besse et aI., 2007). These studies suggest that CD147 has a role in 
regulating the cytoskeleton, cell-cell interaction modules, and vesicle distribution, 
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implying that CD147 may have an essential role in linking organization on the plasma 
membrane with cytoplasmic vesicular networks. 
The Role of CD147 in Cancer Progression 
Tumor cells co-opt many physiological processes and use them to their advantage 
as they attempt to survive, expand, and spread to other tissue compartments. CD147 is 
highly enriched on the surfaces of many cancer types and plays a role in many aspects of 
cancer progression. The following section will review the pleiotropic roles of CD 147 in 
relation to the various mechanisms of tumor evolution and maintenance. 
Cancer Migration and Invasion 
Cellular migration and invasion defined as cell motility and migration through or 
within a barrier, respectively, constitutes an essential biological mechanism used in many 
1 
diverse physiological and pathological situations by various cell types. In epithelial 
cancer, cells depart from the primary tumor bulk by utilizing diverse migratory and 
invasive mechanisms (Yilmaz and Christofori, 2009). In order for cancer cells to 
successfull y metastasize and colonize distant sites, several obstacles must be surmounted: 
they must detach from neighboring cells, break down the local basement membrane, 
activate programs to resist anoikis, migrate and invade through surrounding tissue, gain 
entry into the circulation via lymphatic or endothelial channels, survive mechanical or 
immune-mediated destruction in transit through the circulation, extravasate into a new 
tissue microenvironment, adapt their metabolic phenotype to different surrounding 
nutrient gradients, and recruit supportive stromal cells to the new microenvironment to 
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generate a macroscopic tumor (Chaffer and Weinberg, 2011). Many of the initial steps of 
the metastatic cascade are believed to involve transitions in cellular programs that support 
an increased migratory capacity. Cancer cells have been shown to utilize diverse modes 
of movement, including mesenchymal, amoeboid and collective migration (Sahai, 2005). 
Mesenchymal Movement 
Single cell mesenchymal movement in epithelial cells is believed to be initiated 
during the epithelial-mesenchymal transition (EMT). Established hallmarks of EMT 
include: 1) down-regulation of characteristic cell junctional proteins, 2) increased 
expression and nuclear translocation of several EMT -promoting transcription factors, 
including ~-catenin and the T cell factor/l ymph0Cyte enhancer factor 1 (TCF/LEF 1) 
""~I ~i> 
complex, Snail, and Twist, 3) alterations in cytoskeletal arrangements and protein 
expression, 4) loss of cell polarity, 5) and up-regulation of proteases (Teng et aI., 2007). 
Recently, EMT programs were classified into 3 distinct gropps: 1) EMT involved in 
embryonic implantation and development, 2) EMT involved in wound repair/tissue 
regeneration, and 3) EMT involved in cancer invasion and metastasis; though, these are 
separate biological processes, they most likely have many interrelated signaling networks 
(Kalluri and Weinberg, 2009). Recent evidence also suggests that the EMT program may 
endow cells with a stem-like quality, which has been demonstrated to promote increased 
tumorigenicity, invasiveness and therapy resistance (Dave et aI., 2012). 
Interestingly, CD147 has been shown to regulate biological processes in each of 
these EMT classifications (Gabison et ai., 2009; Igakura et aI., 1998; Zucker et aI., 2001). 
CD147 has been shown to be regulated by the EMT-promoting TF Snail in melanoma 
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cells (Kuphal et aI., 2005) and may be involved in an EMT-like process during 
embryonic stem cell differentiation (Ullmann et aI., 2008). A role for CD147 in EMT 
was recently identified in hepatocytes where up-regulation of CD147 initiated a TGF-~ 
signaling cascade resulting in Slug up-regulation, cadherin switching and morphological 
changes (Wu et aI., 2011a). Whether CD147 is involved in EMT in other cell types is 
unknown. A direct link has also been suggested between EMT and resistance to anoikis, 
a cell death process initiated upon detachment from a supportive ECM potentiating 
survival signals (Onder et aI., 2008). Up-regulation of CD147 in breast cancer cells 
confers resistance to anoikis (Yang et aI., 2006) facilitating survival during matrix 
detachment in invasion. 
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Amoeboid Movement 
Amoeboid cellular movement acts as another mechanism of single cell motility. 
This migratory mechanism is characterized by a plastic rouJtded morphology and 
intermittent actomyosin-regulated blebbing with little dependence on protease activity 
(Sanz-Moreno and Marshall, 2009). It is clear that cell migratory phenotypes exist as a 
fluxing continuum between different forms of membrane protrusion and contraction 
states, which are regulated by diverse signaling and physical matrix cues (Friedl and 
Wolf, 2009). Recently, it was demonstrated that the interplay between mesenchymal and 
amoeboid movement is regulated by the signaling activity differences in the Rho protein 
family members. Guanine nucleotide phosphate (GTP)-bound proteins are regulated by 
GTP exchange factors (GEFs) and GTPase activating proteins (GAPs), which promote 
activation and inactivation, respectively (Vigil et aI., 2010). Inasmuch, amoeboid 
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movement is promoted when Rho-kinase (ROCK) signaling activates a Rac GAP and 
mesenchymal movement is stimulated with increased Rac activity, which in turn 
suppresses amoeboid motility; this study strongly supports the notion that cancer cells 
interconvert their migratory phenotypes (Sanz-Moreno et aI., 2008). 
A new mechanistic study provides evidence that CD 147 can inhibit 
phosphorylation of Annexin II (AnxA2), which leads to attenuation of ROCK-mediated 
suppression of mesenchymal motility. Furthermore, they also found that up-regulation of 
CD147 increased Rae activity and Wiskott-Aldrich syndrome protein family member 2 
(W A VE2) expression and membrane localization, which led to actin polymerization, 
lamellipodia formation and a mesenchymal morphology (Zhao et aI., 2011). In a separate 
study in cardiomyocytes, CD147-induced functi()n~, w'ere also shown to be dependent on 
"'J~J ~i;' 
Racl activity (Venkatesan et aI., 2010). These studies suggest that CD147 may playa 
role in modulating the interconversion of individual cell migratory phenotypes via 
regulation of Rac signaling events. 
Cellular Protrusions Involved In Cell Migration/Invasion 
Filopodia 
It has been suggested that concomitant with the mesenchymal transition and 
migratory phenotype, cells also utilize finger-like projections called filopodia to probe 
and explore the surrounding microenvironment (Yilmaz and Christofori, 2009). 
Filopodia are protrusions extending from the plasma membrane, usually originating from 
lamellipodia, that are composed of parallel actin filaments bundled by cross-linking 
proteins (Arjonen et aI., 2011). Filopodia formation may serve as a precursor for cell-
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ECM adhesion, thus promoting cell migration (Faix et aI., 2009). Increased presence of 
filopodia formation promotes migration (Zhang et aI., 2004) and increased filopodia have 
been seen at the invasive front of colorectal cancer cells, indicating that filopodia may 
facilitate the invasion process (Vignjevic et aI., 2007). In support of this, a subset of 
filopodia have been found to have invasive characteristics in 3D culture and may have a 
role in invadopodia (see below) and mesenchymal invasion (Li et aI., 2010). Knockdown 
of CD147 in prostate cancer cells resulted in a --.J50% decrease in filopodia formation 
(Zhu et aI., 2011) and up-regulation of CD147 in insect cells resulted in similar protrusive 
structures (Curtin et aI., 2005). Fascin, the major actin-bundling protein in filopodia may 
interact with CD147 in promoting aggressive cancer types (Tsai et aI., 2007), though 
further research is needed to elucidate possible molecular interactions between the two. 
"'~'~I ~i:-
Invadopodia 
In the early 80's investigators identified that Rous s~rcoma virus (v-src)-
transformed cells cultured on 2D substrata form ventral protrusions located at points of 
cell-ECM contact, which are enriched in actin and tyrosine phosphorylated proteins. 
Subsequently, these protrusions were found to degrade the ECM at cell contact points and 
thus were termed invadopodia (Chen et aI., 1985). Other investigators found that similar 
protrusions could be formed in osteoclasts, macrophages, dendritic cells, endothelial 
cells, and vascular smooth muscle cells, yet these structures are termed podosomes. 
Recently, it has been suggested that the term 'invadopodia' be reserved for cells with 
transformed properties and the term 'podosome' for normal cells (Murphy and 
Courtneidge, 2011). Due to the presence of these degradative protrusions in both normal 
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and tumorigenic cells, much effort is focused on their potential roles in regulating 
physiological and pathological invasive processes. 
Over the past couple of decades, it has become clear that invadopodia contain an 
actin-rich core inundated with modulators of actin polymerization (Albiges-Rizo et aI., 
2009). Many proteins orchestrate the dynamic reconstruction of the actin cytoskeleton, 
but recent findings have identified key players in invadopodia formation. Invadopodia 
construction has been characterized into initiation, assembly and maturation stages. 
Briefl y, in the initiating stage the cancer cell attaches to the ECM and tyrosine kinase 
substrate with 5 SH3 domains (Tsk5) is recruited to phosphatidylinositol-3,4-
bisphosphate (PIP2)-enriched membranes via a Src-dependent mechanism (Oikawa et aI., 
2008), which leads to subsequent interaction Wi:tli?brtactin. Also, PIP3 may serve as an 
initiating site of invadopoda formation by activating Akt signaling (Yamaguchi et aI., 
2011). In the assembly stage, this protein complex then recruits N-WASP, Arp2/3 and 
cofilin to initiate actin polymerization (Oser et aI., 2009), which is regulated by various 
kinases, soluble mediators and actin polymerization modulators~\ In the maturation stage, 
proteases, including soluble and membrane-type MMPs, become enriched at the 
invadopodial tips and microtubules and vimentin filaments cooperate in the elongation of 
invadopodia (Schoumacher et aI., 2010). MTI-MMP appears to be a vital component of 
invadopodia degradation machinery, as several investigators have demonstrated 
decreased invadopodia activity following attenuation of MTI-MMP activity (Hu et aI., 
2011 ; Nakahara et al., 1997; Sakurai -Yageta et al., 2008). MT 1-MMP trafficking to 
invadopodia has been attributed to a diverse group of proteins, including caveolin-l 
(Yamaguchi et aI., 2009), cortactin (Clark et aI., 2007) and the conserved octameric 
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exocyst complex (Liu et aI., 2009; Sakurai-Yageta et aI., 2008). Delivery of these 
proteases to invadopodia facilitates ECM degradation and promotes the invasion process. 
Active trafficking in invadopodia is also supported by electron micrographs 
demonstrating vesicles within invadopodia (Schoumacher et aI., 2010) and a proclivity 
for the golgi to localize in close proximity to invadopodia (Baldassarre et aI., 2003). See 
a recent article by Murphy et al. for a complete review on invadopodia dynamics 
(Murphy and Courtneidge, 2011). 
Coupled with the dynamic stages described above, invadopodia may be regulated 
by various growth factors (e.g EGF) and signaling inputs (e.g. ERK) (Ayala et aI., 2007; 
DesMarais et aI., 2009; Eckert and Yang, 2011; Mader et aI., 2011), reactive oxygen 
species (Weaver, 2009), pH gradients (Busco ettaL", 2010; Magalhaes et aI., 2011), matrix 
·-"'·~I ~i;' 
composition and orientation (Alexander et aI., 2008) and lipid raft integrity (Caldieri et 
aI., 2009; Yamaguchi et aI., 2009). Thus, it is clear that myriad factors seem to converge 
and dictate the tendency of invadopodia to form and activeo/ degrade the underlying 
ECM barrier. Evidence for EMT involvement in invadopodia was identified when non-
transformed breast epithelial cells stably-expressing Twist or Snail, EMT-promoting TFs, 
formed invadopodia and may be involved in metastasis in vivo (Eckert et aI., 2011). Very 
strong evidence supporting a role of invadopodia in metastasis in vivo was recently 
demonstrated using intravital multiphoton imaging; in this study N-WASP deficient cells 
demonstrated defects in migration, invasion, intravasation and dissemination, which 
seemed to be MMP-mediated (Gligorijevic et aI., 2012). Additionally, knockdown of 
Tsk5 in zebrafish neural crest cells resulted in attenuated EMT -like migration, suggesting 
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that regulators of invadopodia may also be involved in development processes (Murphy 
et aI., 20 11 ). 
As imaging techniques have advanced, high resolution characterization of 
invadopodia dynamics is now possible in 2D and 3D models. Total internal reflection 
fluorescence (TIRF) microscopy, a technique that permits high resolution evaluation of 
events occurring directly at the cell membrane with little cytosolic noise, revealed that an 
invadopodial core attaches to the ECM, which then projects out multiple filament -like 
processes (Artym et ai., 2010); culture of cells in a 3D dermis-based matrix demonstrated 
a similar invasive superstructure (Tolde et aI., 2010). Culture of invasive cancer cells on 
a native basement membrane isolated from rat peritoneum demonstrated that invasive 
cells initially form invadopodia that degrade the. un,derlying ECM, these invadopodia 
/._ I, 
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further elongate to 1-7flm in length and after a period of 5-7 days the whole cell has 
infiltrated through the basement membrane defect (Schoumacher et aI., 2010). A new 
linear invadopodia configuration was identified when cells rere cultured in a collagen I 
model; these invadiopodial structures formed along the collagen fibrils and demonstrated 
proteolytic activity in 3D (Juin et aI., 2012). 
It is evident that many physical and biological inputs are integrated 
spatiotemporall y to determine the configuration( s) of protrusions that a motile cell will 
employ. As it is clear that distinct protrusions are formed in various cells, many studies 
have recognized that similar protein constituents are involved in the dynamics of each of 
these protrusions (Linder et aI., 2011). For instance, invadopodia rely on filopodia-
associated proteins for function and vice versa (Li et aI., 2010; Schoumacher et aI., 2010). 
Hence these protrusive structures may represent a hybrid structure that has different 
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functional capacities in various biological/physical contexts (Ridley, 2011; Yilmaz and 
Christofori, 2009). 
Protease Induction 
In the mid to late 80' s, Chitra Biswas' laboratory attempted to characterize a 
factor present on lung carcinoma cell membranes that stimulated collagenase production 
from co-cultured fibroblasts (Biswas, 1984; Biswas and Nugent, 1987). Later studies 
found that this cell surface factor was CD 147, which was identified as a protein with 
diverse molecular weights both in the membrane fractions and conditioned media (Ellis et 
aI., 1989). Additional studies revealed that MMP-inducing activity via CD147 could be 
;. ,"'. 
achieved by cell-cell contact or via shedding fr~~jhe cell surface. Subsequent studies 
found that CD147 could induce the synthesis ofMMP-1, MMP-2, MMP-3, MMP-9, 
MMP-14, and MMP-15 (Yan et aI., 2005). In addition to induction in fibroblasts, CD147 
has been shown to increase MMP production in endothelial1cells, macrophages, tumor 
cells, and non-immortalized epithelial cells (Weidle et aI., 2010). Supplemental to MMP 
induction, CD147 also participates in the activation of the urokinase-type plasminogen 
activator (uPA) system; in this study, up-regulation of CD147 or treatment with CD147-
enriched membranes were able to stimulate the uPA system in breast cancer, oral 
squamous and endothelial cells (Lescaille et aI., 2012; Quemener et aI., 2007). 
Several mechanisms have been proposed to explain how CD147 induces MMPs, 
yet the exact mechanism on how this occurs is currently unknown. Current variables that 
have been described to influence the ability of CD 147 to induce MMPs include: 
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glycosylation status, dimerization/oligomerization, and association with various protein 
binding partners leading to activation of cell signaling pathways. 
Glycosvlation 
Earlier experiments demonstrated that CD147 cDNA expressed in bacteria 
resulted in a non-glycosylated form around 29 kDa, which had no MMP-inducing activity 
when added to fibroblasts. These studies also suggested that lower glycosylated forms of 
rbCD147 (30-45 kDa) were unable to induce MMP synthesis (Guo et ai., 1997). 
Following studies further demonstrated that deglycosylated endogenous CD147 had no 
MMP-inducing activity and was able to attenuate the ability of HG-CDI47 to induce 
MMPs (Sun and Hemler, 2001). Conversely, others ~ave demonstrated that non-
t •• ', 
glycosyJated CD147 (Attia et al., 2011; Belto~~(i, 2008) or a peptide corresponding to 
the IgC2 domain with a single N-acetylglucosamine (GlcNac) or chitobiose unit 
(Kawakami et ai., 2011) was capable of stimulating MMP production. Studies in 
1 
atherosclerosis and muscle differentiation proposed that different CD 147 glycoforms 
\ 
induce a differing MMP repertoire (Attia et ai., 2010; Sluijter et ai., 2005), though further 
exploration of this phenomenon is needed. A recent study found that multiple colorectal 
cancer cell lines contained synonymous mutations in codons that correspond to 
glycosylation sites in the extracellular domain of CD147, though the significance of these 
alterations is unknown (Zheng et ai., 2011). Clearly, the relationship between CD147 
glycoforms and MMP induction warrants further intense investigation. 
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Homo-DimerizationlOligomerization 
CD 147 was first found to homo-oligomerize in several avian tissues, in which the 
authors proposed that CD 147 can potentially interact both in cis and trans fashion 
forming a macromolecular complex (Fadool and Linser, 1996). Subsequent studies 
found that CD147 forms homo-oligomers only in a cis-like manner and that the IgC2 
domain was sufficient for this dimerization while N-glycosylation appeared to play no 
role (Yoshida et aI., 2000). Since tumor-associated CD147 and soluble CD147 can 
induce MMP synthesis in neighboring cells, this implies that a counter-receptor may 
participate in trans-interactions between these cells (Yan et aI., 2005). Studies using 
immobilized CD 147 fusion protein determined that CD 147 may be a receptor for itself, 
t, :', 
similar to other IgSF members, and that this ass99,jtion was dependent on the IgC2 
domain. Additionally, treatment of cells with a monoclonal antibody demonstrated to 
specifically bind multimerized CD147 inhibited MMP induction, implying oligomerized 
CD147 may facilitate MMP induction (Sun and Hemler, 2061). Subsequent cross-linking 
studies between the Ig-like domains of rbCD147 and fibroblasts Jollowed by MALDI-
MS/MS sequencing identified CD147 as a receptor for rbCD147 (Belton et aI., 2008). 
Other studies using crystallographic approaches have found that Ig-like domains in 
CD147 dimerize in both cis and trans fashion (Yu et ai., 2008) possibly through ~-strand 
domain swapping (Luo et ai., 2009). A systematic mutational analysis of the ectodomain 
of CD147 revealed that multiple mutations in the Ig-like domains inhibited 
dimerization/oligomerization and subsequently MMP induction (Cui et aI., 2012). 
Though the above studies demonstrate that the CD 147 N -terminus can interact 
homophilicaBy between homo/hetero-typic cell types, surface plasmon resonance (Hanna 
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et aI., 2003) and FRET analysis (Wilson et aI., 2002) suggest otherwise. In contrast, a 
new study also suggests that CD147-3 binding to the IgI domain of CD147-2 attenuates 
induction of MMP synthesis and invasion, though this relevance is questionable as 
CD147-3 has been identified as a nonsense-mediated decay gene, thus additional studies 
are needed for further clarification (Liao et aI., 2011). The above studies suggest that 
CD147 may self-associate in a cis or trans orientation on the cell surface, which results in 
MMP induction. 
Heterophilic Protein Interactions 
The protein structure and binding characteristics of CD 147 suggest a role in being 
a component of protein-protein interactions. As described previously, CD147 contains an 
t· • 
unusual glutamate residue as well as a leucinezf;(er motif in its transmembrane domain 
(Jian-Li and Juan, 2007); both of these characteristics have been associated with multi-
protein complex assembly (Humphrey et aI., 2005; Zhou et aI., 2001). Other single span 
transmembrane proteins, such as discoidin domain receptors (Noordeen et aI., 2006), 
erythropoietin receptors (Ruan et aI., 2004) and E-cadherin (Huber et aI., 1999) utilize 
leucine zipper motifs in dimerization. Additionally, further studies indicate that the IgC2 
domain may also interact with Igl/V -like domains on other IgSF proteins (Yu et aI., 
2008) and CD147 may associate with proteins with attached oligomannose moieties 
(Heller et aI., 2003). In addition to these mentioned characteristics, differential 
glycoforms of CD147 provide prodigious advantages to participate in diverse protein-
protein interactions. 
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The most characterized binding partner of CD 147 that regulates MMP induction 
is caveolin-l. As mentioned previously, caveolin-1 is thought to decrease CD147-
induced MMP production by decreasing cell-surface clustering and further complex 
glycosylations, though these appear to be independent of each other (Tang et aI., 2004a; 
Tang and Hemler, 2004). Conversely, studies evaluating MMP synthesis in a lung injury 
model and hepatocellular carcinoma progression suggest that an inverse relationship 
exists between caveolin-1 and CD147 (Barth et aI., 2006; Jia et aI., 2006), though this 
could be due to different cell models and experimental evaluation. 
Another protein that has been shown to interact with CD147 and regulate MMP 
induction is Annexin II (AnxA2). AnxA2 is a multifunctional protein that regulates 
t· :", 
cytoskeleton organization, lipid raft dynamics.,..·~~;endo/exo-cytic trafficking events 
(Gerke et aI., 2005). A recent study found that CD147 and AnxA2 might cooperate in 
hepatocellular carcinoma migration and invasion by regulating MMP production (Zhao et 
aI., 2010). 
, 
Earlier studies found that CD147 interacted with a3~1 and a6~1 integrins at cell-
cell contacts, but not at focal adhesions sites; interestingly, it appears that LG-CD 147 was 
the glycoform primarily associated with integrins (Berditchevski et aI., 1997). Later 
studies found that these CD147-integrin interactions contributed to cancer invasiveness 
by inducing MMP synthesis in hepatoma cells via a PI3K signaling pathway (Dai et aI., 
2009). A recent study identified that ASp179 in the IgI domain of CD147 interacts with 
the metal ion-dependent adhesion site in the ~A domain of the integrin ~1 subunit, this 
interaction was shown to lead to focal adhesion kinase (FAK) signaling events, which 
regulated in vivo tumor growth. This CD147- ~l interaction was facilitated by manganese 
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and was attenuated by competing RGD containing ligands (Li et ai., 2012). Interestingly, 
CD147 also interacts with caveolin-1 via this IgI domain (Tang and Hemler, 2004), 
though whether competing interactions between integrins, caveolin-1 or RGD-containing 
ligands influences CD 147 function is unknown. 
Angiogenesis 
As the primary tumor bulk expands, nutrient availability becomes a limiting 
variable governing the success of further tumor growth. Nutrient, oxygen and metabolic 
waste transport through endothelial cell channels recruited by tumor cells is a major 
mechanism that can supply adequate nutrient s,~p'p~to a primary or newly colonized 
tumor bed. CD147 has been shown to promote increased angiogenesis by upregulating 
soluble vascular endothelial growth factor (VEGF) protein and secretion in breast tumor 
cells and cancer cell-fibroblast cocultures; this induction of ~EGF was also seen in vivo 
(Tang et ai., 2005). Further characterization of this effect revealed that CD147 , 
specifically increased the soluble VEGF121 and VEGF165 splice variants along with 
VEGF receptor 2 (VEGFR-2) via induction of hypoxia-inducible factor 2a (HIF-2a) in 
normoxic conditions (Bougatef et ai., 2009). Similar findings were also observed in 
melanoma cells, where CD147 may be involved in a VEGF autocrine signaling 
mechanism promoting migration, invasion and proliferation (Bougatef et ai., 2010). 
CD147 also appears to be involved in VEGF secretion during Kaposi sarcoma-associated 
herpesvirus' induction of a tumor-associated fibroblast phenotype (Dai et ai., 2012). The 
exact mechanism of how CD147 induces VEGF production is not known, but analysis of 
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tumor-endothelial cross-talk revealed that tumor-derived CD 147-associated microvesicles 
induce invasiveness, MMP production, and tubule formation in endothelial cells 
(Millimaggi et aI., 2007). Thus, CD147 may mediate VEGF signaling and angiogenic 
events either by cell-cell contact, soluble or vesicle-associated CD147 mechanisms. 
To date, a relationship between CD147 and VEGF has been demonstrated in 
breast cancer (Tang et aI., 2005; Tang et aI., 2006), liver cancer (Jia et aI., 2007), renal 
cancer (Liang et aI., 2009), osteosarcoma (Zhou et aI., 2011), bladder cancer (Xue et aI., 
2011), colorectal cancer (Zheng et aI., 2011), pancreatic cancer (Zhang et aI., 2007), 
glioblastoma (Liang et aI., 2005), gastric cancer (Zheng et aI., 2006), melanoma 
(Bougatef et aI., 2010; Chen et aI., 2006a; Voigt et aI., 2009) and head and neck SCC 
, . .-', 
(HNSCC) (Newman et aI., 2008a). AdditionaU,,; !'lfrecent study suggested a potential use 
of CD147 expression to stratify patients and their response to anti-VEGF therapies such 
as bevacizumab (Newman et aI., 2009). CD147 takes part in tumor angiogenesis in 
several cancer types and induces VEGF production autonorhously in tumor cells and in a 
paracrine fashion between tumor cells and fibroblasts and endothelial cells. In addition, 
to angiogenesis, CD 147 also contributes to vasculogenic mimicry, a process in which 
malignant tumor cells form non-endothelial-lined channels and behave like blood vessels 
(Millimaggi et al., 2009). 
Multi-therapy Resistance 
Broad, combined and targeted chemotherapy regimens are limited in their 
efficacy by the development of tumor drug resistance. Tumor drug resistance can be 
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achieved in numerous ways. Cancer cell autonomous mechanisms include: alteration of 
metabolic and morphologic phenotype, amplification of the target, acquired mutation in 
the target via positive selection during drug exposure, bypassing signaling pathway(s) 
being targeted, increased repair and detoxification mechanisms, augmented capability to 
efflux drugs via cell membrane transporters and enhanced activation of cell survivallanti-
apoptotic signaling pathways. Additionally, many of these drug-resistant characteristics 
can be modulated in the tumor tissue by stromal, endothelial and immune cell influences 
as well as the physical matrix/tissue barriers surrounding the vicinity of the growing 
tumor (Garraway and Janne, 2012). 
CD147 expression has been correlated with a multidrug resistance (MDR) 
phenotype in several cancer types (Kuang et .al~;~8; Yang et aI., 2003) possibly by 
regulating expression of the MDRI gene product, P-glycoprotein (P-gp) drug efflux 
pump (Li et aI., 2007a). Subsequent studies revealed that reduction of CD147 expression 
led to increased accumulation of chemotherapy drugs in cahcer cells (Yang et aI., 2007). 
A growing amount of evidence also indicates that CD147 is increased upon 
chemotherapy exposure (Li et aI., 2007b; Qin et aI., 2011) and may associate with P-gp 
during this event (Wang et aI., 2008). In the previously mentioned studies, CD147 has 
been associated with resistance to doxorubicin, paclitaxel, cisplatin, 5-fluorouracil, 
vincristine, and all-trans retinoic acid; therefore CD 147-mediated drug resistance cannot 
be due solely to Pgp regulation. In support of this, a recent study found that CD147 
regulates breast cancer resistance protein (BCRP) expression and plasma membrane 
presence (Qin et aI., 2011), a protein that has a differing substrate profile than Pgp 
(Lemos et aI., 2008). Additionally, CD147 has been shown to regulate the expression of 
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X-linked inhibitor of apoptosis, a protein related to chemotherapy resistance. Recently, a 
study employing laser capture microdissection identified CD 147 expression as the most 
discriminatory protein in stratifying tamoxifen therapy resistance in breast cancer tumor 
samples (Umar et aI., 2009) and CD147 expression in bladder cancer is associated with 
poor survival following cisplatin-based therapy (Als et aI., 2007). 
In addition to the regulation of drug efflux pumps, CD 147 has also been shown to 
potentiate drug resistance by inducing the synthesis of hyaluronan (HA) (Toole and 
Slomiany, 2008). HA is a large non-sulfated extracellular sugar composed of repeating 
N-acetylglucosamine and glucuronic acid units, which can act as a scaffold for other 
ECM constituents in the construction of the interstitial milieu. HA engages cell surface 
receptors, including its main receptor CD44, aR~ Ifbelieved to promote the formation of 
multi-protein cell surface complexes by creating a stabilizing pericellular scaffold 
(Ghatak et aI., 2005; Toole, 2004). Disruption of HA-CD44 interactions leads to 
internalization of CD44 and respective binding partners, indluding metabolic and drug 
transporters (Slomiany et aI., 2009a; Slomiany et aI., 2009b). 
The involvement of CD147 in resistance to radiation therapy is just beginning to 
emerge. A relationship between CD 147 expression following brachytherapy for cervical 
carcinoma was identified, where patients with elevated CD147 tissue staining post-
therapy demonstrated poorer survival (Iu et aI., 2008). The exact mechanisms underlying 
this putative association of CD 147 and radio-resistance are currently unknown, but may 
depend on altered control of reactive oxygen species (Xie et aI., 2011). 
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CD147-induced Cell Signaling Pathways 
It is clear that CD 147 has various roles in diverse cell types in physiological and 
pathological contexts, though the signaling pathways activated in each setting are not 
completely clear. The first activated signaling pathway identified by exogenous CD 147 
treatment was the mitogen activated protein kinase (MAPK) p38-associated pathway, 
which led to MMP-1 synthesis in fibroblasts (Lim et aI., 1998). Following studies found 
that full length soluble CD147 released from breast cancer cells induces a phospholipase 
A2/5-lipoxygenase pathway resulting in arachidonic acid metabolism in fibroblasts 
(Taylor et aI., 2002). Other studies have indicated that CD147 also regulates MAPK 
signaling pathways, including ERK and JNK (Qian et aI., 2008; Xu et aI., 2007). CD 147 
associates with the heparan sulfate-containingfr~in syndecan-l, resulting in CypB-
mediated ERK activation (Pakula et aI., 2007) and can also interact with a osteopontin 
peptide-CypC complex to elicit Akt 1/2 signaling (Mi et aI., 2007). Other studies have 
demonstrated that CD 147-integrin interactions lead to focal1 adhesion kinase (FAK)-PI3K 
related pathways (Dai et aI., 2009; Tang et aI., 2008). A recent study found that CD147 
was a regulator of the canonical Wnt/~-catenin pathway in lung cancer. Specifically, up-
regulation of CD147 led to an EMT-like phenotype, nuclear accumulation of ~-catenin 
and additional tumorigenic characteristics (Sidhu et aI., 2010). Co-culture of tumor cells 
and fibroblasts revealed a novel mechanism involving fibroblast growth factor (FGF) 
signaling and CD147 (Liu et aI., 2011). In this study it was proposed that early in tumor 
progression CD 147 expression may be low and tumor growth is dependent on fibroblasts 
and FGF signaling, whereas later stages of tumor growth have elevated CD 147 
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expression with a concomitant reduction in FGFR signaling allowing the tumor to 
become independent of fibroblasts for further progression. 
In inflammatory scenarios, CD147 can stimulate ERK and NF-K~ signaling (Kim 
et aI., 2009; Schmidt et aI., 2008) and inflammatory cytokines/chemokines IL-l, IL-6 and 
IL-8, CCL3, CCL20, CXCL2 and CXCL5 (Chen et aI., 2009; Dean et aI., 2009). 
As mentioned above, CD147 can also interact with CD44 (Slomiany et aI., 
2009b), though no activated pathways have been ascribed to this interaction. Since 
CD147 has been shown to regulate HA synthesis (Edward et aI., 2011; Ghatak et aI., 
2005; Kato et aI., 2011; Marieb et aI., 2004; Qin et aI., 2011), it is possible that CD147-
induced HA-CD44 interactions may activate similar pathways that HA alone induces. In 
t· ;', 
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this manner, CD 1 47-mediated HA-CD44 inte'~~~tig~s have led to activation of PI3K and 
ERK signaling pathways (Marieb et aI., 2004). Whether the other aforementioned 
CD 147-induced signaling pathways are intertwined with HA-CD44 signaling complexes 
1 
is unknown. 
In conjunction with inducing activation of 'linear' signaling pathways, CD147 
also appears to be involved in autocrine signaling loops. For instance, TGF~ has been 
shown to increase CD 147 expression and in turn CD 147 increased TGF~ signaling 
leading to an EMT phenotype (Wu et aI., 20l1a). In melanoma, CD147 may stimulate an 
autocrine VEGF-VEGFR2 signaling loop (Bougatef et aI., 2010) and VEGF-D may 
potentiate this by increasing CD 147 expression at the plasma membrane (Papiewska-
Pajak et aI., 2010). During inflammatory or wound healing processes CD147 may also 
participate in an autocrine loop consisting of interleukin signaling (Gabison et aI., 2009; 
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Venkatesan et aI., 2009). A positive feedback loop for CD147 itself has also been 
identified (Tang et aI., 2004b). Finally, the influence of CD147 in regulating HA 
synthesis also raises the question of whether CD 147-induced HA-CD44 interactions also 
mediate autocrine signaling events, seen with up-regulation of HA alone (Misra et aI., 
2005). 
Though no kinase motif has been identified in CD 147, other studies have emphasized 
that interactions in the extracellular Ig-like domains activate downstream signaling 
pathways. CD147 dimerization/oligomerization has been shown to be a major factor in 
regulating ERK phosphorylation (Cui et aI., 2012) and association with integrin B 1 is 
associated with FAK signaling (Li et al., 2012). The short cytoplasmic tail contains 
partially conserved serine residues (Weidle et"a~,:f010) and our own preliminary analysis 
"f 
suggests that Serine 246 may be a putative Casein Kinase 1 phosphorylation site, though 
this needs further clarification. Whether the cytoplasmic domain has a role in signaling is 
not known, currently one study suggests that this may not bb the case in CypA-CD147-
induced signaling (Pushkarsky et aI., 2007). Another study in activated T cell suggests 
that a membrane-localized CD147 cytoplasmic tail was sufficient to mediate the 
signaling effect mediated by CD147 (Ruiz et aI., 2008). 
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The Role of CD147 in Metabolic Processes of the Cell 
As described previously, CD147 is an inducible molecule governed by many 
diverse stimuli. CD147 has been demonstrated to be regulated by TSH, an active 
fragment of SCP-2, PPAR proteins, PGCl-a and NAMPT, which are all direct regulators 
of cell metabolic processes. In addition, exposure of cells to glucose, butyrate or pectin 
increases CD147 expression (Kirat et aI., 2009). CD 147-depleted oral SCC cells 
demonstrated a differential gene expression pattern with most of these genes being 
related to cellular metabolism (Kuang et aI., 2008). 
The strongest evidence, thus far, for CD 147 being involved in cellular energetics 
is the observed associations between CD 147 and mo~ocarboxylate transporter (MCT) 
t· :", 
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family members MCT1/2/3/4, which are proton'-lifiked transporters that facilitate the 
movement of pyruvate, lactate, and ketone bodies across cell membranes (Halestrap, 
2011b). CD147 has been shown to be an essential chaperone needed for surface 
t 
expression of these MCTs, since overexpressed MCTs don't traffic to the plasma 
\ 
membrane unless CD147 is co-expressed (Gallagher et aI., 2007; Kirk et aI., 2000; Philp 
et aI., 2003). The role of MCTs in lactic acid flux has been exploited by cancer cells as 
they utilize these transporters to maintain metabolic homeostasis. 
Otto Warburg observed that cancer cells exhibited increased glycolysis to 
generate adenosine triphosphate (ATP), even in the presence of abundant oxygen supply; 
this process has now been coined the 'Warburg effect' (Warburg, 1956). A number of 
studies have gone on to demonstrate that accumulation of lactate is associated with poor 
prognosis in several cancer types and is strongly associated with highly invasive 
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phenotypes (Kennedy and Dewhirst, 2010). In addition to genetic/epigenetic 
heterogeneity in the tumor, metabolic heterogeneity is also present. For example, tumors 
contain cell populations localized in oxygenated and hypoxic regions and evidence of 
metabolic symbiosis between lactate-producing and lactate-utilizing cells has been 
demonstrated in vivo with MCT inhibitors (Sonveaux et aI., 2008). Thus it appears that 
many cancers rely on glycolysis to generate ATP to synthesize the biomass needed for 
various anabolic reactions during proliferation (Vander et aI., 2009). 
Multiple studies have identified that inhibition of CD 147 expression in various 
cancer types results in perturbed MCT -mediated lactic acid flux across the plasma 
membrane (Baba et aI., 2008; Floch et aI., 2011; Schneiderhan et aI., 2009; Slomiany et 
aI., 2009b; Su et aI., 2009); in some studies thi~;l#to highly decreased ATP levels and 
cell death. A recent study has provided very strong evidence that one of the main 
functions of CD147 in tumorigenesis is the escorting of MCTs to the cell surface, which 
is vital for highly glycolytic and aggressive cancers (Floch ~t aI., 2011). An elegant study 
employing cell surface crosslinking in the midst of different detergent conditions 
followed by mass spectrometry analysis identified that CD 147 associates in a super 
metabolic complex on the cell surface. Specifically, CD147 was found to complex with 
the following: MCTs (lactate and pyruvate transporters), CD98hc (a multifunctional 
chaperone for nutrient transporters), L-type amino acid transporter 1 (LAT 1), ASCT2 
(neutral amino acid transporter) and epithelial cell adhesion molecule (EpCAM). The 
organization of the complex is proposed to consist of a CD 147-MCT complex with direct 
linkage of CD147-to CD98, which associates with the other amino acid transporters and 
EpCAM (Xu and Hemler, 2005). Finally, this study identified that CD147 and CD98 
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regulated the surface expression of one another and that depletion of either one resulted 
in increased activation of the cellular energy sensor AMP kinase. 
In addition to association with MCTs on the cell surface, CD147 has also been 
shown to associate in the inner mitochondrial membrane with MCT 1, lactate 
dehydrogenase and cytochrome oxidase in a lactate oxidation complex (Hashimoto et aI., 
2006). This mitochondrial complex may aid in the utilization of lactate transferred 
between glycolytic and respiring cancer cell populations or aid in the consumption of cell 
autonomous lactate produced in the cytosol, thus maintaining redox balance (Hussien and 
Brooks, 2011). 
CD147 has also been proposed to regulate G,rp75 (mortalin) expression (Kuang et 
,. "", 
1-" ,.. 
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aI., 2008), a 70 kDa heat shock protein (Hsp70) f{mily member involved in the cellular 
response to glucose deprivation, mitochondrial import, vesicular trafficking and 
regulation of p53 activity (Wadhwa et aI., 2002). 
Clearly, CD147 appears to be involved in multiple aspe~ts of cellular metabolism. 
This is supported by elevated expression of CD147 on many metabolically active cell 
types, such as lymphoblasts (Spring et aI., 1997), brown adipocytes ((Nehme et aI., 
1995), inflammatory and malignant cancer cells (Muramatsu and Miyauchi, 2003). It 
may be inferred from the studies above that diminished CD 147 expression may result in 
impaired lactate, pyruvate and amino acid transport across cell membranes, thus leading 
to an altered metabolic phenotype and may explain how CD 147 inhibits starvation-
induced autophagy (Gou et al., 2009). 
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Hypothesis and Experimental Rationale 
Hypothesis 
It is hypothesized that CD147 induces breast cancer invasion by regulating 
invadopodial dynamics via the assembly of multi-protein signaling complexes. 
Rationale 
CD147 expression is associated with an invasive phenotype in a wide array of 
cancer types, including breast cancer. CD147 is a predominant marker in breast cancer 
micrometastases (Klein et aI., 2002; Reimers et aI., 2004) and is enriched in malignant 
pleural effusions and circulating tumor cells (Davidson et aI., 2004; Pituch-Noworolska 
et aI., 2007), suggesting a prominent role for CD147 in tumor progression. The role of 
CD147 in invasion has been demonstrated in§xY~fi model systems, including a study in 
vivo in which CD 147-transfected breast cancer cells injected into mammary fat pads of 
nude mice were found to be more locally invasive than control transfected cells and in 
several animals metastasized to the liver, spleen, mediastinum, lymph nodes, and 
mesentery (Zucker et aI., 2001). The mechanism mostly attJributed to CDl47-induced 
invasion is the induction of proteases, including soluble and membrane-type MMPs, 
though the mechanism regulating this process have not been fully elucidated. 
Cancer cells employ multiple mechanisms to migrate, degrade and invade through the 
ECM. Invadopodia, actin-based proteolytic superstructures, have gained much attention 
for their role as vital organelles in cellular invasion (Murphy and Courtneidge, 2011) both 
in vitro and in vivo. The purpose of this project was to further characterize the 
mechanism(s) by which CD147 facilitates breast cancer invasion by evaluating the role of 
CD147 in invadopodia activity and potential related signaling pathways. 
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Chapter 2: Regulation of Invadopodia Formation and Activity by CD147 
Abstract 
A defining feature of malignant tumor progression is cellular penetration through the 
basement membrane and interstitial matrices that separate various cellular compartments. 
Accumulating evidence supports the notion that invasive cells employ specialized 
structures termed invadopodia to breach these structural barriers. Invadopodia are actin-
based, lipid raft-enriched membrane protrusions. c01)taining membrane-type-l matrix 
'f'~'~/' ~j;' 
metalloproteinase (MTI-MMP) and several signaling proteins. CD147 (emmprin; 
basigin), an immunoglobulin superfamily protein that is associated with tumor invasion 
and metastasis, induces the synthesis of various matrix met,lloproteinases in multiple 
systems. In this study we show that up-regulation of CD147 is sufficient to induce MT1-
MMP expression, invasiveness, and formation of invadopodia-like structures in non-
transformed, non-invasive, breast epithelial cells. We also demonstrate that CD147 and 
MTI-MMP are in close proximity within these invadopodia-like structures and co-
fractionate in membrane compartments with the properties of lipid rafts. Moreover, 
manipulation of CD 147 levels in invasive breast carcinoma cells causes corresponding 
changes in MTI-MMP expression, invasiveness, and invadopodia formation and activity. 
These findings indicate that CD147 regulates invadopodia formation and activity, most 




Focal penetration through the basement membrane is a defining event in the transition 
from a dysplastic carcinoma in situ to an invasive and malignant cancer. Invasive cancers 
most likely utilize various mechanisms to breach the surrounding extracellular matrix 
(ECM) scaffolds that segregate different tissue compartments (Friedl and Wolf, 2003). 
Cellular protrusions directly abutting and penetrating the ECM have been observed in 
multiple cancers as invasion progresses (Rowe and Weiss, 2008) and very similar, 
ventrally-localized, membrane superstructures called invadopodia are seen when invasive 
cells are cultured on 2D substrata (Artym et aI., 2006). A recent study demonstrated a 
direct role for invadopodia in promotion of metastasis (Eckert et aI., 2011). Invadopodia 
... ;'[ 
are composed of actin filaments and modulatot~/(jfRctin polymerization, including 
cortactin (Artym et aI., 2006; Clark et aI., 2007), and are enriched in kinases, cell-
adhesion molecules, and matrix metalloproteinases (MMPs), notably membrane-type 1 
MMP (MTl-MMP), a crucial enzyme for basement membr!ne and interstitial matrix 
degradation (Frittoli et aI., 2010; Poincloux et aI., 2009). A coordinated step-wise model 
for invadopodia formation has been described, in which cortactin-actin puncta form 
initially at sites of matrix attachment, followed by delivery and accumulation of MT 1-
MMP at the invadopodia-ECM interface (Artym et aI., 2006; Oser et aI., 2009; 
Schoumacher et aI., 2010). Importantly, multiple studies have demonstrated that cancer 
cells primarily employ MTl-MMP targeted to invadopodia to degrade underlying ECM, 
which is orchestrated by a number of diverse proteins that integrate various signals to 
induce focalized MTl-MMP localization and matrix degradation (Artym et aI., 2006; 
Clark et aI., 2007; Frittoli et aI., 2010; Liu et aI., 2009; Murphy and Courtneidge, 2011). 
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Interestingly, a recent study found that MT1-MMP and other major invadopodia 
constituents localize in detergent-resistant membrane fractions characteristic of lipid raft 
domains (Yamaguchi et aI., 2009). Thus, an emerging model describes invadopodia as 
dynamic cellular depots where diverse cell signaling inputs, vesicular trafficking, and 
protease activity converge in spatially-defined membrane compartments at the leading 
edge of an invasive cancer cell. 
Emmprin/basiginlCD 147 is a single pass integral membrane protein, belonging to the 
Ig superfamily, that is variably glycosylated across different tissue types. It is usually 
expressed at low levels in most normal tissues, but is highly up-regulated during dynamic 
cellular events, such as tissue remodeling and cancer progression (Gabison et aI., 2009; 
t ...... 
Nabeshima et aI., 2006; Yan et aI., 2005). EmrpPrJn was originally identified as a cell 
surface factor that induces MMP production in stromal cells (Ellis et aI., 1989; Kataoka et 
aI., 1993), but later studies revealed that emmprin is identical to basigin-2 (Biswas et aI., 
1995; Liao et aI., 2011), and is multifunctional; it is now widely known as CD147. 
CD147 induces several MMPs at both the message and protein level, including MMP-1, 
MMP-2, MMP-3, MMP-9, MT1-MMP, and MT2-MMP, though there is variation in the 
particular MMPs induced in different systems (Nabeshima et aI., 2006; Yan et aI., 2005). 
Furthermore, CD147 has been shown to induce MMPs in tumor cells themselves as well 
as in stromal cells (Caudroy et aI., 2002; Sun and Hemler, 2001). CD147 is a 
predominant marker in breast cancer micrometastases (Klein et aI., 2002; Reimers et aI., 
2004) and is enriched in malignant pleural effusions and circulating tumor cells 
(Davidson et aI., 2004; Pituch-Noworolska et aI., 2007), suggesting a prominent role for 
CD 147 in tumor progression. The role of CD 147 in invasion has been demonstrated in 
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several model systems, including a study in vivo in which CD 147 -transfected breast 
cancer cells injected into mammary fat pads of nude mice were found to be more locally 
invasive than control transfected cells and in several animals metastasized to the liver, 
spleen, mediastinum, lymph nodes, and mesentery (Zucker et aI., 2001). 
In this study we show that up-regulation of CD 147 is sufficient to induce many 
features of invadopodia in non-transformed breast epithelial cells and that manipulation 
of CD147 levels in invasive breast carcinoma cells causes corresponding changes in the 
formation and activity of invadopodia. 
Materials and Methods 
Cell culture 
The human breast adenocarcinoma cell line MDA-MB-231 was obtained from American 
1 
Type Culture Collection (ATCC) and was cultured in RPMI 1640 (R-8755) with 2.38 gIL 
HEPES, 2 gIL sodium bicarbonate, and 10% FBS (pH 7.4). The spontaneously 
immortalized human breast epithelial cell line MCF-I0A was obtained from ATCC. The 
immortalized human mammary epithelial cell line HMLE was a generous gift from Dr. 
Robert Weinberg (MIT, Cambridge, MA). Low passage MCF-I0A and HMLE cells were 
maintained in Mammary Epithelial Cell Growth Medium (MEGM) with BulletKit 
supplements (Lonza). All cells were cultured in a humidified 95% air/5% CO2 incubator 
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Antibodies and Reagents 
The following primary antibodies were obtained for these studies: CD147 (BD 
Pharmingen); Alexa Fluor 488-conjugated CD147 (Biolegend); cortactin (clone 4F11) 
and MT1-MMPI hinge-region polyclonal (Millipore); MT1-MMP monoclonal 
(Epitomics); caveolin-1 (BD Biosciences); rabbit and mouse EEA1 (AbCam); and ~-actin 
(Sigma). Alexa Fluor-488 goat anti-mouse, Alexa Fluor-488 goat anti-rabbit, Alexa 
Fluor-647 goat anti-rabbit, Alexa Fluor-555 goat anti-mouse, Alexa Fluor-555 goat anti-
rabbit, and Alexa 647-phalloidin were purchased from Invitrogen. Goat anti-mouse HRP 
and goat-anti-rabbit HRP (Chemicon) were used as secondary antibodies for 
immunoblotting. Western blotting detection reagent (enhanced chemiluminescence) was 
purchased from Pierce. Recombinant TIMP ... J,';a~'-TIMP-2 were purchased from 
Chemicon and were used at concentrations indicated in the figure legends. A function 
blocking antibody targeting the catalytic domain of MT1-MMP (LEM-2/15.8) and the 
IgG control antibody were obtained from Millipore. 
Recombinant adenovirus infections 
Recombinant human CD147 adenovirus and control ~-galactosidase (~-gal) adenovirus 
were constructed and used as described previously (Li et aI., 2001). 
RT-PCR 
Total RNA was isolated using the RNeasy Mini kit (Qiagen) and quality control and 
quantification was performed with the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Inc., Santa Clara, CA) and Agilent RNA 6000 Pico LabChip kits. cDNA was synthesized 
from equal total RNA using iScript cDNA synthesis kit (Biorad) according to the 
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procedures of the manufacturer. The primers designed for targeting the genes included 
the following: CD147 sense, 5' GGAATAGGAATCATGGCGGCTGCG 3'; CD147 
antisense, 5'GAGCCTCAGGAAGAGTTCCTCTGGC 3'; MTI-MMP sense, 5' 
CCATTGGGCATCCAGAAGAGAGC 3'; MTI-MMP antisense, 5' 
GGATACCCAATGCCCATTGGCCA 3'; GAPDH sense, 5' 
ATGTTCGTCATGGGTGTGAA 3'; GAPDH antisense, 5' 
GGTGCTAAGCAGTTGGTGGT 3'. The PCR was performed in a DNA thermal cycler 
(Thermo Hybrid PCR Express Thermo Cycler, ) under conditions of 95°C for 2 minutes; 
30 cycles each at 95°C for 30 seconds, 59°C for 30 seconds, and 72°C for 60 seconds; 
followed by 72°C for 5 minutes. 
RNAi 
Control non-silencing siRNA and target-specific pooled CD147 siRNAs (#35298) were 
purchased from Santa Cruz Biotechnology and used according to manufacturer's 
1 
protocol. For all experiments, cells were transfected with siRNA 72 hrs before each 
experiment. 
Matrigei invasion assay 
Matrigel invasion inserts (8 J!m pores) for 24-well tissue culture plates were purchased 
from BD Biosciences. Briefly, the matrigel inserts (upper and lower chambers) were re-
hydrated for 2 hrs at 37°C with serum culture medium (MDA-MB-231) or non-
supplemented MEGM (MCF-IOAlHMLE). 4.0xl05 MDA-MB-231 cells treated with 
siRNA (72 hrs) or adenoviruses (24 hrs) were detached and seeded in the upper chamber 
of the inserts and cultured for 24 hrs at 37°C. 8.0xl04 MCF-IOA or HMLE cells, non-
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treated or treated with adenoviruses, were placed in the upper chamber in non-
supplemented MEGM, while medium in the lower chamber was replaced with complete 
growth medium containing 20 nM EGF, and cultured for 36 hrs at 37°C. After incubation, 
the cells were fixed in 3.7% paraformaldehyde for 15 minutes at room temperature, the 
chambers were rinsed with PBS and stained with 0.2% crystal violet for 10 minutes, 
followed by extensive washing. After scraping off the cells at the top of the matrigel 
membrane with a Q-tip, the cells that passed through the 8 ~m pores in the membrane 
were visualized by imaging with a phase contrast microscope (Leica DFC320). Cells 
were counted in 4 separate fields for 3 independent experiments. 
Gelatin degradation assay for invadopodia 
This assay was perfonned as described previ~~~i~ith minor modifications (Artym et 
aI., 2009). Briefly, gelatin was conjugated with 568 Alexa Fluor dye (Molecular Probes) 
using the manufacturer's protocol. Glass coverslips (18 mm) were acid washed with 1 M 
1 
HCI for 12-16 hours and washed extensively with water. 70% Ethanol-sterilized 
coverslips were coated with 50 ~g/ml poly-L-Iysine for 20 minutes at room temperature, 
washed with PBS, and fixed with ice cold 0.5% glutaraldehyde for 15 minutes followed 
by extensive washing. The covers lips were then inverted on an 80 ~L drop of 
fluorescent gelatin matrix (0.2% gelatin and Alexa Fluor-gelatin at an 8: 1 ratio) and 
incubated for 15 minutes at room temperature. The coverslips were washed with PBS 
and the residual reactive groups in the gelatin matrix were quenched with 5 mg/ml 
sodium borohydride in PBS for 10 minutes followed by further washing in PBS. The 
coated coverslips were placed in 12-well plates, sterilized in 70% ethanol for 10 minutes, 
washed in PBS, and equilibrated in serum free medium and switched to serum medium 
55 
30 minutes before the addition of cells. For invadopodia assays, 5.0x104 cells were plated 
on the coated coverslips and incubated at 37°C for 5-6 hrs (MDA-MB-231) or 15 hrs 
(MCF-IOA). Cells were fixed-permeabilized with 3.7% paraformaldehyde/O.l % Triton 
X-100 for 10 minutes, washed with PBS, blocked in 3% BSA in PBS for 1 hour, and 
incubated with appropriate primary and secondary antibodies in 3% BSA in PBS. Actin 
filaments were visualized with Alexa 647 -phalloidin. 
In Situ Proximity Ligation Assay 
Interaction of CD 147 and MT 1-MMP was detected in situ using the Duolink II secondary 
antibodies and detection kit (Olink Bioscience, Uppsala, Sweden) according to 
manufacturer instructions. Briefly, primary antibodies targeting CD147 (BD Pharmingen) 
to :", '. , 
and MTl-MMP (Millipore) were applied uSi~g;~;iudard procedures. Oligonucleotide-
conjugated Duolink secondary antibodies were then added, followed by Duolink Ligation 
solution. The oligonucleotides ligate together in a closed circle only when the secondary 
1 
antibodies are in close proximity «40 nm) (Soderberg et aI., 2006). Finally, polymerase 
was added, which amplified any existing closed circles, and detection was achieved with 
complementary, fluorescently labeled oligonucleotides. Specificity of the reaction was 
determined by treating cells with a single primary antibody followed by Duolink 
secondary antibodies, which results in no signal amplification due to absence of a second 
oligonucleotide needed for ligation and subsequent closed circle amplification. 
Microscopy and image analysis 
Images were captured with a Leica Total Confocal System SP5 Acoustic Optical Beam 
Splitter Confocal (TCS SP5 AOBS) microscope using a 63X/1.4 N.A. oil objective in the 
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Josh Spruill Molecular Morphology & Imaging Center in the Department of Regenerative 
Medicine and Cell Biology (MUSC, Charleston, SC). Images were acquired at high 
confocality (pinhole = 1 Airy unit) to achieve the thinnest possible optical slices at the 
matrix-cell interface. Potential overlaps in emission spectra were eliminated by 
sequential scanning and tuning of the AOBS. Differential interference contrast (DIC) 
microscopy was performed using the Leica SPS Confocal System. 3-dimensional (3D) 
volumetric reconstruction of invadopodia-producing cells was carried out using the 3D 
reconstruction software Amira S.2 (Visage Imaging, San Diego, CA). Image processing 
and compilation were performed using Canvas Software (Deneba Systems Inc.) and 
Adobe Photoshop. 
To assess the ability of cells to form in~dJbdia and degrade matrix, at least 10 
" 
randomly chosen fields were imaged per trial and evaluated for foci of degraded matrix, 
which appear as dark "holes" in the bright fluorescent matrix field. A cell degrading at 
1 
least one hole under the cell or near the cell edge was counted as a cell able to degrade 
matrix. Invadopodia, defined as actin puncta that colocalize with cortactin, were 
manually counted and analyzed for underlying matrix degradation and graphed as 
number of invadopodia per cell or percentage of cells with invadopodia over degraded 
matrix. Quantification of matrix degradation area per cell was analyzed as described 
previously (Liu et aI., 2009) and was reported as normalized degradation, which is total 
area of degraded matrix relative to the area of the whole cell. Briefly, the area of 
degraded matrix in the cell field was measured using ImageJ 1.43s software. Areas of 
degraded matrix in the bright fluorescent field were converted to 8 bit grayscale files, 
automatically thresholded into black dots on a white background, followed by automatic 
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outlining of the dots. The area of each individual cell was measured by manually 
outlining the cell boundary using the p-actin channel. Data was collected in an Excel 
spreadsheet and was used to calculate degradation area per cell area. 
Detergent-resistant membrane fractionation 
Detergent-resistant membrane domains (e.g. lipid rafts) were isolated from MCF-I0A 
cells as described previously (Thankamony and Knudson, 2006) with minor 
modifications. Briefly, cells cultured on gelatin-coated D150 plates were washed with 
ice cold PBS 3 times. Cells were lysed in 500 ~llysis buffer (25 mM Tris-HCI, pH 7.5, 
150 mM NaCI, 1 mM DTT, 10% sucrose, 1 % Triton X-100, and protease inhibitors) on 
ice for 30 minutes. The cells were mechanicall y dis~upted by passaging 20 times through 
, .- 'J~ 
a 3-inch 22-guage needle. The lysates were ~i~:idirect1y with iodixanol stock solution 
(60% solution of Optiprep iodixanol) to yield a 40% (v/v) iodixanol-Iysate solution, 
which was placed at the bottom of an ultracentrifuge tube. Equal volumes of 35%,30%, 
1 
25%,20% and 0% Optiprep in lysis buffer without Triton X-IOO were carefully overlaid 
above the iodixanol-Iysate solution. The samples were centrifuged at 160,000 x g for 8 
hours at 4°C in a SW41-Ti rotor (Beckman Coulter). Equal fractions were carefully 
collected from the top of the tube and equivalent aliquots of each fraction were subjected 
to immunoblotting using antibodies recognizing proteins of interest. 
Immunoblot analysis 
Whole cellI ysates were prepared for immunoblotting using a RIP A buffer modified to 
contain I mM PMSF, 10 ~g/ml aprotinin and leupeptin, 2 mM sodium orthovanadate, 
and 10 mM sodium fluoride. Protein content was determined by BCA assay (Pierce; 
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Rockford, IL), and aliquots were solubilized in SDS sample buffer, resolved on Pierce 4-
20% reducing polyacrylamide gels, transferred to nitrocellulose (Osmonics, 
Westborough, MA) with a Pierce apparatus, and stained with antibody. 
Results 
Up .. regulation of CD147 is sufficient for induction of invasiveness in non .. 
transformed breast epithelial cells 
We first evaluated endogenous CD147 protein levels expressed by non-transformed 
MCF-10A cells, a spontaneously immortalized, phenotypically normal, human breast 
epithelial cell line, and the resulting expression'~f~D 147 after treatment of these cells 
with recombinant CD147 adenovirus or ~-galactosidase (~-gal) adenovirus (as control). 
We found that an MOl of 2 was effective in expressing CD147 protein expression to a 
moderate degree (Fig. 2-1A), within the range observed pre~iously in invasive cancer 
cells; an Mal of 2 was used for the following experiments. It should be noted, however, 
that the --38kDa form of CD147 was increased to a greater extent than the ..... 52kDa form, 
as observed previously when using recombinant CD147 adenovirus (Li et aI., 2001). The 
38kDa and 52kDa forms of CD147 have been shown previously to differ in their degrees 
of glycosylation of the same ..... 27 kDa protein core (Li et aI., 2001; Tang et aI., 2004a) 
We then evaluated the effect of increased CD 147 on invasion of reconstituted 
basement membrane, Matrigei. We found that the ~-gal-treated MCF-10A cells were 
non-invasive whereas increased CD147 expression induced their ability to invade (Fig. 2-
1B, C). To ensure that this effect was not restricted to MCF-10A cells, we examined the 
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effect of increased CD147 on invasiveness in HMLE cells, another immortalized, non-
transformed, human breast epithelial cell line; these cells also express low endogenous 
levels of CD147 (not shown). In similar fashion to the MCF-IOA cells, up-regulation of 
CD 147 induced invasion by these cells as compared with ~-gal adenovirus treated cells 
(Fig. 2-1B, C). These results suggest that up-regulating CD 147 is sufficient to induce an 
invasive cellular phenotype in non-transformed breast epithelia. 
Up-regulation of CD147 is sufficient for induction of matrix-degrading invadopodia-
like structures in non-transformed breast epithelial cells 
Parental MCF-lOA cells normally do not fo~W~?opodia (Sung et aI., 2009). Thus we 
next investigated whether the CD 147-induced increase in invasion is associated with 
invadopodia formation and activity. Initially, we found that untreated and control ~-gal 
virus-treated cells cultured on thin fluorescent matrices were unable to degrade the 
underlying matrix, whereas CD 147-adenovirus-treated cells degraded the matrix 
significantly; moreover the areas of degradation appeared as discrete spots in the matrix 
(Fig. 2-2A, left panels). To evaluate whether this matrix degradation is due to 
invadopodia activity, we probed the cells for cortactin and actin; we observed that only 
cells with increased CD 147 demonstrated significant co-localization of cortactin and 
actin in a punctate manner (Fig 2-2A), which is indicative of invadopodia formation. 
CD147 up-regulation increased the percentage of cells degrading matrix to approximately 
40%, compared to less than 5% in the control groups (Fig. 2-2B, left panel); the areas of 
matrix degradation corresponded to areas of actin-cortactin co-localization in --30% of 
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cells examined (Fig. 2-2C, left panel), indicating induction of active invadopodia by 
CD 147 in these cells. We further evaluated the degradation areas and number of 
invadopodia present in each of the cell groups and found that CD 147 up-regulation 
resulted in a greater area of matrix degradation per total cell area compared to parental 
and ~-gal-treated cells (Fig. 2-2B, right panel). Moreover, whereas the parental and ~-gal-
treated cells had essentially no invadopodia, cells with increased CD147 expression had 
an average of -6 invadopodia per cell (Fig. 2-2C, right panel). 
In order to visualize the induction of invadopodia more clearly, we compiled a 
volumetric 3D-reconstruction of serial confocal images of MCF-l OA cells treated with 
CD147 adenovirus, using Amira 3D image software. In Figure 2-3, panel A depicts the 
t, (", 
3D environment for a single cell, where the fl~.r~ent matrix appears as red, the actin 
cytoskeleton is blue, and cortactin is labeled in green. Approximately six invadopodia 
are penetrating through to the bottom of the matrix (Fig. 2-3B) and a cross-section 
through the cell-matrix interface demonstrates co-Iocalizati6n of actin and cortactin in 
these protrusions (Fig. 2-3C); supplementary videos illustrate protrusion of several of 
these invadopodia-like structures through the underlying matrix (supplementary material: 
Movies 1 and 2). 
These observations indicate that CD 147 plays an important role in the induction of 
invadopodia formation and activity. 
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CD147-induced, invadopodia-mediated, matrix degradation is dependent on 
membrane-type MMPs 
Although multiple MMPs effectively degrade components of the ECM and mediate 
invasiveness in vitro, several studies show that invadopodia utilize membrane type 
MMPs, particularly MTI-MMP, to degrade the ECM (Artym et aI., 2006; Frittoli et aI., 
2010; Liu et aI., 2009; Poincloux et aI., 2009; Rowe and Weiss, 2008). Since CD147 
induces both soluble and membrane type MMPs in various systems (Nabeshima et aI., 
2006; Yan et aI., 2005), we employed the MMP inhibitors, TIMP-I and TIMP-2, to 
distinguish which class of MMP was responsible for CD 147-induced, invadopodia-
mediated matrix degradation. TIMP-I selectively inhibits the activity of soluble MMPs 
whereas TIMP-2 is an inhibitor of both solublt}';a~;membrane-bound MMPs (Hotaryet 
aI., 2006). As expected, TIMP-2 inhibited most CD 1 47-induced matrix degradation 
whereas TIMP-I did not (Fig. 2-4A, B). These results show that cells expressing 
increased levels of CD147 utilize MT-MMPs to facilitate in\radopodia-mediated matrix 
degradation. 
Since the major membrane type-MMP associated with invadopodia formation and 
activity is MTI-MMP, we next evaluated whether increased CDl47 in MCF-IOA cells 
induces MTI-MMP expression. We found that MCF-IOA cells express low amounts of 
MTI-MMP, but treatment with CD147 adenovirus increases MTI-MMP as well as 
CDl47 protein levels (Fig 2-4C). CD147 induced expression of both the active form (--50 
kDa) and pro-form (-63 kDa) of MTI-MMP when the cells were cultured on gelatin 
(Fig. 2-4C), the conditions employed for invadopodia formation. However, when the 
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CD 147 -upregulated cells were grown on polystyrene, only the ~63 kDa MT 1-MMP pro-
form was detected (data not shown). 
To evaluate further whether the invasive phenotype of CD 147 -upregulated cells was 
due to MT1-MMP activity, we treated the cells with a function blocking antibody 
targeting the catalytic domain of MTI-MMP. We found that the MTI-MMP blocking 
antibody significantly decreased both CD 147-induced matrix degradation and Matrigel 
invasion compared to cells treated with a control IgG antibody (Figures 2-4D and E). 
CD147 associates with MTI-MMP in CD147-induced invadopodia-Iike structures 
and in membrane sub-fractions with the propertles' of lipid rafts 
'~'"'~i -.~/~' 
Since the data above support regulation of MT 1-MMP expression by CD 147, we 
investigated whether CD 147 co-localizes with MT 1-MMP and whether co-localization 
occurs within the induced invadopodia-like structures. We found that the two proteins 
co-localize over a subset of foci of degraded matrix (Fig 2-SA; yellow arrows), but also 
co-localize in foci that do not coincide with matrix degradation (Fig 2-SA; red arrows). 
Corresponding staining of ~-gal-infected cells showed relatively weak staining for MT1-
MMP or CD147 (Fig. 2 Supplemental 1). Previous studies have shown that CD147 and 
MTI-MMP are present in endocytic compartments, as well as in the plasma membrane 
(Eyster et aI., 2009; Jiang et aI., 2001). Thus, we evaluated whether SUb-populations of 
CD147 and MT1-MMP were present in a vesicular compartment within MCF-10A cells 
over-expressing CD147, and found that distinct sub-populations ofCD147 and MTl-
MMP are co-localized in EEA1-positive vesicles (Fig. 2-SB). These results, together with 
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those in Fig. 2-5A, indicate that sUb-populations of CD147 and MTI-MMP are present in 
vesicular compartments distinct from the populations that are localized in invadopodia. 
These findings are consistent with FACS analyses (data not shown), which showed that 
up-regulation ofCD147 induced ..... 30% increase in cell surface MTI-MMP compared to a 
total increase in MTI-MMP expression of ..... 80% (from Western blots), implying that a 
significant fraction of induced MT I-MMP remains inside the cells. 
Recent studies have shown that invadopodia are highly enriched in lipid raft domains 
and are dependent on these raft domains for invadopodia initiation and degradative 
activity (Yamaguchi et ai., 2009). Independent studies have shown that CD147 (Schwab 
et ai., 2007; Tang and Hemler, 2004) and MTI-MMP (Annabi et aI., 2001; Yamaguchi et 
, .- J J~ 
aI., 2009) are at least in part localized in membra¥'compartments similar to lipid rafts. 
Thus, we examined whether CD147 influences MTI-MMP localization into lipid rafts. 
Using a detergent-based lipid raft isolation protocol we showed that up-regulation of 
CD147 in MCF-IOA cells results in an enrichment of both tD147 and MTI-MMP in the 
raft fractions (light fraction) compared to ~-gal-treated cells (Fig. 2-5C). Notably, most of 
the CD147 in the raft fractions was the lower molecular weight form of -38kDa. These 
results, in conjunction with earlier findings (Yamaguchi et ai., 2009), imply that up-
regulation of CD 147 leads to enrichment of MT 1-MMP within specialized regions of the 
plasma membrane, most likely within invadopodia. However some of these lipid raft 
domains might reside in the membranes of intracellular vesicles, as discussed above. 
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CD147 regulates invadopodia function in invasive breast cancer cells 
Multiple cell models have been used to study invadopodia dynamics, but the majority of 
these studies have utilized the invasive human breast cancer cell line MDA-MB-231 
(Artym et aI., 2006; Hu et aI., 2011; Liu et aI., 2009; Yamaguchi et aI., 2009). Thus, we 
also evaluated whether CD147 regulates invadopodia dynamics in MDA-MB-231 cells. 
Figure 2-6A shows the endogenous level ofCD147 expression in MDA-MB-231 cells 
and the resulting expression of CD 147 after treatment of these cells with recombinant 
CD147 adenovirus or p-gal adenovirus as control. We found that an MOl of 2 was 
effective in up-regulating CD147 protein expression to a moderate degree (Fig 2-6A), 
within the range observed in various invasive cells; this MOl was used for the following 
,. :", 
experiments. As with the MCF-10A cells, the~3S;rDa form of CD147 was increased to a 
greater extent than the --52kOa form. The MOA-MB-231 cells express MT1-MMP and 
invade Matrigel to a moderate level. However, up-regulation of CD147 in these cells was 
accompanied by increased MTI-MMP expression (Fig. 2-6B) and increased Matrigel 
invasiveness (Fig. 2-60) as compared to controls. Bands corresponding to pro-form and 
active form of MTI-MMP were induced. We also treated MOA-MB-231 cells with 
pooled target-specific siRNAs. Dose-dependent down-regulation of CD147 was observed 
and was accompanied by corresponding partial decreases in MTI-MMP message and 
protein levels (Fig. 2-6C), as well as invasiveness in Matrigel (Fig. 2-60). 
We next determined whether changes in CD147 expression in MDA-MB-231 cells 
led to corresponding changes in invadopodia formation and activity. Cells treated with p-
gal adenovirus showed a moderate number of invadopodia and degradation spots in the 
fluorescent matrix field, in similar numbers to those reported in earlier studies (Artym et 
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aI., 2006). However, when cells were treated with CD147 adenovirus there was an 
increase in the percentage of cells degrading the matrix, concomitant with an increase in 
the percentage of cells with invadopodia (Fig. 2-7 A-C). Up-regulation of CD147 resulted 
in an increase in invadopodia number from ,..,4 per cell to ,..,8 per cell (Fig. 2-7C, right 
panel), coincident with large increases in degradation area per cell (Fig 2-7B, right 
panel). Partial down-regulation of endogenous CD147, using pooled siRNAs (Fig. 2-
6C), resulted in corresponding partial decreases in the percentage of cells degrading 
matrix, cells with invadopodia, number of invadopodia per cell, and area of matrix 
degradation per cell, whereas cells treated with control siRNA were comparable to ~-gal-
treated cells (Fig 2-7 A-C). 
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Co ... localization of CD147 and MTl ... MMP in invasive breast cancer cells 
In similar manner to our experiments with CD 1 47-treated NICF-IOA cells (Fig. 2-5A), 
parental MDA-MB-231 cells displayed CD147 and MTI-MMP that co-localized over 
foci of degraded matrix (Fig 2-8A; yellow arrow/asterisk) and non-degraded matrix (Fig. 
2-8A; red arrow/asterisk). These results were confirmed with a monoclonal antibody 
against MTI-MMP from Epitomics Inc. (Fig. 2 Supplemental 2) 
To further evaluate the observed co-localization of CD147 and MTI-MMP, we 
performed a proximity ligation assay (PLA), which can detect endogenous protein-
protein interactions that occur within 40 nm (Soderberg et aI., 2006). Probing for CD147 
and MTI-MMP in MDA-MB-231 cells using the proximity ligation method revealed that 
endogenous CD147 and MTI-MMP associate closely (Figure 2-8B). In a control 
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experiment using only CDl47 primary antibody followed by secondary PLA probes and 
amplification, no interaction was observed; additional field images demonstrated that 
CD147-MTl-MMP interactions occur throughout the cell population (Fig. 2 
Supplemental 3). Furthermore, we confirmed the specificity of the reaction by 
performing DIC microscopy, which demonstrated that the interactions occurred only in 
association with cells and did not represent non-specific staining of the culture 
substratum (Figure 2-SB, right panels; Fig. 2 Supplemental 3). We found approximately 
12-15 CD 147 -MT 1-MMP interactions per cell and, when the proximity ligation method 
was combined with the gelatin degradation assay, these CDI47-MTl-MMP interactions 
were found over areas of both degraded and non-degraded matrix (Fig. 2-SC), similar to 
the results in Fig. 2-SA. These data strongly suppoxt close interactions of sub-
" t~~;' 
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populations ofCD147 and MTI-MMP in actively degrading invadopodia, as well as in 
other areas of the cell such as EEAl-positive vesicles (Fig. 2-5B). 
Discussion 
Cancer cells employ various strategies to compromise the ECM scaffolds that inhibit 
their spreading through different tissue compartments. A major mechanism used by 
many cancer cell types to degrade the surrounding ECM is the formation of specialized 
actin-enriched membrane protrusions called invadopodia. The proteolytic activity of 
invadopodia has been mainly attributed to the localization of MTl-MMP at the cell 
surface in specialized membrane domains with the properties of lipid rafts, a process that 
is orchestrated by a diverse group of interacting molecules (Frittoli et aI., 2010; Murphy 
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and Courtneidge, 20 11; Poincloux et aI., 2009). Here we have made several novel 
findings indicating that CD 147 has a major mechanistic role in invadopodia formation 
and activity, and consequently in invasion. 
CDI47 expression is associated with many malignant phenotypes, including chemo-
and radio-therapy resistance, aerobic glycolysis, anchorage-independent growth, 
angiogenesis, invasion and increased metastatic potential. Among the best characterized 
functions of CDI47 is induction of MMPs, including MTI-MMP (Nabeshima et aI., 
2006; Yan et al., 2005). The exact mechanisms by which CD147 induces MMPs is not 
known, but current evidence indicates that h~mophilic CD 147 interactions mediate this 
induction (Sun and Hemler, 2001; Tang et aI., 2004b) and result in various downstream 
signaling events that promote MMP synthesi8'~n~fother activities (Ghatak et aI., 2005; 
Lim et aI., 1998; Tang et aI., 2008; Venkatesan et aI., 2010; Yang et aI., 2006). In 
agreement with earlier studies, we demonstrated that up-regulation or down-regulation of 
CDI47 increases or decreases, respectively, the levels of Mrl-MMP and invasiveness. 
In addition, we have demonstrated that modulation of CD147 expression correspondingly 
alters invadopodia function. 
Most strikingly, we found that up-regulating CD147 expression in non-transformed 
breast epithelia was sufficient to induce an invasion program similar to that seen in 
already invasive cancer cells, which was characterized by Matrigel invasion and 
formation of MT -MMP-dependent, actively degradative invadopodia. This suggests that 
up-regulation of CDI47 enriches the cell surface with active pools of MTI-MMP that 
subsequently degrade the matrix, as depicted in the gelatin degradation assays (Fig. 2-
2A). Though the mechanisms are not fully understood, earlier reports have demonstrated 
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that CD147 interacts with actin (Schlosshauer et aI., 1995) and that manipulation of 
CD147 expression results in reorganization of the actin cytoskeleton (Qian et a!., 2008) 
and formation of actin-rich lamellipodia in Drosophila cells (Curtin et a!., 2005); whether 
these findings are related to the mechanism of invadopodia formation is not known. In 
addition to its interactions with the actin cytoskeleton, CD 147 interacts with several other 
invadopodia-enriched molecules, such as integrins (Berditchevski et a!., 1997) and CD44 
(Slomiany et a!., 2009), that mediate attachment of ECM components to the cell surface 
and influence cytoskeleton remodeling. Recent evidence also suggests that CD147 can 
up-regulate various transcription factors leading to multiple downstream signaling events 
associated with ECM remodeling and invasion (Venkatesan et a!., 2010). Thus, CD147-
regulated invadopodia formation may be due in tpartto interactions with other ancillary 
'f'~~/' ~;; 
invadopodia-associated proteins. 
Another established function of CD 147 is in lactate transporter trafficking to the cell 
surface, where CD 147 is an essential chaperone needed to display sub-classes of lactate 
transporters on the cell surface (Halestrap and Meredith, 2004) .. Though it is currently 
unknown whether CD147 is also involved in trafficking of MMPs to the cell surface, our 
data demonstrate that endogenous CD147 and MT1-MMP are in close proximity and that 
sub-populations of this complex occur in actively degrading invadopodia whereas other 
sub-populations are present in EEA1-positive endocytic vesicles. These results suggest 
the possibility that CD 147 -MT 1-MMP complexes may cycle between these two 
compartments. Other investigators have shown that CD147 associates with both the pro 
and active forms of MT1-MMP (Egawa et a!., 2006; Niiya et a!., 2009). In addition, we 
found that up-regulation of CD147 in non-transformed MCF-IOA epithelial cells results 
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in enrichment of both CD147 and MT1-MMP in membrane compartments with 
characteristics similar to lipid raft domains, supporting previous observations that 
invadopodia formation and activity are dependent on these domains (Yamaguchi et aI., 
2009). These results are compatible with the idea that CD147 may playa role in 
subcellular trafficking or surface presentation of MT 1-MMP. However, further work is 
required to determine whether CD147 is involved at multiple steps during initiation and 
maturation of invadopodia or whether it aids solely during the degradation process. 
Of interest also is our observation that a relatively low-glycosylated form of CD147 
was induced by treatment with recombinant CD147 adenovirus and that this form was the 
major form targeted to the lipid raft domains (Figure 2-5C). The results of some previous 
,. :", 
studies suggest strongly that high levels of gly¢o~fation are necessary for induction of 
MMP production (Guo et aI., 1997; Tang and Hemler, 2004), whereas others have 
demonstrated robust MMP production after treatment with non-glycosylated CD147 
(Belton et aI., 2008) or CD147 substituted only with the diiaccharide, chitobiose 
(Kawakami et aI., 2011). Clearly, further investigation is required to elucidate the role of 
glycosylation in CD147 activities within different contexts. 
Mechanisms of regulation of endogenous CD 147 expression are not well established, 
although several growth factors and cytokines have been shown to increase CD 147 levels 
in a variety of contexts (Hagemann et aI., 2005; Menashi et aI., 2003; Reddy et aI., 2010; 
Rucci et aI., 2010). Previous studies have shown that Src is a critical regulator of 
invadopodia formation (Murphy and Courtneidge, 2011), and a recent study showed that 
the Src family kinase, Fyn kinase, induces emmprin expression (Ramos and Dang, 2011). 
We have also found that CD147 is elevated in cells over-expressing wild-type or 
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constitutively active Src (O.D.G, unpublished data), suggesting that Src may act at least 
in part via induction of CD 147. 
In the present study, we provide evidence that increased CD147 alone is sufficient 
to induce the formation of actively degradative invadopodia-like structures in non-
transformed epithelial cells and that CD147 may regulate localization of MT1-MMP in 
lipid raft domains. Furthermore, we have demonstrated that CD147 and MT1-MMP are 
in close proximity to each other and these interacting pools are present in part within 
active invadopodia. Since CD 147 is enriched on the surface of numerous malignant 
cancer cell types, it represents a plausible molecular target to evaluate for future cancer 
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Figure 2-1. Up-regulation of CD147 in non-transformed breast epithelial 
cells increases invasion. (A) Western blot showing endogenous CD147 
protein expression in MCF-lOA cells and increased CD147 expression after 
up-regulation with increasing MOl of CD147 adenovirus. An MOl of 2 was 
used in all subsequent experiments. (B) MCF-lOA or HMLE cells that were 
untreated or infected with ~-gal or CD147 adenovirus were plated on Matrigel-
coated invasion chambers and analyzed for invasion. (C) Quantitation of 
invasion; columns represent means +/- SEM of numbers of cells invaded per 
field in 3 independent experiments. ** P < 0.01. 
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Figure 2-2. CD147 induces the formation of matrix-degrading invadopodia-
like structures in non-transformed breast epithelial cells. MCF-I0A cells, non-
infected or infected with ~-gal or CD147 adenovirus, were cultured on a 
fluorescent gelatin matrix for 15 hours. (A) Representative micrographs of non-
infected, ~-gal, and CD147 adenovirus-infected cells cultured on fluorescent 
matrix. After fixation, cells were immunolabeled for cortactin (primary 4Fll 
antibody followed by secondary Alex Fluor-488 antibody) and Alexa Fluor 647-
phalloidin. Actin and the gelatin matrix were pseudo-colored to red and blue, 
respectively; this allows easier visualization of colocalization (yellow) of actin 
(red) and cortactin (green). Invadopodia-mediated matrix degradation appears as 
dark black foci in the bright fluorescent matrix field. Boxed insets, higher 
magnifications of examples of invadopodia (arrowheads), identified by 
colocalization of cortactin and actin punctae over areas of degraded matrix. Scale 
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Figure 2-2 (continued). CD147 induces the formation of matrix-degrading 
invadopodia-Iike structures in non-transformed breast epithelial cells. (B-C) 
Quantification of invadopodia characteristics: (B) Left panel: Percentage of cells 
degrading matrix. Right panel: Normalized degradation, calculated as area of 
degradation/total cell area defined by actin channel. (C) Left panel: Percentage of 
cells with active invadopodia, defined as cortactin-actin aggregates over degraded 
matrix. Right panel: Number of invadopodia/cell. Each parameter was calculated 
by evaluating 10 random fields containing at least 15 cells/field over 3 independent 




Figure 2-3. Three-dimensional volumetric reconstruction of CD147-induced 
invadopodia-like structures penetrating the underlying matrix. CD147 
adenovirus-infected MCF-IOA cells cultured on a fluorescent-gelatin matrix were 
analyzed with confocal microscopy. Leica SP5 confocal softw,are was employed to 
obtain an optimal image stack from single cell images and was further processed with 
Amira software to reconstruct a 3D volumetric image of a cell producing invadopodia-
like protrusions that are penetrating the underlying fluorescent matrix. Cells were 
stained with Alexa-phalloidin (blue) to image actin filaments and cortactin (green) to 
identify invadopodia; fluorescent matrix is depicted in red. A) Overhead view of a 
single cell cultured on fluorescent matrix; B) View underneath the fluorescent matrix 
showing -6 invadopodia (arrows) penetrating the matrix; C) Magnified cross-section 
through cell demonstrating one of the invadopodia-like protrusions (actin and cortactin 




Adv CD147 + TIMP-1 
Adv CD147 + TIMP-2 
D. Matrix Actin 
Cortactin Merge 
Adv CD147 + IgG 






















Figure 2-4. CD147-induced, invadopodia-mediated, matrix degradation is 
dependent on membrane-type MMPs. (A-B) MCF-10A cells infected with CD147 
adenovirus were pre-treated with the protease inhibitors, TIMP-1 (0.5 ~g/ml) and TIMP-
2 (0.5 ~g/ml) for 30 minutes and then plated on fluorescenr matrices for 12 hours in the 
presence of these inhibitors. A) Representative micrographs of matrix degradation in 
control and CD147 up-regulated cells in the presence of proteas,e inhibitors. Scale bar, 
1 0 ~m. B) Quantitation of normalized degradation area, expressed as means +/ - SEe * * 
p < 0.01. Experiment was repeated 3 times. C) Western blot of CD147 and MT1-MMP 
in aliquots of lysates obtained from MCF-10A cells that were cultured on gelatin and 
untreated or treated with control (~-gal) or CD 147 adenovirus. Actin was used as a 
loading control; n=3. (D-E) MCF-10A cells infected with CD147 adenovirus were pre-
treated with function-blocking antibody against MT1-MMP (LEM-2/1S.8; 12 J.lg/ml) or 
control IgG and then plated on fluorescent matrices for 12 hours in the presence of the 
blocking antibody or IgG. D) Representative micrographs of matrix degradation in 
control and CD147 up-regulated cells in the presence of blocking antibody or IgG. Scale 
bar, 10 ~m. E) Left panel: Quantitation of normalized degradation area. Right panel: 
Quantitation of invasion through Matrigel. Expressed as means +/- SEe **p < 0.01; 
***p<O.OOl; experiments were repeated 3 times. 
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Figure 2-5. CD147 associates with MTI-MMP in invadopodia-Iike 
structures and in membrane sub-fractions with the properties of lipid 
rafts. A) Representative micrographs of CD147 and MTI-MMP colocalizing 
over degraded matrix in CD 147-overexpressing MCF-I0A cells. Yellow arrows 
indicate colocalization of CD147 (green) and MTI-MMP (red) over foci of 
degraded matrix; red arrows indicate colocalization of CD147 and MTI-MMP 
over areas not showing degraded matrix. Scale bar, 10 ~m. B) Representative 
micrographs showing co-localization of CD147 (top panels) or MTI-MMP 
(bottom panels) with EEA I-positive vesicles. Yellow arrows indicate co-
localization of proteins; green arrows indicate lack of co-localization. Scale, 10 
Jlm C) MCF-I0A cells infected with ~-gal or CD147 adenovirus were plated on 
gelatin-coated plates overnight and were subjected to detergent-resistant 
membrane isolation. Light fraction represents the gradient interface (0-20%) 
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Figure 2-6. CD147 regulates MTI-MMP expression and Matrigel invasion in 
invasive breast cancer celIs. (A) Western blot showing endogenous CD147 protein 
expression, CD147 expression following treatment with control adenovirus (~-gal), 
and CD 147 expression following treatment with increasing amounts of recombinant 
CD147 adenovirus in MDA-MB-231 cells; n=2. An MOl of 2 was chosen for up-
regulating CD 147 in subsequent experiments. ~-actin was used as the loading control. 
(B) Representative western blot of increased MTI-MMP levels following CD147 up-
regulation in MDA-MB-231 cells; n=3. f3-gal treatment was used as the control; 13-
actin demonstrates equal loading. C) Left panel: Western blot demonstrating that 
knockdown of CD 147 with increasing concentrations (3 and 611,1) of pooled target-
specific siRNA results in decreased MTI-MMP protein expression. Non-specific 
siRNA was used as a control and ~-actin was used to demonstrate equal loading; n=3. 
Right panel: RT-PCR analysis of CD147 and MTI-MMP mRNA after treatment with 
control or CD147 siRNAs. D) Left panel: Representative images of Matrigel invasion 
assay with MDA-MB-231 cells treated with ~-gal or CD147 adenovirus or with 
control or CD 147-specific siRNA. Right panel: Quantification of invaded cells per 
field by evaluating four separate fields in 3 independent experiments. Columns 




















Figure 2-7. CD147 regulates invadopodia dynamics in invasive breast cancer 
cells. (A) Representative micrographs demonstrating MDA-MB-231 cells treated 
with ~-gal or CD147 adenovirus or with control or CD 147-targeted siRNA. Cells 
were cultured on Alexa Fluor 568-conjugated gelatin for 5 hours, fixed, and 
probed for actin (Alexa 647 phalloidin) and cortactin (primary 4Fl1 antibody 
followed by secondary Alex Fluor-488 antibody). Actin and the gelatin matrix 
were pseudo-colored to red and blue, respectively; this allows for easier 
visualization of colocalization (yellow) of actin (red) and cortactin (green). The 
left panels demonstrate invadopodia-mediated matrix degradation (dark holes). 







• : )~, f 
."' ..... ,.t.;J.-





















Figure 2-7 (continued). CD147 regulates invadopodia dynamics in invasive breast 
cancer cells. (B-C) Quantification of invadopodia characteristics for MDA-MB-231 
cells: (B) Left panel: Percentage of cells degrading matrix; calculated as cells with at 
least one area of degradation underneath the cell or near cell border. Right panel: 
Normalized degradation, calculated as area of degradation/total cell area defined by 
actin channel. (C) Left panel: Percentage of cells with invadopodia, defined as actin-
cortactin aggregates localized over degraded matrix. Right panel: Number of 
invadopodia/cell in cells exhibiting at least one invadopodium. Each parameter was 
calculated by evaluating 10 random fields containing at least 20 cells/field over 3 
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Figure 2-8. Co-localization of CD147 and MTI-MMP iQ. invasive breast cancer cells. 
(A) Representative image demonstrating CD147 and MTI-MMP co-localization in 
MDA-MB-231 cells. Cells were cultured on Alexa Fluor 568-conjugated gelatin for 5 
hours and probed with CD147-488 and MTI-MMP followed by an Alexa Fluor-647 
secondary antibody. Polyclonal antibody against MTI-MMP (Millipore) was used for 
these images; monoclonal antibody against MTI-MMP (Epitomics) gave similar results 
(Supplemental Figure 2). MTI-MMP and the gelatin matrix were pseudo-colored to red 
and blue, respectively; this allows easier visualization of colocalization (yellow) of 
CD147 (green) and MTI-MMP (red). Yellow arrow depicts CD147-MTI-MMP co-
localization over foci of degraded matrix; red arrow indicates colocalization of CD147 
and MTI-MMP over an area not showing degraded matrix. XZ section: Yellow asterisk, 
CD147-MTI-MMP over a region of degraded matrix; red asterisk, CD147-MTI-MMP 
over an area not showing matrix degradation. n=3. (B-C) A proximity ligation assay 
(PLA) was employed to detect close protein-protein interactions «40nm) of CD147 and 
MTI-MMP in MDA-MB-231 cells (see Materials and Methods for details). B) Left 
panel: interactions of CD147 and MTI-MMP (small green dots at arrowheads); cells 
were also stained with DAPI (blue). Right panel: DIC images of a single cell; arrowheads 
indicate sites of CD147-MTI-MMP interactions, which are restricted to areas over the 
cell. C) PLA combined with gelatin degradation assay, showing that CD147- MTI-MMP 
interactions occurred over areas of degradation (arrowheads), as well as over areas 
lacking degradation. Bars, 1 0 ~m. 
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Figure 2. Supplementall. CDl47 and MTl-MMP expression in MCF-lOA 
cells treated with p-gal adenovirus. MCF-IOA cells were treated with ~-gal 
adenovirus, fixed and stained for CD147 and MTI-MMP. Images demonstrated 
that staining is relatively weak for both proteins. 
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Figure 2. Supplemental 2. CD147 and MTI-MMP co-localize in MDA-
MB-231 cells (alternative MTI-MMP antibody). Representative micrograph 
depicting MDA-MB-231 cells probed with CD147-488 conjugated antibody 
(Biolegend) and a monoclonal MTI-MMP antibody (Epitomics) followed by an 
Alexa Fluor-647 secondary antibody. 
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Figure 2. Supplemental 3. Proximity ligation assay demonstrates that 
endogenous CD147 and MTI-MMP are in close proximity in MDA-MB-231 
cells. A) Cells were probed with CD147 (BD Pharmingen) and MT1-MMP 
(Millipore) primary antibodies using standard labeling ~ethods. They were then 
probed with Duolink II secondary antibodies and detectIon kit reagents 
according manufacturers protocol. Protein-protein interactions appear as green 
dots. Red arrows depict examples of CD 147 -MT 1-MMP interactions 
throughout the cell population. B) Using similar techniques as stated in A), DIC 
microscopy demonstrates that CD 147-MT1-MMP interactions are specific to 
cells and do not represent non-specific staining. Red arrows depict multiple 
interactions throughout the cell population. C) Control PLA experiment 
demonstrating specificity of Duolink reaction. Cells were initially probed with 
only CD147 (BD Pharmingen) primary antibody. This was then followed by 
reagents of the Duolink II kit. No signal (e.g. protein-protein interaction) was 
detected due to the lack of rolling circle amplification, which is dependent on 
the 2 primary antibodies localizing in close proximity. 
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Chapter 3: CD147 and the Ras-ERK signaling pathway co-regulate breast 
epithelial cell invasiveness 
Abstract 
Breast cancer is a heterogeneous disease, and similar to other cancers, metastases 
to distant vital organs is the main cause of mortality. It has become evident that invasive 
breast cancer cells employ various mechanisms to spread from their tissue of origin. One 
of the main mechanisms utilized is the formation of actin-rich membrane protrusions 
called invadopodia. Invadopodia are enriched:<vtth various signaling proteins, adhesion 
molecules and proteolytic enzymes and are thought to be a major superstructure at the 
leading edge of an invasive cell. 
The IgSF protein, CD 147 is associated with an invasive phenotype in various 
cancer types, including malignant breast cancer. CD 147 was first identified as a major 
matrix metalloproteinase (MMP) inducer localized to the tumor cell surface. It has 
become clear, in addition to stimulation of soluble and membrane-type MMP synthesis, 
that CD 147 has pleiotropic functions in various aspects of cancer progression, including 
cytoskeleton remodeling. Recent evidence suggested that up-regulation of CD147 alone 
in non-transformed and non-invasive breast epithelial cells induced an invasive 
phenotype characterized by MT1-MMP (MMP-14)-dependent invadopodia activity. 
Earlier evidence suggests that CD 147 cooperates with various binding partners, including 
CD44 the main hyaluronan (HA) receptor, to promote a tumorigenic phenotype. 
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In this study we found that up-regulation of CD147 activates an EGFR-Ras-ERK 
signaling cascade that mediates invasiveness, and that these effects are partially 
dependent on HA-CD44 interactions. We also discovered that oncogenic Ras regulates 
CD147 expression and may elicit a positive feedback loop involving ERK signaling. We 
further found that enrichment of cells with differential CD 147 surface levels afforded us 
the ability to isolate sub-populations of breast cancer cells with distinct phenotypes. 
Introduction 
CD147 (emmprin; basigin) is a highly and variably glycosylated transmembrane protein 
that is involved in both physiological and patholqgl¢al cellular processes (Nabeshima et 
·'·"·~/·{f· 
aI., 2006; Yan et aI., 2005; Yurchenko et aI., 2010). CD147 expression is elevated in a 
wide range of cancer types, including breast cancer (Li et aI., 2009; Riethdorf et aI., 
2006). Earlier studies employing in situ hybridization and \mmunohistochemistry 
techniques found that CD147 was expressed at pre-invasive and invasive areas, as well as 
proliferative regions in breast lesions; though CD 147 was identified in normal breast 
tissue, it was expressed at much lower levels (Caudroy et aI., 1999; Polette et aI., 1997). 
CD147 expression gradually increases during progression from atypical ductal 
hyperplasia to invasive breast cancer and is correlated with hormone receptor negative 
and Erbb2 over-expressing breast cancers (Liu et aI., 2010). Originally identified as a 
tumor-associated factor that induces stromal fibroblasts to synthesize and secrete matrix 
metalloproteinases (MMPs) (Biswas, 1984; Biswas et aI., 1995; Ellis et aI., 1989; Guo et 
aI., 1997), CD147 has since been shown to have pleiotropic functions. In addition to 
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inducing MMP synthesis in stromal, tumor, and endothelial cells, CD 147 contributes to 
therapy-resistance, angiogenesis, inflammatory signaling, cytoskeletal remodeling, and 
migration/invasion programs (Weidle et aI., 2010). CD147 also participates in regulating 
the synthesis of the large extracellular polysaccharide, hyaluronan (HA), the main ligand 
for the cell surface receptor CD44 (Edward et aI., 2011; Ghatak et aI., 2005; Kato et aI., 
2011; Marieb et aI., 2004; Qin et aI., 2011). CD 147-induced HA-CD44 interactions 
modulate various signaling pathways and potentiate tumorigenic properties in various cell 
types (Toole and Slomiany, 2008). CD147 also cooperates with cyclophilins to induce 
intracellular signaling pathways (Yurchenko et aI., 2010), and with MCTs to influence 
tumor cell metabolism (Kennedy and Dewhirst, 2010), although in each case the exact 
mechanisms by which CD147 activates signaling cascades are not fully understood. 
'"·~·~/.~jr 
Dysregulated expression of Ras genes has been identified in many cancer types 
(Karnoub and Weinberg, 2008) and oncogenic Ras expression is associated with 
aggressive cancer phenotypes, such as proliferation, invasidnlmetastasis and therapy 
resistance (Pylayeva-Gupta et aI., 2011). Though the common point mutations identified 
in oncogenic forms of Ras are a very rare occurrence in breast cancer, chronic Ras 
activity has been documented in breast cancer cell lines and patient tumor tissue in the 
absence of Ras mutations (Eckert et aI., 2004; Lintig et aI., 2000; Rochlitz et aI., 1989). 
In the absence of oncogenic Ras signaling, up-regulation of normal Ras activity can 
facilitate similar transformed phenotypes (Zhang et aI., 2009). Aberrant Ras signaling 
may be due to amplified expression and activation of cell surface receptor tyrosine 
kinases (RTKs), such as epidermal growth factor receptor (EGFR) family members, 
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mutations in modulators of the Ras activation state or effectors downstream of Ras 
(Campbell and Der, 2004; Stamatakos et aI., 2010). 
In this study we have identified novel signaling associations between CD 147, 
HA-CD44 interactions, and EGFR, Ras and ERK signaling that regulate the invasive 
properties of breast epithelial cells. 
Materials and Methods 
Cell Culture 
The human breast adenocarcinoma cell lines MQA~,MB-231 and MCF-7 were obtained 
",.,'", jj" 
from American Type Culture Collection (ATCC}/and were cultured in RPMI 1640 (R-
8755) with 2.38 gIL HEPES, 2 gIL sodium bicarbonate, and 10% FBS (pH 7.4). The 
spontaneously immortalized human breast epithelial cell line MCF-10A was obtained 
l 
from ATCC. MCF-IOA cells stably expressing a lentivirus construct containing K-
Ras V12 (lOA-K-Ras V12) or empty vector (10A-EV) were generously provided by Dr. Ben 
Ho Park (Konishi et aI., 2007). Low passage MCF-IOA cells and MCF-IOA derivatives 
were maintained in Mammary Epithelial Cell Growth Medium (MEGM) with BulletKit 
supplements (Lonza) unless noted otherwise in legends. All cells were cultured in a 
humidified 95% air/5% CO2 incubator at 37°C. 
Antibodies and Reagents 
The following primary antibodies were employed for these studies: CD 147, 
CD 147-FITC, IgG-FITC and caveolin-l (BD Biosciences); Alexa-Fluor 647-conjugated 
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CD147, Alexa-Fluor 488-conjugated CD147 and PE-conjugated EGFR (Biolegend); 
cortactin (clone 4Fll) and MTI-MMPI hinge-region polyclonal (Millipore); phospho-
ERK1/2 (Thr202/Tyr204), pan-ERKI/2, phospho-EGFR (TyrI173), phospho-EGFR 
(Tyrl068), and EGFR (Cell Signaling Technology, Inc); CD44IHCAM (mouse) and 
Alexa-Fluor 647-conjugated CD44 (Santa Cruz Biotechnology, Santa Cruz, CA); PE-
conjugated CD44 (Cedarlane Laboratories); CD44 (rabbit) (Epitomics); ~-actin and ~-
tubulin (Sigma). Goat anti-mouse-HRP and Goat anti-rabbit-HRP (Chemicon) were used 
as secondary antibodies for immunoblotting. The inhibitors Tyrphostin (Calbiochem), 
U0126 and PD98059 (Cell Signaling Technology, Inc) were used at concentrations 
indicated in figure legends. 
.. "", 
Recombinant adenovirus infections "'~'~" ~; .. 
Recombinant human CD 147 adenovirus and control ~-galactosidase (~-gal) adenovirus 
were constructed and used as described previously (Grass et aI., 2012; Li et aI., 2001). 
\ 
Surface Biotinyiation ' 
Cell surface biotinylation was performed using a Cell Surface Protein Isolation Kit 
according to manufacturer's protocol (Pierce). Briefly, cells were treated with EZ-Link 
Sulfo-NHS-SS-Biotin for 45 minutes at 4°C, followed by quenching and harvesting of 
celllysates. Equivalent amounts of protein from each experimental group was added to 
spin columns containing NeutrA vidin resin, incubated for several hours with rocking at 
4°C, washed, eluted and followed by immunoblotting. 
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Ras Activity Assay 
Ras activation status was evaluated by employing the Active Ras Pull-Down and 
Detection Kit according to manufacturer's protocol (Pierce). This assay is based on the 
observation that Ras-GTP (active), but not Ras-GDP (inactive), binds Raf-l with high 
affinity. Briefly, fresh lysates from MCF-10A cells non-treated or treated with 
adenovirus were collected using standard procedures. GTPyS (0.1 mM) or GDP (1 mM) 
was added to controllysates for a positive and negative control, respectively. GST -Raf1-
Ras-binding domain (GST-Raf1-RBD) fusion protein was added to the spin column 
containing a glutathione resin, followed by addition of 400-500 ~g of protein from 
positive/negative controls and ~-gal or CD147 treated cells. Lysates were incubated for 1 
hour at 4°C with rocking, followed by elutiofi~d;ilbsequent immunoblotting with a 
pan-Ras antibody. 
Hyaluronan ELISA 
Hyaluronan concentrations in the media were determined using an enzyme-linked 
immunosorbent-like assay described previously (Gordon et aI., 2003). 
Preparation of Hyaluronan Oligosaccharides 
Hyaluronan oligosaccharides (oHAs) were prepared as described previously (Zeng et aI., 
1998). Briefly, oHAs used in this study were derived from degradation products of 
hyaluronan purified from rooster combs (Sigma). Hyaluronan was dissolved in sodium 
acetate buffer at a pH of 5.0 and treated with testicular hyaluronidase (Type I-S, Sigma) 
overnight. The digest was precipitated with TCA on ice, dialyzed for 48 hours using a 
1000 dalton molecular weight cutoff (MWCO) and fractionated with 5000 MWCO spin-
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dialysis tubes. Fractions mainly composed of 6-12 oligosaccharide units were further 
concentrated with lyophilization and concentration was determined using a Carbazole 
assay, which detects uronic acid. Oligomer size was assessed with the Morgan-Elson 
assay by determining the ratio between N-acetyl-D glucosamine D-glucuronic acid. 
Matrigel invasion assay 
Matrigel invasion inserts (8~m pores) for 24-well tissue culture plates were purchased 
from BD Biosciences. Briefly, the Matrigel inserts (upper and lower chambers) were 
rehydrated for 2 hours at 37°C with non-supplemented MEGM. 7.0x105 MCF-I0A-EV 
and MCF-I0A K-Ras V12 or MCFI0A-K-Ras V12 cells treated with siRNA (72 hours) or 
MEK inhibitors were detached and seeded in the upper chamber of the inserts and . ", 
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cultured for 24 hours at 37°C in non-supplemented MEGM, and medium in the lower 
chamber was replaced with MEGM containing 20 nM EGF. After incubation, the cells 
were fixed in 3.7% paraformaldehyde for 15 minutes at room temperature, rinsed with 
1 
PBS and stained with 0.2% Crystal Violet for 10 minutes, followed by extensive 
washing. Cells were scraped from the top of the Matrigl membrane with a Q-tip and the 
cells that invaded through the 8~m pores in the membrane were imaged using a phase-
contrast microscope (Leica DFC320). Cells were counted in four separate fields in three 
independent experiments. 
Gelatin degradation assay for invadopodia 
This assay was performed as described previously (Grass et aI., 2012). Briefly, gelatin 
was conjugated with Alexa-Fluor-568 dye (Molecular Probes) using the manufacturer's 
protocol. 18 mm round glass coverslips were acid washed with 1 M HCI overnight 
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followed by extensive washing in water. Coverslips were sterilized with 70% ethanol 
and then coated with 50 ~g/ml poly-L-lysine for 20 minutes at room temperature, washed 
with PBS, and fixed with ice-cold 0.5% glutaraldehyde for 15 minutes followed by 
extensive washing. The coverslips were then inverted on an 80 ~l drop of fluorescent 
gelatin matrix (0.2% gelatin and Alexa-Fluor-gelatin at an 8: 1 ratio) and incubated for 15 
minutes at room temperature. The coverslips were washed with PBS and quenched in 5 
mg/ml sodium borohydride in PBS for 10 minutes, followed by further washing in PBS. 
The coated coverslips were then placed in 12-well plates, sterilized in 70% ethanol for 10 
minutes, washed in PBS and equilibrated in serum-free MEGM and switched to fully 
supplemented MEGM 30 minutes before the addition of cells. For invadopodia assays, 
5.5 X 104 cells were plated on the coated coverslip&.'"and incubated at 37°C for 15-18 
"., .. ;. 1,'- ~ 
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hours. Cells were fixed and permeabilized with 3.7% paraformaldehyde and 0.1 % Triton 
X-I00 for 10 minutes, washed with PBS, blocked in 3% BSA in PBS for 1 hour, and 
incubated with appropriate primary and secondary antibodifs in 3% BSA in PBS. Actin 
filaments were visualized with Alexa-Fluor-647-phalloidin. 
In situ proximity ligation assay 
Protein-protein interactions were detected in situ, as described previously (Grass et aI., 
2012), using Duolink II secondary antibodies and detection kit (Olink Bioscience, 
Uppsala, Sweden) according to manufacturer's instructions. Briefly, primary antibodies 
targeting CD147 (mouse; BD Pharmingen), EGFR (rabbit; Cell Signaling), CD44 
(mouse; Santa Cruz Biotechnology), CD44 (rabbit; Epitomics) were applied using 
standard procedures. Oligonucleotide-conjugated Duolink secondary antibodies were 
then added, followed by Duolink ligation solution. The oligonucleotides ligate together 
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in a closed circle only when the secondary antibodies are in close proximity «40 nm) 
(Soderberg et aI., 2006). Polymerase was added, which amplified any existing closed 
circles, and detection was achieved with complementary, fluorescently labeled 
oligonucleotides. Specificity of the reaction was determined by treating cells with a 
single primary antibody followed by Duolink secondary antibodies, which results in 
minimal to no signal amplification because of the absence of a second oligonucleotide 
needed for ligation and subsequent closed circle amplification. 
Microscopy and image analysis 
Images were acquired with a Leica Total Confocal System SP5 acoustic optical beam 
splitter confocal (TCS SP5 AOBS) microscope using ~ 63x, 1.4 NA oil objective at the 
r ;", 
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Josh Spruill Molecular Morphology & Imaging Center in the Department of Regenerative 
Medicine and Cell Biology (MUSC, Charleston, SC). Images were captured at high 
confocality (pinhole =1 Airy unit) to achieve the thinnest possible optical slices at the 
1 
cell-matrix interface. Potential overlaps in emission spectra were eliminated by 
sequential scanning and tuning of the AOBS. Differential interference contrast (DIC) 
microscopy was performed using the Leica SP5 Confocal System. 
Assessment of invadopodia characteristics was performed as described previously (Grass 
et ai., 2012). Briefly, at least 10 randomly chosen fields were imaged per experiment and 
evaluated for degraded matrix foci, which appear dark 'holes' in the fluorescent matrix 
field. A cell with at least one degradation foci underneath or near the cell edge was 
counted as a cell able to degrade matrix. Invadopodia, defined as actin puncta that 
colocalize with cortactin, were manually counted and analyzed for underlying matrix 
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degradation. Results were presented as percentage of cells degrading the matrix, number 
of invadopodia per cell or percentage of cells displaying cortactin-actin aggregates with 
or without degradation underneath. 
qRT.PCR 
For qRT-PCR experiments, total RNA was isolated using the RNeasy Mini kit according 
to the manufacturer's instructions (QIAGEN, Valencia, CA) and quality control and 
quantification was performed with the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Inc., Santa Clara, CA) and Agilent RNA 6000 Pico LabChip kits. Complementary DNA 
(cDNA) was synthesized from equivalent concentrations of total RNA using the iScript 
cDNA Synthesis Kit (Bio-Rad) according to manufa~turer's instructions. Coding 
.. .'J" 
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sequences for CD147 and fJ-actin (internal controf) were amplified from synthesized 
cDNA using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). Custom primer 
sequences used for amplification were as follows: CD147 sense 5'-
'1 
CAGAGTGAAGGCTGTGAAGTCG -3'; CD147 antisense 5'-TGCGAGGAACTCACGAAGAA-
3'; fJ-actin sense 5'-GGAAATCGTGCGTGACATT -3'; fJ-actin antisense 5'-
GACTCGTCATACTCCTGCTTG -3'. Amplification was performed using an iCycler IQ 
Real-Time PCR Detection System and cycle threshold (Ct) values were determined in 
duplicate for CD147 and fJ-actin transcripts for each experiment. 'No template' (water) 
and 'no-RT' controls were used to ensure minimal background signal from DNA 
contamination. Using mean Ct values tabulated for different experiments and Ct values 
for fi-actin as loading controls, fold changes for experimental groups relative to assigned 
controls were calculated using automated iQ5 2.0 software (Bio-Rad). 
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RNA interference 
Control non-silencing siRNA and target-specific pooled siRNAs for CD147 and CD44 
were purchased from Santa Cruz Biotechnology and used according to manufacturer's 
protocol. For all experiments, cells were transfected with siRNA 72 hours before each 
experiment. 
Detergent-resistant membrane fractionation 
Detergent-resistant membrane domains (e.g. lipid rafts) were isolated as described 
previously (Grass et aI., 2012). Briefly, cells cultured in D150 plates were washed with 
ice-cold PBS three times. Cells were lysed in 500~L lysis buffer (25 mM Tris-HCI, pH 
7.5, 150 mM NaCI, 1mM dithiothreitol, 10% sucro'$,c,' 1 % Triton X-100 and protease 
d ~~'1' 
inhibitors) on ice for 30 minutes. The cells were scraped and mechanically disrupted by 
passaging 20 times through a 3-inch 22-guage needle. The lysates were mixed directly 
with iodixanol stock solution (60% solution of Optiprep iodixanol) to yield a 40% (v/v) 
iodixanol-Iysate solution, which was placed at the bottom of an ultracentrifuge tube. 
Equal volumes of 35%, 30%, 25%, 20% and 0% Optiprep in lysis buffer without Triton 
X-100 were carefully overlaid above the iodixanol-Iysate solution. The samples were 
centrifuged at 160,000 x g for 8 hours at 4°C in a SW41-Ti rotor (Beckman Coulter). 
Equal fractions were collected from the top of the tube and equivalent aliquots of each 
fraction were subjected to immunoblotting using antibodies recognizing proteins of 
interest. 
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Labeling of live cells with Cholera toxin-B (Ctx-B) to identify lipid rafts 
Lipid raft labeling was performed using the Vybrant Alexa-Fluor-488 Lipid Raft labeling 
kit using the manufacturer's protocol (Invitrogen Molecular Probes). Briefly, live cells 
were washed with ice cold PBS, labeled with Alexa-Fluor-488-conjugated Ctx-B, cross-
linked with anti-CtxB antibody, followed by standard immunofluorescence staining and 
mounting techniques. 
Cell surface analysis and fluorescent activated cell sorting of CD147Lo and CD147Hi 
Sub-populations 
For cell surface analysis, 2.0x 105 cells were trypsinized to achieve single cell 
suspensions, counted and blocked with 3% BSA' in/PBS, and incubated with primary-
'/"'~/' .~J' 
conjugated antibodies for 30 minutes on ice. Unbound antibody as removed in 
subsequent washes and cells were analyzed no longer than 1 hour post-staining. Cell 
sorting of CD147Lo and CD147Hi sub-populations was achiQved in the following manner: 
cells (10A-K-Ras V12, MDA-MB-231, and MCF-7) were trypsinized into single cell 
suspensions, counted, blocked with 3% BSA in PBS, and treated with antibodies in 
culture medium. Cells were incubated with anti-CDI47-FITC or IgG-FITC (negative 
control) for 30 minutes on ice. Unbound antibody was washed off and cells were 
resuspended in fresh media with DNase (Promega), filtered and sorted. Cells expressing 
the lowest surface levels of CD 147 (bottom 20%) and the highest surface levels of 
CD147 (top 20%) were selected as CD147Lo and CD147Hi SUb-populations, respectively. 
For subsequent invadopodia or immunoblotting analyses, cells were directly seeded on 
gelatin or lysed post-sort, respectively. All FACS analysis and cell sorting was 
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performed with a Beckman Coulter MoFlo Astrios instrument in the Department of 
Regenerative Medicine and Cell Biology Flow Cytometry Facility (MUSC, Charleston, 
SC). 
Immunoblotting 
Whole celllysates were prepared for immunoblotting using a RIP A buffer modified to 
contain ImM PMSF, 10 ~g/ml aprotinin and leupeptin, 2 mM sodium orthovanadate and 
10 mM sodium fluoride. Protein content was quantified using a BCA assay (Pierce), 
aliquots were solubilized in reducing sample buffer, resolved on Pierce 4-20% 
polyacrylamide gels, transferred to nitrocellulose (Osmonics, Westborough, MA) with a 
Pierce apparatus, and stained with antibody. Densit9metric analysis of western blots was 
.. "", ' 
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performed using Image J software (version 1.43s)'. 
Results 
Up-regulation of CD147 induces activation of EGFR-Ras-ERK signaling 
In a recent study we showed that up-regulation of CD 147 is sufficient to induce invasion 
and formation of active invadopodia in the non-transformed human breast epithelial line, 
MCF-I0A (Grass et aI., 2012). Here we have investigated the signaling pathways that 
might be involved in mediating the effects ofCD147 on these processes. As shown in 
our previous study, an MOl of 2 of our CD147 adenovirus construct gives rise to levels 
of CD147 in MCF-10A cells that are commonly found in aggressive human breast cancer 
cells. In addition, we have now shown that the level of CD147 at the surface of MCF-
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lOA cells, resulting from treatment with an equivalent MOl of virus, is similar to that 
expressed on the surface of the malignant breast carcinoma cell line, MDA-MB-231, but 
as shown previously the adenovirus induces mainly the less glycosylated form of CD147 
found endogenously in cancer cells (Fig. 3-1A). As in our previous study, we used cells 
infected with a p-galactosidase (p-gal) adenovirus construct as a control; this adenovirus 
did not cause significant changes in CD 147 expression. 
Prior evidence suggests that CD147 can activate ERK signaling (Cui et aI., 2012; 
Marieb et aI., 2004; Misra et ai., 2003; Tang et ai., 2006), though the upstream regulators 
of this pathway have not been fully characterized. First we evaluated the effect of 
increased CD147 on the activation status of Ras in MCF-I0A cells, as Ras is frequently 
t. ,.J.,' . 
upstream of ERK activation (Bodart, 2010). W~~t1nd that up-regUlation of CD147 led 
to increased Ras activation, measured as an increased proportion of Ras-bound GTP, as 
well as a concomitant increase in phosphorylated ERK (Figure 3-1B). Next we 
investigated EGFR signaling since it is often dysregulated ih breast cancer and is 
commonly upstream of Ras and ERK (Eccles, 2011). We found that subsequent 
treatment of CD 147 -upregulated MCF-1 OA cells with increasing concentrations of the 
specific EGFR kinase inhibitor, AG 1478, resulted in attenuated p-ERK (Fig. 3-1C), 
suggesting that CD147 may be involved in EGFR activation. Since phosphorylation of 
tyrosine 1173 or 1068 on the cytoplasmic tail of EGFR has been associated with 
regulation of Ras-MAPK signaling (Rojas et aI., 1996; Sakaguchi et aI., 1998), we 
determined whether one or both of these tyrosine residues is activated in response to 
increased CD 147 expression. We found that there was no difference in phosphorylation 
of the Tyr 1173 residue, but increased CD 147 led to increased phosphorylation of the Tyr 
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1068 residue. This Tyr 1068 phosphorylation occurred whether or not EGF was present 
in the medium (Fig. 3-10). 
Hyaluronan-CD44 interaction mediates CD147-induced activation ofEGFR 
signaling. 
Previously we demonstrated that C0147 stimulates the synthesis of HA in breast 
carcinoma cells (Marieb et aI., 2004). Here we found that up-regulation of CO 147 in non-
transformed, MCF-I0A breast epithelial cells also leads to ,..,2-fold increase in HA 
production compared to control cells (Fig. 3-2A). Several studies have demonstrated that 
either endogenous or exogenous HA can elicit the activation of multiple signaling 
pathways, including those involving RTKs such as pGFR and downstream effectors such 
, '-", 
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as Ras and ERK (Toole, 2009), which are frequently dysregulated in breast cancer. 
Consequently we determined whether the effects of C0147 on activation of EGFR and 
ERK were dependent on HA-receptor interactions. We first employed treatment with 
1 
oligosaccharides of HA (oHA) that are 6-18 residues in length, which compete with 
multivalent, HA-receptor interactions, replacing them with monovalent, oHA-receptor 
interactions (Lesley et aI., 2000; Underhill and Toole, 1979) and thus attenuating 
endogenous HA-receptor signaling (Ghatak et aI., 2002; Ghatak et aI., 2005). We found 
that treatment of CO 147 -upregulated MCF-l OA cells with oHA resulted in attenuated 
phosphorylation of EGFR-Tyr 1068 and ERK (Fig. 3-2B). Interestingly, the levels of p-
ERK reached near baseline activation levels before Tyr 1068 phosphorylation returned to 
baseline. To determine whether this perturbation of HA-receptor signaling may be 
dependent on C044, the main HA receptor in breast cancer cells, we determined the 
effects of pooled siRNA-mediated knockdown of C044 in CDl47-upregulated MCF-
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lOA cells. This treatment resulted in a partial decrease in p-Tyr l068 and p-ERK levels, 
whereas no significant difference was seen in membrane type-l MMP (MTI-MMP; 
MMP-14) protein levels (Fig. 3-2C); this suggests that CD 147-induced activation of the 
EGFR-ERK pathway was at least partially mediated by HA-CD44 interactions and that 
CD 147-induced MTI-MMP expression may be separate from this pathway. 
CD44 has been shown to interact with EGFR family members in aHA-dependent 
manner (Bourguignon et aI., 2006; Ghatak et aI., 2005; Wang and Bourguignon, 2006) 
and our above data suggests that up-regulation of CD147 results in increased HA-CD44-
mediated activation ofEGFR. To evaluate whether up-regulation of CD147 increases 
EGFR-CD44, CD147-CD44, or CD147-EGFR interactions, we employed a proximity 
ligation assay technique that detects associations ¢'proteins occurring within 40 nm of 
each other (Soderberg et aI., 2006). We found that there were significant differences 
between CD 1 47-upregulated and control MCF-IOA cells in regards to the percentage of 
1 
the cell population demonstrating close protein-protein associations of EGFR with CD44, 
CD147 with CD44 and CD147 with EGFR (Fig. 3-2D, E). We and others have 
demonstrated that CD147, CD44, and EGFR partially localize in membrane fractions 
with properties of lipid rafts in malignant cancer cells (Ghatak et aI., 2005; Grass et aI., 
2012; Irwin et aI., 2010; Tang and Hemler, 2004; Toole, 2009). To determine whether 
this also occurs in MCF-I0A cells with up-regulated CD147, we showed that CD147 
colocalizes with cholera toxin-B (CtxB), a lipid raft marker, at the leading edge of cells 
and appears to arrange in a single-file fashion along CtxB-enriched filopodial projections 
(Fig. 3-3A). We also found that CD147, CD44 and EGFR are enriched in caveolin-rich 
raft domains after up-regulation of CD147, as compared to the control cells (Fig. 3-3B). 
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To evaluate whether enrichment in lipid rafts may be due to increased trafficking of 
CD44 and EGFR to the cell surface in cells with up-regulated CD147, we utilized FACS 
analysis to evaluate surface expression levels. We found that the MCF-lOA cells with 
up-regulated CD147 demonstrated no significant differences in levels of CD44 or EGFR 
at the cell surface (Fig. 3-3C), suggesting that the major effect is on organization of these 
proteins into raft-like complexes. 
Activated Ras and ERK regulate hyaluronan, CD147 and MTI-MMP expression, 
and invasiveness 
We previously found that up-regulation of CD147 alone in MCF-I0A cells is 
sufficient to induce an invasive program characteriz~d by matrigel invasion and active 
.. .. J~} 
invadopodia formation, the latter being depe~d~:1~n MTl-MMP activity (Grass et al., 
2012). Our data here indicate that up-regulation of CD147 increases activation of the 
Ras-MEK-ERK pathway via HA-CD44 interactions. However, other evidence indicates 
1 
that the MEK-ERK pathway may also regulate CD147 expression (Pons et aI., 2011; 
Ramos and Dang, 2011; Venkatesan et aI., 2009), suggesting the possibility of a positive 
feedback loop. Therefore we evaluated if this was the case in our system. To evaluate 
whether the Ras-MEK-ERK signaling pathway influences CD147 expression we 
employed a MCF-I0A cell line stably expressing the oncogenic K_RasV12 mutant (lOA-
K-Ras V12), since this cell line has been shown to activate ERK signaling to a greater 
extent than PI3K (Konishi et aI., 2007). First, we found that the 10A-K-Ras Vl2 cells 
contain significantly higher levels of HA, CD147 and MTl-MMP than empty vector 
MCF-lOA (lOA-EV) cells (Fig. 3-4A,B). Interestingly, qPCR demonstrated only a slight 
increase in CD147 message compared to 10A-EV cells, suggesting that K_RasV12 may 
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regulate CD147 expression post-transcriptionally (Fig. 3-4C). We also found that the 
10A-K-Ras V12 cells invaded matrigel (Fig. 3-4D) and formed active invadopodia (Fig.3-
4E) to a greater extent than 10A-EV cells. In the invadopodia assay, ..... 60% of the cells 
degraded underlying fluorescent matrix compared to the 10A-EV (Fig. 3-4F). Of the 
10A-K-Ras V12 cells with invadopodia, the majority of the population had a mean of 10-12 
invadopodiatcell, with a range of 1-28 invadopodia/cell, whereas 10A-EV cells 
demonstrated essentially no invadopodia (Fig. 3-4G). Thus, this data indicates that the 
K-Ras V12 oncogene imparts an invasive phenotype in MCF-1 OA cells, similar to that 
demonstrated previously in pancreatic cells (Botta et aI., 2011; Campbell and Oer, 2004; 
Neel et aI., 2012). 
As we and others have shown previotlS'.\y~at CD147 regulates MTI-MMP 
expression and HA synthesis (Marieb et aI., 2004; Yan et aI., 2005), we determined 
whether the increased expression of MT1-MMP or HA in 10A-K-Ras V12 cells was due to 
the increase in CD147. Knockdown of CD147 using siRNA demonstrated that MTl-
MMP expression and HA production were partially dependent on CD147 (Fig. 3-5A,B). 
Since CD 147 plays a prominent role in breast cancer cell invasion and invadopodia 
formation (Grass et aI., 2012; Zucker et aI., 2001), we also evaluated effects on matrigel 
invasion and invadopodia formation and activity. We found that knockdown of CO 147 
resulted in a partial, yet significant, decrease in matrigel invasion in the 10A-K-Ras V12 
cells (Fig. 3-5C). Likewise, in the invadopodia assay, we found that CD147 knockdown 
decreased the percentage of cells degrading matrix (Fig. 3-50,E) and that most of this 
inhibition was due to decreased activity of invadopodia rather than formation (Fig. 3-SF). 
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Next we determined whether increased CD147 expression in lOA-K-Ras Vl2 cells 
was dependent on ERK signaling. Treatment of lOA-K-Ras Vl2 cells with two different 
MEK inhibitors resulted in a decrease in CD147 and MTI-MMP protein levels as well p-
ERK (Fig. 3-6A), though this effect did not appear to be at the transcriptional level for 
CD147 (Fig. 3-6B). We next evaluated whether ERK signaling mediates the invasive 
characteristics that we described above in lOA-K-Ras V12 cells. We found that MEK-ERK 
inhibition greatly decreased matrigel invasion (Fig. 3-6C), as well as invadopodia 
formation and activity (Fig. 3-6D,E,F). In contrast to CD147 depletion in lOA-K-Ras Vl2 
cells, MEK inhibition greatly decreased invadopodia formation as well as activity. 
Similar to our approach with CD147-upregulated MCF-IOA cells, we evaluated 
endogenous protein-protein associations of CP4f~ith EGFR, CD147 with EGFR, and 
CD147 with CD44 in lOA-K-RasV12 cells, using the PLA. We found that lOA-K-RasVI2 
cells also exhibited these associations (Fig. 3-7 A), but the incidence of these associations 
varied in the following manner: CD147-CD44> CD 1 47-EbFR > CD44-EGFR (Fig. 3-7 
A,B). This data suggests a similar relationship to what we identified in CD147-
upregulated MCF-IOA cells (Fig. 3-2D,E). As with MCF-IOA cells with up-regulated 
CD147, we showed that endogenous CD147 co-localizes with Ctx-B (Fig. 3-7C) and that 
CD147, CD44 and EGFR are enriched in caveolin-rich raft domains in lOA-K-Ras VI2 
cells as compared to the lOA-EV cells (Fig. 3-7D). 
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lOA-K-Ras VI2 cells with high constitutive levels of CD147 are more invasive than 
those with low constitutive levels of CD147 
It has been clearly demonstrated that cancer cells exhibit heterogeneity in cell surface 
marker expression and contain sub-populations with different functional capacities 
(Ricardo et aI., 2011). Therefore we extended our current findings further by evaluating 
whether sub-populations of 10A-K-Ras Vl2 cells with different levels of constitutive 
CD147 expression could be isolated from the parent cells. Immuno-staining of 10A-K-
Ras Vl2 cells demonstrated a sub-population of cells with greater CD 147 and CD44 
staining intensity (Fig. 3-8A). Next, using FACS, we isolated cells with relatively low 
surface expression of CD147 (CDI47Lo) versus relatively high surface expression of 
.. :'1 
CD147 (CDI47Hi). We separated the bottom'2{'~)[nd top 20% with respect to CD147 
cell surface expression and found that these two sUb-populations exhibited distinct 
properties as indicated by scatter analysis (Fig. 3-8B). The CD147Hi population also 
1 
demonstrated 3-fold more CD44 and 2.5-fold more EGFR on the surface compared to the 
CD147Lo population (Fig. 3-8C; left panel). Similar analysis of highly invasive MDA-
MB-231 breast cancer cells, which possess an endogenous K_RasG13D mutation (Kozma 
et aI., 1987), demonstrated a 1.8-fold increase in CD44 and 1.9-fold increase in EGFR in 
CD147Hi vs. CD 147Lo cells (Fig. 3-8C; middle panel) while much less invasive MCF-7 
cells demonstrated very little CD44 or EGFR surface staining, and sUb-population 
analysis for differential CD147 expression revealed no significant differences (Fig. 3-8C; 
right panel). We also measured levels of various proteins in the two sub-populations by 
immuno-blotting and found that CD 14 7Hi cells demonstrated increased p-ERK and p-
EGFR compared to CD147Lo cells, whereas the total levels of CD44 and EGFR were 
104 
similar (Fig. 3-8D). Finally, we evaluated the invasive characteristics of the CD 147Hi vs. 
CD147Lo cells and similar to our above results in CD 147-depleted 10A-K-Ras Vl2 cells 
(Fig. 3-5F), we found that CD 147Hi cells had a much greater percentage of cells with 
actively degrading invadopodia than CD147Lo cells, whereas no significant difference 
was observed between CD147Hi vs. CD147Lo cells in regards to invadopodia formation 
(Fig. 3-8E). 
Discussion 
Breast cancer is a heterogeneous disease and, as with other cancers, metastases to distant 
organs remains the primary cause of mortality,{S~ffer and Weinberg, 2011). Currently 
the evaluation of hormone receptor expression, ErbB2 amplification and the presence of 
cytokeratin forms represent the mainstay utilized clinically for treatment stratification, 
though much effort has also been placed on characterizing distinct sub-populations 
isolated from the tumor bulk with differing cell surface expression profiles. One of the 
main surface markers that has emerged in identifying invasive and therapy-resistant 
cancer cells is CD44 (Alexander and Friedl, 2012). Hyaluronan (HA), a primary CD44 
ligand, facilitates construction of pericellular matrix scaffolds which stabilize signaling 
and transporter complexes (Slomiany et aI., 2009a; Slomianyet aI., 2009b). Multiple 
studies have shown that HA-CD44 interactions are intimately involved in the integration 
of signaling pathways leading to RTK activation, therapy resistance and invasion (Toole, 
2009). 
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Accumulating evidence suggests that the IgSF glycoprotein CD147 regulates HA 
synthesis in various cell types (Edward et aI., 2011; Ghatak et aI., 2005; Kato et aI., 2011; 
Marieb et aI., 2004; Qin et aI., 2011), though the mechanism of this regulation is not fully 
understood. In addition, CD 147 has an essential role in regulating MMP production, and 
our recent study found that CD147 plays a role in invadopodia activity (Grass et aI., 
2012). In this study we have begun to evaluate the functional relationship between 
CD147, HA, CD44 and MMP production in regards to breast cancer invasion. 
We and others have previously demonstrated that CD147 influences migration 
and invasion via protease induction and cytoskeletal remodeling (Grass et aI., 2012; 
Weidle et aI., 2010; Zhao et aI., 2011), though the exact signaling mechanisms regulating 
these processes have not been fully elucidated~'~JI¥te we have shown that up-regulation 
of CD147 in non-transformed breast epithelial cells leads to increased EGFR, Ras and 
ERK activation. Moreover, we show that the activation of EGFR and ERK by CD147 is 
mediated in large part by increased HA-CD44 signaling an~ is accompanied by enhanced 
interactions between CD147, CD44 and EGFR. These interactions most likely take place 
within lipid raft-like regions of the plasma membrane, which are known to participate in 
cell signaling complex formation (Staubach and Hanisch, 2011). Of interest, our 
microscopic evaluation of CD147 and lipid rafts revealed that CD147 co-localizes with 
Ctx -B at the leading edge of the cells and appears to arrange in a single-file fashion along 
Ctx-B-enriched filopodial projections (Fig. 3-3A). Our evidence suggests that 
enrichment of CD44 and EGFR in lipid rafts is not due to increased trafficking to the cell 
surface, since our cell surface analysis revealed no significant differences in either CD44 
or EGFR expression (Fig. 3-3C). Rather, we hypothesize that this may be due to 
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increased assembly of signaling complexes in lipid rafts on the cell surface, which are 
vital for invadopodia formation and activity (Caldieri et aI., 2009; Yamaguchi et aI., 
2009). 
Oncogenic Ras signaling has a less appreciated role in breast cancer pathology 
since Ras mutations are infrequent (Pylayeva-Gupta et aI., 2011). However, chronic Ras 
activity has been found in multiple breast cancer cell lines and patient tumor tissues 
without any apparent Ras mutations (Eckert et aI., 2004; Lintig et aI., 2000). A recent 
study suggests that increased activity of wild type Ras can result in a similar phenotype 
induced by oncogenic Ras (Zhang et aI., 2009). The present study suggests that CD 147 
can stimulate wild type Ras activity, as MCF-10A cells have not been found to contain 
any mutant Ras forms (Soule et aI., 1990). TO~~V~1iate this relationship between CD147 
and Ras further, we utilized 10A-K-Ras V12 cells, as K-Ras mutations are the most 
frequent of those that do occur in breast cancer (Karnoub and Weinberg, 2008). We 
found that oncogenic Ras increases HA synthesis (Fig. 3-4A), as found previously 
(Hamilton et aI., 2007), and also stimulates expression ofCD147 and MT1-MMP protein 
(Fig. 3-4B). Interestingly, qPCR analysis revealed only minor differences in CD147 
message between empty vector and 10A-K-Ras V12 cells (Fig. 3-4C), suggesting that Ras 
may influence CD147 expression predominantly at the post-transcriptional level. 
We also showed that 10A-K-Ras V12 cells are highly invasive in matrigel and 
formed highly active invadopodia (Fig. 3-4D,E,F), which is similar to earlier studies in 
pancreatic cancer cells (Neel et aI., 2012). The invasiveness of these cells was found to 
be dependent on MEK-ERK signaling. Also, in agreement with our previous study 
demonstrating that CD147 is involved in invadopodia activity (Grass et aI., 2012), we 
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showed that CD147, at least in part, mediates the invasive phenotype seen in 10A-K-
Ras v 12 cells. We found that CD 147 expression in these cells is also dependent on MEK-
ERK signaling and that endogenous CD44, EGFR, and CD147 associate and co-localize 
in lipid raft fractions in these cells in similar fashion to cells with upregulated CD147. 
Again, CD147 message levels were not significantly affected by the MEK-ERK signaling 
pathway, suggesting that regulation of CD147 expression by this pathway is also 
predominantly post-transcriptional. A striking finding was that, although HA-CD44 
interactions clearly mediate most CDl47-induced EGFR and ERK activation, disruption 
of HA-CD44 interactions with oHA or CD44 siRNA did not significantly affect CD147-
induced MTI-MMP protein levels, as shown herein, or invasiveness (data not shown). 
This may be due to a divergence in CD147-induc~q"signaling, where one effect of CD147 
'/"."'/' 
is mediated by HA extrusion and subsequent CD44 binding, and the other is mediated by 
other CD 147-binding interactions independent of CD44. 
We also found that CD147Hi and CD147Lo cell sub-populations isolated from 
10A-K-Ras V12 cells, and from the metastatic breast cancer cell line MDA-MB-231, have 
distinct properties. The CD147Hi cells have significantly more CD44 and EGFR on the 
cell surface than their CD 147Lo counterparts. Additionally, CD147Hi lOA-K-Ras V12 cells 
had increased pEGFR and pERK levels as well as more active invadopodia compared to 
CD147Lo cells. Interestingly, densitometric analysis of CD147 in the CD147Hi and 
CD 147Lo western blots demonstrated small changes in total CD147 protein (data not 
shown). This suggests that increased CD147 on the cell surface may be due to increased 
retention at the cell surface and/or rapid recycling rather than increased protein synthesis. 
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Finally, our data shows that up-regulation of CD147 in non-transformed and non-
invasive breast epithelial cells leads to activation of the EGFR-Ras-MEK-ERK signaling 
cascade. Ras mutations in breast cancer are a rare event (Pylayeva-Gupta et aI., 2011), 
though chronic Ras activation is evident in patient-derived breast cancer tissue and cell 
lines without Ras mutations (Eckert et aI., 2004; Lintig et aI., 2000). Our data suggests 
that wild-type Ras activity is increased in CD 147-upregulated MCF-10A cells and this 
may be a potential mechanism that CD147 employs to elicit the previous invasive 
phenotype we identified in CD147-upregulated MCF-IOA cells (Grass et aI., 2012). To 
our knowledge, no mutations or intrinsic signaling motifs have been identified in CD 147, 
thus it is probable that CD147 mediates breast cancer progression by facilitating the 
assembly of pro-tumorigenic multi-protein compll'~f{es< on the cell surface. Also, though 
'J'~'~/'~/" 
we saw differences in protein levels of CD147 with MEK inhibition or comparison of 
10A-EV to 10A-K-Ras V12 cells, negligible changes in the mRNA level of CD147 were 
observed in both cases. This may suggest that the influenct1 of Ras-MAPK signaling on 
CD147 expression occurs more at a post-transcriptional level; similar post-transcriptional 
regulation of CD147 has been observed in previous studies (Chen et aI., 2010; Deora et 
aI., 2005; Fanelli et aI., 2003; Gallagher et aI., 2007; Noguchi et aI., 2003). Thus, even 
though CD147 expression is clearly increased in most aggressive cancers, identification 
of CD147 as a differentially expressed message in microarray analyses may not always 
be apparent. CD147 may act as an independent prognostic factor in some breast cancer 
types (Liu et aI., 2010; Reimers et aI., 2004) and further studies should evaluate the utility 
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Figure 3-1. Up-regulation of CD147 induces activation of EGFR-Ras-ERK 
signaling. (A) Western blot depicting surface biotinylation of MCF-l OA cells, treated 
with an Mal of 2 of ~-gal or CD147 adenovirus, and parental MDA-MB-231 cells. 
An Mal of 2 was used in all subsequent adenovirus experiments. A lane with beads 
only was used as a negative control; n=3. (B) Evaluation ofRas activity in MCF-I0A 
cells treated with ~-gal or CD147 adenovirus. Lanes with GDP and GTP were used as 
negative and positive controls, respectively. Activated Ras was identified by probing 
with a pan-Ras antibody. ~-actin was used as a loading control; n=4. (C) MCF-10A 
cells were treated with ~-gal or CD147 adenovirus, starved and subsequently treated 
with vehicle (DMSO) or 0.5 ~M and 5.0 ~M tyrphostin (AG 1478) overnight. ~-actin 
was used as a loading control; n=3. (D) MCF-10A cells were treated with ~-gal or 
CD 147 adenovirus, starved and evaluated for EGFR activation by probing for 
phosphorylation at the Tyrosine 1173 or 1068 residues in the presence or absence of 
EGF in the medium. For controls, MCF-I0A cells were starved or starved and treated 
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Figure 3-2. Hyaluronan-CD44 interaction mediates CD147-induced 
activation of EGFR signaling. (A) MCF-l OA cells treated with ~-gal or 
CD147 adenovirus were seeded into 24 well plates. The media was 
replaced with fresh media and after 24 hours it was collected and analyzed 
for hyaluronan concentration using an ELISA-like assay. Hyaluronan in 
the media was normalized to cell number and depicted as mean fold 
change; each column represents triplicate wells in three independent 
experiments. (B) MCF-IOA cells treated with ~-gal or CD147 adenovirus 
were subsequently treated with 100 ~g/ml of o-HA for 1, 12 and 24 hours 
and probed for p-EGFR (TyrI068) and p-ERK. ~ -actin was used as a 
loading control; n=3. (C) MCF-10A cells treated with CD147 adenovirus 
were treated with non-specific control siRNA or pooled CD44-specific 
siRNA as described in Materials and Methods and probed for indicated 
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Figure 3-2 (continued). Hyaluronan-CD44 interaction mediates CD147-induced 
activation of EGFR signaling. CD) Representative images demonstrating protein-
protein interactions « 40 nm) using a proximity ligation assay (see Materials and 
Methods for details). CD 1 47-treated MCF-IOA cells were probed with primary 
antibodies in the following combinations: CD44 (mouse) and EGFR (rabbit) (top 
row); CD147 (mouse) and EGFR (rabbit) (middle row); and CD147 (mouse) and 
CD44 (rabbit) (bottom row) to detect protein-protein interactions in the cell 
population. Protein-protein interactions appear as small punctate green signals (i.e. 
dots) and cell nuclei were identified by co-staining with DAPI. Treatment of cells 
with a single primary antibody only was used as a negative control and indicates the 
specificity of the reaction (right panels in each row). (D) Quantification of indicated 
protein-protein interactions in the cell population over 5 random fields with at least 50 
























Figure 3-3. Up-regulation of CD147 promotes CD44 and EGFR enrichment in 
lipid rafts. (A) Representative image of MCF-IOA cells treated with CD147 
adenovirus and evaluated for CD147 (red) and cholera toxin-B (green) colocalization 
(yellow). Scale bar: 10 ~m. (B) MCF-I0A cells treated with ~-gal or CD147 
adenovirus were subjected to detergent -resistant membrane isolation and probed for 
indicated proteins. Light fractions are from the gradient interface (0-20%) where 
detergent-resistant membrane domains such as lipid rafts localize; n=3. (C) CD44 
and EGFR surface expression was analyzed by FACS in CDl47-treated MCF-I0A 
cells. Distributions with dark gray shading, solid black lines with no shading and 
dotted black lines with light gray shading represent IgG-isotype control, ~-gal and 
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Figure 3- 4. Activated Ras and ERK regiil3't~4i'yaluronan synthesis, CD147 and 
MTI-MMP expression and cancer invasiveness. (A) Hyaluronan synthesis was 
quantified from 10A-EV and 10A-K-Ras Vl 2 cells using an ELISA-like assay. 
Hyaluronan in the media was normalized to cell number and depicted as mean fold 
change ± s.e.m.; each column represents triplicate wells in three independent , 
experiments. (B) Representative western blot depicting CDl47 and MTI-MMP 
expression in 10A-EV and 10A-K-Ras Vl 2 cells. ~-actin was used a loading control; 
n=4. (C) Comparison of CDl47 mRNA levels in 10A-EV and 10A-K-Ras Vl 2 cells, as 
measured by qPCR; normalized to ~-actin; n=3. (D) Quantification of invasion through 
Matrigel by 10A-EV and 10A-K-Ras V1 2 cells. Columns represent the mean number of 
cells invaded (± s.e.m.) per field; n=3. (E) Representative micrograph demonstrating 
10A-EV and 10A-K-Ras V1 2 cells cultured on fluorescent matrix. After fixation, cells 
were immunolabeled for cortactin followed by secondary Alexa-Fluor-488 antibody and 
Alexa-Fluor-64 7 phalloidin. Actin and gelatin matrix were pseudo-colored red and 
blue, respectively to allow easier visualization of colocalization (yellow) of actin (red) 
and cortactin (green). Invadopodia-mediated matrix degradation appears as dark black 
foci in the bright fluorescent matrix field. The boxed regions with red arrow heads 
depict actively degrading invadopodia. Scale bar: 10 ~m. (F) Percentage of cells 
degrading the matrix; defined as a cell with at least one degradation spot underneath the 
cell or near the cell edge. (G) Quantification of invadopodia/cell; defined as actin-
cortactin aggregate over degraded matrix. Each invadopodia parameter was calculated 
by evaluating random fields containing at least 15 cells per field over three independent 
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Figure 3-5. Knockdown of CD147 in MCF-I0 J$:.~RasV12 cells results in decreased 
hyaluronan synthesis, MTI-MMP expressio.n ;~hd invasiveness. (A) Western blot 
depicting CD147 and MTI-MMP protein levels in 10A-K-Ras V1 2 cells depleted of 
CD147 by treatment with pooled siRNAs. Scrambled (scr) siRNA was used as a 
control and ~-actin was used as a loading control; n=3. (B) Comparison of HA 
production in 10A-K-Ras V1 2 cell treated with scrambled o~ pooled CD 147-specific 
siRNA. Hyaluronan in the media was normalized to cell nbmber and depicted as mean 
fold change ± s.e.m.; each column represents triplicate wells in three independent 
experiments. (C) Quantification of invasion through Matrigel by 10A-K-Ras V1 2 cells 
treated with scrambled or pooled CDl47-specific siRNA. Columns represent the mean 
number of cells invaded (± s.e.m.) per field; n=3. (D) Representative micrograph 
demonstrating 10-K-Ras V1 2 cells treated with scrambled or pooled CDl47-specific 
siRNA cultured on fluorescent matrix. Red arrow heads indicate actin-cortactin 
aggregates. Scale bar: 10 ~m. (E) Percentage of cells degrading underlying matrix or 
(F) percentage of cells with actin-cortactin aggregates with or without underlying 
degraded matrix in 10A-K-Ras V1 2 cells treated with scrambled or pooled CD147-
specific siRNA. Each invadopodia parameter was calculated by evaluating random 
fields containing at least 15 cells per field over three independent experiments. 
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Figure 3-6. MCF-IOA-K-RasV12 cells employ MEK-ERK signaling for CD147 and 
MTI-MMP expression and invasiveness. (A) Western blot depicting 10A-K-Ras Vl 2 
cells treated with vehicle, U0126 (10 ~M), or PD98059 (25 ~M). B-tubulin was used as 
a loading control; n=3. (B) mRNA levels of 10A-K-Ras V12 cells treated with vehicle or 
U0126 (10 ~M); normalized to B-actin; n=3. (C) Quantificltion of invasion through 
Matrigel by 10A-K-Ras Vl 2 cells treated with vehicle, U0126 (10 ~M) or PD98059 (25 
~M). Columns represent the mean number of cells invaded (± s.e.m.) per field; n=3. (D) 
Representative micrograph of 10A-K-Ras V1 2 cells seeded on fluorescent matrix and 
treated with vehicle, U0126 (10 ~M) or PD98059 (25 ~M). Red arrow heads depict 
examples of invadopodia. Scale bar: 1 0 ~m. (E) Percentage of cells degrading 
underlying matrix and (F) quantification of invadopodialcell in 10A-K-Ras VI 2 cells 
treated with vehicle, UO 126 (1 0 ~M) or PD980539 (25 ~M). Each invadopodia 
parameter was calculated by evaluating random fields containing at least 15 cells per 
field over three independent experiments. Column values are means ± s.e.m. *P<0.05; 
**P<O.OI; *** P<O.OOI. 
116 
A. CD44·EGFR CD147-EGFR CD147-CD44 
c. 

































Figure 3-7. Identification and localizatioft"pf<~dogenous proten-protein 
interactions in MCF-IOA-K-Rasv12 cells. (A) Representative DIC-fluorescent merge 
images demonstrating endogenous protein-protein interactions « 40 nm) using a 
proximity ligation assay (see Materials and Methods for details). 10A-K-Ras V12 cells 
were probed with primary antibodies in the following combinations: CD44 (mouse) 
and EGFR (rabbit) (left column); CD147 (mouse) and EGFR (rabbit) (middle column); 
and CD147 (mouse) and CD44 (rabbit) (right column) to detect protein-protein 
interactions in the cell population. Protein-protein interactions appear as punctate 
green signals (i.e. dots) and cell nuclei were identified by co-staining with DAPI 
(bottom row). The boxed regions are shown as higher magnification insets. Examples 
of protein-protein interactions are highlighted by arrow heads. Top row depicts 
automatic threshold images of the protein-protein interaction channel for easier 
visualization. Scale Bar: 25 ~m. (B) Quantification of indicated protein-protein 
interactions per cell; Scatter plot with mean ± s.e.m.; n=3. (C) Representative image 
demonstrating colocalization (yellow) of endogenous CD147 (red) and cholera toxin-B 
(green) in 10A-K-Ras VI2 cells. Scale bar: 10 ~m. (D) Western blot comparing 
endogenous protein distribution between 10A-EV and 10A-K-Ras V12 cells subjected to 
detergent -resistant membrane isolation and probed for indicated proteins. Light 
fractions are from the gradient interface (0-20%) where detergent-resistant membrane 
domains such as lipid rafts localize; n=2. ***P<O.OOl. 
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Figure 3-8. MCF -lOA-K-Ras VI2 cells with high constitutive surface levels of 
CD147 have elevated activation of EGFR-ERK signaling and are more invasive. 
(A) Representative micrograph demonstrating heterogeneity in CD147 and CD44 
staining intensity across the 10A-K-Ras V12 cell populatioh. Scale bar: 25 ~m. (B) 
FACS scatter distribution of total 10A-K-Ras V12 cell population (left panel). 
Identification of CD147Lo and CD147Hi cells, bottom and top 20%, respectively, in the 
distribution of CD 147 -expressing cells (right top panel) with corresponding scatter 
characteristics (bottom right panels). Note that this cell sorting scheme identifies two 
distinct cell populations. (C) FACS analysis of cell surface expression of CD44 and 
EGFR in CD147Lo and CD147Hi cells in 10A-K-Ras V12 (left column; n=3), MDA-MB-
231 (middle column; n=3), and MCF-7 (right column; n=2) cells. Distributions with 
dark gray shading, solid black lines with no shading and dotted black lines with light 
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Figure 3-8 (continued). MCF-IOA-K-RasV12 cells with high constitutive surface 
levels of CD147 have elevated activation of EGFR-ERK signaling and are more 
invasive. (D) Left panel: Immunoblot comparing protein expression of indicated 
proteins in CD 147Lo and CD147Hi 10A-K-Ras V1 2 cells. ~-actin was used as a 
loading control; n=2. Right panel: Histogram demonstrates fold change between 
CD147Hi and CD147Lo cells for pEGFR (Tyr 1068), pERKl and pERK2 protein 
levels; densitometric intensities were normalizeq tq,.total EGFR and ERKl/2 protein. 
(E) Quantification of percentage of cells with-a¢ti.?ktortactin aggregates with or 
without underlying degraded matrix in CD147Lo and CD147Hi 10A-K-Ras V1 2 cells 
was calculated by evaluating random fields containing at least 15 cells per field over 
three independent experiments. Column values are means ± s.e.m. *P<O.05; 
**P<O.Ol; ****P<O.OOI. 
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Chapter 4: Overview, Novel Contributions and Future Work 
As described above, CD 147 participates in a variety of biological functions. 
CD147 expression is associated with an invasive phenotype in a wide array of cancer 
types, including breast cancer. One of the most significant findings supporting a role for 
CD147 in breast cancer invasion was a study discovering that weakly malignant breast 
cancer cells overexpressing CD147, which were injected into mouse mammary fat pads, 
demonstrated increased local invasion and extensive metastases to the liver, mediastinum, 
pleura, spleen, lymph nodes and mesentery (Zuck~~<,et"al., 2001). CD147 is a 
'"'"''''''/-
I ."/ 
predominant marker ( ..... 90%) in bone micrometastases (Klein et al., 2002; Reimers et aI., 
2004) isolated from breast cancer patients, is enriched in malignant pleural effusions 
(Davidson et aI., 2004) and is expressed on circulating tumqr cells (Pituch-Noworolska et 
aI., 2007), suggesting a prominent role for CD147 in cancer progression. CD147 
expression may also be an independent prognostic factor in some breast cancer types (Liu 
et aI., 2010; Reimers et aI., 2004). 
CD 147-induced MT l-MMP Induction Mechanism 
The mechanism mostly attributed to CD 147-induced invasion is the induction of 
proteases, including soluble and membrane-type MMPs (Yan et aI., 2005). In support of 
this, CD147 has been identified at the invasive edge of breast carcinomas 
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(Polette et aI., 1997) and in some invasive breast and lung cancers it colocalizes on the 
cell surface with MT1-MMP and MMP-1, respectively (Dalberg et ai., 2000; Guo et ai., 
2000). CD147 regulates MT1-MMP synthesis and cell surface expression in various cell 
models (Sameshima et aI., 2000; Schmidt et ai., 2006; Seizer et aI., 2010). MT1-MMP 
regulation is very stringent, as the increased presence of a highly proteolytic enzyme on 
the cell surface could be detrimental to cells not needing to cleave matrix substrates or 
cell surface factors that facilitate invasion. Similar to other MMPs, MT 1-MMP is 
synthesized as a zymogen that needs processing to the active form. In the case ofMT1-
MMP, processing occurs via a furin-mediated cleavage event in the Trans-Golgi network 
during protein trafficking to the cell surface. MT1-MMP is then endocytosed and 
recycled back to the cell surface or sent for degrapation, thus active MTl-MMP is the 
·/-,'·I*'Jr 
, ,/ 
predominant form localized on the cell surface (Frittoli et aI., 2011). Our recent 
publication suggests that CD147 may regulate the trafficking of MTl-MMP into cell 
surface localized lipid rafts within invadopodia (Grass et alh 2012). Support for CD147 
having a role in MTl-MMP trafficking is found in a study identifying that CD147 
associates with both pro and active forms of MTl-MMP (Niiya et aI., 2009), though 
further work with live-cell imaging will be needed to fully prove this hypothesis. 
Alternatively, CD147 may be associated in a complex that regulates pro-MT1-MMP 
processing in the golgi. 
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CD147-induced EGFR-Ras-ERK Signaling 
It has been recognized that xenografts of CD 147 -overexpressing breast cancer 
cells contain increased ERK activation at the advancing margin of the tumor (Tang et aI., 
2006). The current mechanisms explaining CD 147-mediated ERK activation are cis 
homodimerization of CD147 (Cui et aI., 2012), cooperation with cyclophilins 
(Yurchenko et aI., 2010), syndecan-1 (Pakula et aI., 2007) or HA-CD44 interactions 
(Marieb et aI., 2004). Our studies provide further evidence of an involvement of CD147 
cooperating with HA-CD44 signaling. In this respect, we found that up-regulation of 
CD147 increases HA synthesis, which in turn led to EGFR activation and subsequent 
activation of ERK. Abrogation of HA-receptor interactions with oHAs attenuated 
CD147-induced EGFR and ERK phosphorYlat-i~~kD44 depletion also reduced EGFR 
and ERK activation, but to a lesser extent. Our earlier findings identified that up-
regulation of CD147 in MCF-10A cells led to increased MT1-MMP protein levels (Grass 
et aI., 2012), though when CD44 was knocked down in CD\47-overexpressing MCF-10A 
cells no difference in MT 1-MMP protein was noticed. Similar results were obtained in a 
previous study where it was shown that increased HA stimulates invasiveness and MMP 
expression, but subsequent treatment with oHAs had no effect on MMP expression and 
only moderate inhibitory effect on invasion (Zoltan-Jones et aI., 2003). Thus, there may 
be diverging pathways elicited by CD147: one that is mediated via HA-CD44 
interactions and others that may utilize other molecular partners. In conjunction with our 
earlier findings, this data suggests that up-regulation of CD 147 may lead to an invasive 
phenotype by facilitating assembly of CD44-EGFR-CD147 signaling complexes that 
activate ERK and result in increased MT1-MMP protein levels. 
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When initially evaluating upstream regulators of CD 147-induced Ras activation, 
we found that the specific EGFR inhibitor AG 1478 attenuated CD 147 -mediated ERK 
activation. The cytoplasmic tail of EGFR contains six tyrosine residues, which can be 
trans-autophosphorylated via the intrinsic tyrosine kinase activity of EGFR (Eccles, 
2011). Earlier studies have identified that the Tyrosine 1173 (Sakaguchi et aI., 1998) and 
1068 (Rojas et aI., 1996) residues are important for EGFR-mediated Ras-MAPK 
signaling by acting as docking sites for the scaffold proteins Shc and Grb2, respectively. 
Further evaluation of CD 147-induced EGFR activation revealed that EGFR was 
specifically phosphorylated on the Tyrosine 1068 residue. Why CD147 induced only 
Tyrosine 1068 phosphorylation and not 1173 is currently not known, but may depend on 
the spatio-temporal interactions between the pho~phbrylated tyrosine residues and 
"~~;1/'~ 
associated scaffold proteins. Such a relationship was identified between Tyrosine 1173 
and SHP-l, a protein-tyrosine phosphatase, where binding attenuated EGFR-mediated 
signaling (Keilhack et aI., 1998) and later studies suggeste~ that the main role of Tyrosine 
1173 phosphorylation was to recruit SHP-l and inactivate ERK signaling (Hsu et aI., 
2011). Individual phospho site activation may correlate with bias toward specific cellular 
phenotypes. For instance, a recent study identified that specific EGFR tyrosine residue 
activation resulted in differential abilities of cells to undergo chemotaxis and wound 
healing (Yamaoka et aI., 2011). Furthermore, a study evaluating non-small cell lung 
cancer tissues identified that specific EGFR tyrosine residues are biased in their 
activation state (VanMeter et aI., 2008). Even though CD147 increases Tyrosine 1068 
phosphorylation, the specific function of this phosphosite activation is not known. 
Additionally, this may be due to a cell- or tissue-specific context, since EGFR is known 
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to promiscuously dimerize with other ErbB family members; thus EGFR activation bias 
may depend on which isoforms of Erb receptors a cell expresses (Eccles, 2011). In line 
with this, we found that treatment of MCF-l OA cells with EGF resulted in a greater 
activation of Tyrosine 1068 than 1173; as mentioned above this may be due to certain 
cellular contexts, as MCF-I0A cells express very low levels of ErbB2, a potential 
heterodimeric binding partner for EGFR. 
CD147 and Ras in Breast Cancer 
Oncogenic Ras forms are rarely identified in breast cancer (Pylayeva-Gupta et aI., 
2011), yet chronic Ras activation has been o~~~:r~,d in several breast cancer cell lines and 
, -,l 
patient-derived tumor tissues with no evident Ras mutations (Eckert et aI., 2004; Lintig et 
aI., 2000). A recent study identified that up-regulation of wild type Ras resulted in an 
oncogenic phenotype in non-transformed breast epithelial reUs (Zhang et aI., 2009). 
CD147 expression intensity seems to progressively increase as breast cancer transitions 
from a benign proliferation to an invasive carcinoma (Liu et aI., 2010), but whether 
CD147 alone is a driver or just a passenger oncogene is not known. We have identified 
that up-regulation of CD 147 alone in non-transformed breast epithelial cells initiates an 
invasive program, increases HA synthesis and activates an EGFR-Ras-MEK-ERK 
signaling cascade, supporting its possible role as a driver of oncogenesis, especially with 
respect to invasiveness. 
Complex signaling networks have been suggested between HA and Ras and 
descriptions of these relationships follow. Some of the strongest evidence comes from 
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studies employing HA synthase 2 (Has2) null mice, which are embryonic lethal, are 
defective in EGFR family signaling, and demonstrate Ras dependence in cellular invasion 
and the ability to undergo an EMT (Camenisch et aI., 2002; Camenisch et aI., 2000). 
Additionally, HA has been shown to increase Ras activity in vitro (Fitzgerald et aI., 2000; 
Serbulea et aI., 1999) and oncogenic Ras has been shown to increase HA synthesis 
(Hamilton et aI., 2007), thus forming a potential positive feedback loop. CD44, the main 
HA receptor, also cooperates with Ras activation (Sohara et aI., 2001) and HA-CD44 
interactions have been demonstrated to activate various RTKs upstream of Ras 
(Bourguignon et aI., 2006; Misra et aI., 2006; Wang and Bourguignon, 2006) as well as 
downstream effectors of Ras (Bourguignon et aI., 2005; Hamilton et ai., 2007). An 
additional feedback loop was identified between ,Ras and CD44, where Ras induced 
,/J"J '~/'-
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CD44 alternative splicing, which in turn facilitated further Ras activation (Cheng et aI., 
2006). Later studies found that CD44 splice isoform switching was important in 
initiating an EMT program in breast epithelial cells (Browq et aI., 2011) and different 
CD44 splice isoforms may correlate with different breast cancer subtypes (Olsson et aI., 
2011). Our finding that CD147 increases HA synthesis and EGFR-Ras-ERK activation 
suggests that CD147 integrates into this HA-CD44-Ras signaling module. Previous 
evidence indicates that HA is involved in assembling signaling complexes in lipid rafts 
(Ghatak et aI., 2005), thus CD 147-induced HA signaling may also lead to a similar 
phenomenon. We have found that increased CD147 expression leads to enrichment of 
MT1-MMP, CD44 and EGFR in lipid raft domains, suggesting that CD 147-induced HA-
CD44 interactions, higher order oligomerization of CD 147 or heterophilic protein 
interactions between CD147 and other binding partners results in multi-protein complex 
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assembly. It will be interesting to see if the integration of CD147 with HA-CD44-Ras-
ERK signaling plays a role in different aspects of tumor progression. A previous study 
suggested that initiation of tumor growth is dependent on Ras-mediated effector 
pathways, but a reduction in the requirement of Ras occurs during tumor maintenance, 
even though Ras effector pathways still remain active (Lim and Counter, 2005). It is clear 
that the tumor microenvironment changes during cancer progression, hence it will be 
important to evaluate whether CD 147-induced signaling pathways can potentiate Ras 
effector pathways independent of Ras. This may be the case because increases in HA 
synthesis confer an anchorage-independent growth advantage to cells (Zoltan-Jones et aI., 
2003). Since CD147 induces HA-CD44-dependent anchorage-independent growth 
(Marieb et aI., 2004), it is likely that CD147-med!~ted resistance to anoikis (Yang et aI., 
"'"'7 J ,1,1 
2006) is dependent on HA-CD44 interactions, which supply the cell with supplemental 
pro-survival ECM signals in the absence of integrin-based adhesion. 
Glycosylation and CD147 Function and Stability 
As mentioned previously, the core protein of CD147 may contain diverse 
combinations of carbohydrate attachments. Several authors have observed that CD 147 
migrates on SDS-P AGE between 31-65 kDa, a characteristic attributed to heterogeneous 
glycosylations, composed of branched polylactosamine, fucosylation, sialylation and 
LewisX glycan attachments. CD147 glycoforms were previously characterized as 
mannose-rich LG-CD147 and branched polylactosamine HG-CD147 (Tang et aI., 2004a). 
Currently, HG-CD147 is the only glycoform that has been attributed with a specific 
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function; in this case HG-CD 147 is associated with MMP induction. In contrast, 
accumulating evidence suggests that the high-glycosylated form is not necessary to 
induce MMPs (Attia et aI., 2011; Belton et aI., 2008; Kawakami et aI., 2011). 
Protein N-glycosylation begins in the endoplasmic reticulum and is followed by 
sequential addition or removal of sugar residues by various enzymes as the protein 
transits through the golgi apparatus (Lau and Dennis, 2009). An elegant study 
demonstrated that the protein gl ycoform synthesized by the cell is highly dependent upon 
cooperation between the expression profile of golgi transferases and metabolic flux 
through the hexosamine pathway (Lau et aI., 2007). This cooperativity between cell 
environment (e.g. metabolic substrates) and cell-type specific expression of tranferases 
may explain the variation in CDI47 glycoform~/i#ntified from cell lines derived from 
the same tissue of origin (Riethdorf et aI., 2006). 
The HG-CDI47 form contains ~1,6-branched, polylactosamine-type sugars 
1 
attachments initiated by the activity of N-acetlyglucosaminyltransferase V, which is 
encoded by the gene Mgat5 (Lau and Dennis, 2009). Interestingly, Mgat5 transcription is 
increased by Ras signaling (Chen et aI., 1998) and Ras has been shown to lead to 
differential sialylation of integrins (Seales et aI., 2003). Whether Ras regulates CD147 
glycosylation by initiating branching of polylactosamines or addition of sialic acid 
residues is unknown, but our current evidence suggests that this may be plausible as Ras 
does not appear to increase CDI47 transcription dramatically and our immunoblots 
demonstrate differential CD 147 gl ycoforms between cells with or without oncogenic Ras. 
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The LG-CDI47 form was characterized to contain high-mannose type 
carbohydrates, possibly via caveolin-1-mediated inhibition of further branching by Mgat5 
in the golgi (Tang et aI., 2004a). Earlier studies proposed that the LG-CDI47 form is 
immature and remains confined to the endoplasmic reticulum (Gallagher et aI., 2007), yet 
our surface biotinylation results as well as others demonstrate that the LG-CD 147 form is 
present on the cell surface (Tang et aI., 2004a; Tang and Hemler, 2004). As discussed 
previously, LG-CDI47 preferentially associates with caveolin-l, but may also associate 
with a3~1 or a6~1 integrins (Berditchevski et aI., 1997). Pulse-chase analysis discovered 
that LG-CDI47 was converted to HG-CDI47 or degraded in less than two hours (Tang 
and Hemler, 2004), suggesting that the kinetics of LG-CDI47 may be different than HG-
CD147. t I'" 
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Whether LG-CDI47 participates in different functions than HG-CD147 is 
unknown. It is possible that LG-CD 147 preferentially localizes in the rapid recycling 
compartments previously identified (Eyster et aI., 2009) and takes part in dynamic 
cellular processes such as matrix remodeling and metabolic substrate transport, whereas 
HG-CD 147 is more confined to the cell surface and aids in cell adhesion events (Sun and 
Hemler, 2001). Possibilities for the differences in membrane retention may be depend 
upon HG-CDI47 N-glycan interactions with extracellular matrix protein scaffolds such 
as galectins (Liu and Rabinovich, 2005). For instance, branched glycans in HG-CD147 
would be expected to have stronger avidity for galectins compared to high-mannose LG-
CD147 forms (Lau et aI., 2007), which could lead to retention of HG-CDI47 on the cell 
surface and allow dynamic trafficking of the LG-CD 147 form. Additionally, decreased 
glycosylation has been shown to promote ubiquitination and subsequent degradation of 
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CD147 (Wang et aI., 2008), yet further work is needed to elucidate how recycling and 
protein turnover cooperate in regulating CD 147 function. Whether specific 
glycosylations on CD147 dictate function is unknown and future studies should 
,determine localization patterns of different glycoforms using various lectin approaches 
coupled with subcellular organelle characterization techniques. 
Utility of CD147 as a Cell Surface Marker for Breast Cancer Cell Sub-population 
Analysis 
Breast cancer is a heterogeneous disease that has been separated into several 
clinical subsets (Voduc et aI., 2010). Profilingqthreast cancer specimens using genetic 
'-'~~I -1 
profiling and immunohistochemistry demonstrates that breast cancer is divided into 
distinct subtypes: Luminal A, Luminal B, Luminal-ErbB2 positive, ErbB2-amplified, 
basal-like and triple negative. The latter two are considered similar by some 
investigators, though much debate currently exists with respect to this classification 
(Foulkes et aI., 2010). A recent study found that six additional subtypes can be clustered 
into triple negative breast cancer, making the classification scheme even more complex 
(Lehmann et aI., 2011). Currently, evaluation of hormone receptor status, cytokeratin 
expression and ErbB2 amplification represent the mainstay utilized clinically for 
treatment stratification, but higher resolution characterization of breast cancers is needed 
to identify responders and non-responders to our current treatment modalities. 
Complementary to these analytical approaches, evaluation of cell surface 
expression profiles on individual cancer cells has also demonstrated utility (Ricardo et aI., 
129 
2011). In this respect, differential surface expression of CD44, CD24 and others markers 
have aided in identifying cells with stem-like properties that are invasive and resistant to 
current therapies (Visvader and Lindeman, 2008). CD147 associates with CD44 
(Slomiany et aI., 2009b) and EpCAM (Xu and Hemler, 2005), two proteins that were 
employed in the initial isolation of highly tumorigenic breast cancer cells (AI-Hajj et aI., 
2003) and cells from breast cancer cell lines with stem-like qualities and intrinsic 
resistance to chemotherapy (Fillmore and Kuperwasser, 2008). We have shown that 
enrichment of cells with differing CD 147 surface expression patterns affords us the 
ability to isolate cells with different capacities to invade and activate EGFR-ERK 
signaling pathways. Additionally, cells with high constitutive surface expression of 
CD 147 have increased CD44 and EGFR surface lelvers. Future studies should address 
'~'-"~I '(,' 
whether enriching for cells with differential surface levels of CD147 may be an 
alternative approach to isolate cells with diverse functional phenotypes in breast cancer or 
aid in classifying certain breast cancer subtypes. 
Translating CD 147 to the Clinic 
The presence of CD147 on the cell surface makes it a plausible molecular target for 
various targeted therapies, including monoclonal antibody therapy. In this regard, a dose-
escalation study with a murine IgM monoclonal antibody targeting CD 147 was evaluated 
in the context of steroid-refractory acute graft-versus-host disease. In this study, the 
dose-limiting factor was severe myalgias at 0.3 mg/kg, which could be controlled by 
narcotics. Additionally, no significant differences were seen in T cell or B cell numbers, 
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though the treatment demonstrated efficacy in this setting (Deeg et aI., 2001). Neutrophil 
or erythrocyte counts were not evaluated in this study. 
The first cancer-related study targeting CD147 in patients was performed in Phase 
IIII trials in China using a CD 147-specific F(ab')2 fragment conjugated to iodine l3l , 
which is called metuximab (Licartin). In this study metuximab was infused into the 
hepatic artery and the safety and efficacy of this therapy was evaluated in hepatocellular 
carcinoma (HCC) patients. No life-threatening toxic side effects were identified, though 
Grade 3 hematologic and hepatic toxicity was identified in some patients. The CD 147-
targeting antibody fragment was found to concentrate primarily in the tumor tissue and 
resulted in an improved survival rate, with a median survival time of 19 months; 
normally patients with HCC progress rapidly--a:r&Jiave a survival time of 3.2 months. 
" 
Interestingly, unconjugated metuximab demonstrated low clinical efficacy alone and was 
not tested in these trials (Chen et aI., 2006b). 
Preclinical studies in HNSCC are also underway. In tumor xenografts in mice, 
administration of CNT03899, a chimerized monoclonal human IgG 1 antibody targeting 
CD 147, resulted in decreased cell proliferation and in combination with irradiation 
resulted in additive toxic effects to the tumor (Dean et aI., 2009). Additional studies 
found that this antibody also induced apoptosis (Dean et ai., 2010) and partially slowed 
down glucose uptake in pancreatic cancer xenografts (Shah et ai., 2011). 
Though CD 147 -targeting monoclonal antibody therapy appears to have clinical 
benefit, the epitope targeted by the antibody should be closely examined. Antibodies 
directed against different epitopes of the extracellular domain of CD 147 have resulted in 
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opposing effects. For example, a study characterizing antibodies generated toward 
CD147 found that some inhibited invasion and MMP synthesis, whereas others increased 
both invasion and MMP synthesis (Wang et aI., 2006). Furthermore, studies in immune 
cells identified that CD147 may contain two separate bioactive domains, one involved in 
cell aggregation and the other in T cell activation (Chiampanichayakul et aI., 2006), thus 
binding of natural ligands or targeted antibodies may elicit differing cellular responses. 
Alternatively, antibodies targeting CD147 may alter CD147 homo- or hetero-philic 
protein interactions leading to reorganization of lipid raft domains (Staftler et aI., 2003). 
Thus before CDl47-targeted antibody therapy makes a stride towards the clinic, stringent 
evaluation of epitope-associated CD147 function needs to be clarified. A better suited 
use of CD 147-targeted antibodies may be in thetutHity of in vivo detection of tumor cells 
'-"~'~, 0/' 
by employing fluorescently-conjugated CD147 antibodies (Newman et aI., 2008b). 
Due to the pleiotropic nature of CD 147 function, consideration should be taken 
into account when evaluating therapies to down-regulate CD 147. Various physiological 
processes, such as fertilization, immune cell differentiation, transport of metabolic 
intermediates, wound healing and blood-brain barrier maintenance have all been 
attributed to CD 147 function. It is of interest, that in the above clinical studies, no 
mention of deleterious side effects was noted. This may be due to the highly targeted 
administration of metuximab through the hepatic artery and subsequent concentration 
primarily in liver tissue or the masking of side effects seen in the graft-versus-host 
disease cohort, which had poor baseline function of various organs. Further prospective 
randomized controlled studies are needed for evaluating CD 147 efficacy in patients, since 
the CD 147 -targeting cancer trial did not compare results to any standard of care. 
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Various studies have evaluated tumor biology by examining patient tumor 
samples before, during or after therapy regimens. Many of these studies focus primarily 
on the mRNA levels of proteins and rate whether differences are significant by setting a 
threshold ratio. Our data presented in this thesis, as well as data from other groups, have 
found that CD 147 expression may be regulated more at a post-transcriptional level (Chen 
et aI., 2010; Deora et aI., 2005; Fanelli et aI., 2003; Gallagher et aI., 2007; Noguchi et aI., 
2003). Thus, in some experimental contexts underestimation of differences in CD 147 
expression may occur when evaluating tumor samples. Additionally, CD147 is 
extensively modified by post-translational carbohydrate additions and interacts in diverse 
cellular compartments with various binding partners, all features that are missed in broad 
microarrayanalyses. Future studies should be dire~ted to elucidating the mechanisms 
'>'~~/?j 
that regulate CD147 post-transcriptionally, including: message stability, translation 
regulators, and glycosylation modulators. 
Closing Remarks 
It is becoming evident that the name Extracellular Matrix MetalloPRoteinase 
INducer (EMMPRIN) does not suffice to describe the role ofCD147 in cell biology. 
Though CD 147 has a prominent role in MMP induction in various cell models, it also 
appears to have a distinct role in organizing multi-protein complexes consisting of RTKs, 
metabolic transporters, drug efflux pumps and cell adhesion molecules. Additionally, 
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CD 147 is emerging as a regulator of the cytoskeleton and participates in the 
migration/invasion phenotype of various cancer cells, both in vitro and in vivo. 
In this thesis, we have identified several novel roles of CD 147 in breast cancer 
invasion. We have demonstrated that CD147 can regulate invadopodial dynamics, 
membrane reorganization events and the assembly of signaling complexes. Specifically, 
we found that interweaved relationships are present between MT1-MMP, HA-CD44 
interactions and EGFR-Ras-ERK signaling in breast cancer biology (Figure 4-1). Further 
studies should investigate whether similar relationships exist in other cancer types, 
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Figure 4-1. Working model: CD147 regulates invadoppdia dynamics by 
facilitating the assembly of multi-protein signaling complexes in lipid rafts. A) 
Distribution of endogenous CD147, EGFR, MTI-MMP and CD44 in the absence of 
CDl47 up-regulation. Thin yellow membrane indicates non-raft membrane. See 
Figures 2-5C and 3-3B for supporting data. B,D) Up-regulation of CDl47 leads to 
MTI-MMP accumulation in lipid raft domains (dark brown membrane) possibly 
enriched in invadopodia. C) Up-regulation of CDl47 leads to assembly of multi-
protein complexes containing CD147, MTI-MMP, EGFR and CD44, which 
facilitate invasion. Also, these complexes activate EGFR-Ras-MEK-ERK signaling 
cascades that are dependent on HA-CD44 interactions. Of note, the Ras-MEK-ERK 
pathway may regulate CD147 via post-transcriptional modulation. 
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